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ABSTRACT 
Visceral adipose tissue (AT) mass increases risk for cardiovascular disease and 
diabetes. Glucocorticoids (GCs) cause preferential expansion of visceral compared to 
subcutaneous AT through poorly understood mechanisms. GCs are necessary for 
adipogenesis, the differentiation of adipose stem cells (ASCs) to mature adipocytes. 
However, this process may be impaired in visceral depots. Insufficient adipogenesis can 
lead to excessive hypertrophy of existing adipocytes. This hypertrophic expansion 
increases cell death and inflammation, driving AT dysfunction. To better understand the 
genes and pathways by which high GCs cause preferential expansion of visceral fat we 
performed transcriptomic profiling (microarray) on paired samples of visceral (Omental, 
Om) and abdominal subcutaneous (Abdsc) AT explants cultured with the GC receptor 
agonist, dexamethasone (Dex), for 7 days. Gene set enrichment analysis showed the 
transforming growth factor beta (TGFβ) signaling pathway, most notably the secreted 
anti-adipogenic factors, TGFβ and activin A, was highly enriched in Om and suppressed 
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less by Dex. We hypothesized that Om AT and ASCs secrete factors that inhibit 
adipogenesis in an autocrine/paracrine manner. Conditioned media (CM) from Om tissue 
and ASCs suppressed differentiation by 70-80% compared to control; Dex attenuated this 
anti-adipogenic effect. Both TGFβ and activin A levels were 4-5 fold higher in CM from 
Om compared to Abdsc ASCs. Both factors signal via cell surface receptors that increase 
SMAD2 phosphorylation (P-SMAD2), basal levels of which were 3-4 fold higher in Om 
ASCs. Additionally, CM from Om ASCs increased P-SMAD2. siRNA mediated 
knockdown of activin A improved differentiation of Om ASCs, but did not reach levels 
observed in Abdsc. Blocking TGFβ and activin A signaling using SB431542 robustly 
increased adipogenesis of Om ASCs and prevented the anti-adipogenic effect of CM. 
GCs decreased production of TGFβ and activin A, but both remained higher in OmCM. 
Overnight Dex treatment decreased P-SMAD2 and increased the expression of the TGFβ 
co-receptor, TGFBR3, which decreases TGFβ signaling, in Abdsc ASCs. GCs failed to 
decrease P-SMAD2 and increased TGFBR3 in Om ASCs only at high concentrations. 
Taken together, these data implicate GC-TGFβ crosstalk as a determinant of depot 
differences in adipogenic capacity and hypertrophic vs. healthy hyperplastic expansion of 
AT. 
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CHAPTER ONE: General Introduction 
 
Adipose tissue serves as the major site of energy storage in the body as well as an 
endocrine tissue that secretes numerous factors that influence local and systemic 
metabolism. White adipose tissue is located in anatomically distinct depots; the major 
depots in humans are subcutaneous (SAT, abdominal, gluteal, femoral) and visceral 
(VAT, omental, mesenteric). Fat distribution is influenced by numerous factors, including 
sex, age, and circulating hormones, (1) and both VAT and SAT have distinct effects on 
metabolic health.  
 
VISCERAL ADIPOSITY IS ASSOCIATED WITH METABOLIC DISEASE 
The size of visceral adipose depots is strongly associated with high serum 
triacylglycerols (TAG) and insulin resistance that contribute to the development of 
multiple metabolic disorders including non-alcoholic fatty liver disease, type 2 diabetes, 
and cardiovascular disease (2). A multitude of epidemiological studies established a link 
between central obesity, as measured by waist-to-hip ratio or waist circumference, and 
type 2 diabetes and cardiovascular disease (3, 4). Later studies examined individuals with 
similar total body fatness but high or low amounts of VAT (5, 6) and demonstrated those 
with more VAT had higher glucose and insulin responses following an oral glucose 
tolerance test, independent of total body fat.  
Two prevalent hypotheses have emerged to explain these observations: (1) due to 
the anatomical location of VAT depots, fatty acids (FA) and other secreted products from 
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the depot drain directly into the portal vein to the liver before entering general 
circulation, bathing the liver in potentially adverse products of adipose metabolism and 
adipokines that can result in insulin resistance and increased liver fat and (2) cell 
autonomous variations between the depots drive functional differences in adipocyte and 
surrounding cell biology, such as inflammation, metabolism and cell turnover that exert 
negative effects on overall physiology (2). These two explanations are not mutually 
exclusive, and more than likely magnify the deleterious effects of larger VAT depots. 
Jensen’s group showed hepatic FFA delivery in fasting individuals is increased with 
greater visceral adiposity in men and women (7). Additionally, liver steatosis is strongly 
associated to the size of visceral adipose tissue (8, 9), which could be due to increased 
delivery of FA to the liver from VAT. Functional differences that can contribute to the 
association of VAT with metabolic disease risk include: (1) a higher inflammatory state 
and production of inflammatory cytokines such as TNFα and IL-6 that can adversely 
affect insulin sensitivity (10), (2) the poor capacity to recruit new adipocytes from a 
precursor pool, driving hypertrophic growth and adipose tissue dysfunction (11) and (3) 
visceral adipocytes have lower basal (per adipocyte) but higher lipolytic responses to β-
adrenergic stimulation and are less sensitive to the anti-lipolytic effect of insulin, driving 
higher release of FA from the depot, potentially increasing FFA delivery to the liver in 
the fasted and fed state (12-14). Understanding the factors that regulate VAT expansion 
and the mechanisms underlying its association with metabolic disease can provide 
potential targets for attenuating the poor outcomes associated with VAT growth.  
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DIFFERENCES IN CELL COMPOSITION BETWEEN VAT AND SAT LIKELY 
CONTRIBUTE TO VARIATIONS IN TISSUE FUNCTION 
Both omental (Om) and abdominal subcutaneous (Abdsc) adipose depots are 
comprised of multiple cell types that contribute to the overall microenvironment of each 
tissue. These populations of cells are divided into adipocytes and the stromal vascular 
fraction (SVF), which includes endothelial cells, several immune cell populations, 
smooth muscle cells and adipose stem cells (ASCs). The terms adipose precursor cells 
(APCs), preadipocytes, and ASCs are often used interchangeably in the literature, for the 
purposes of this thesis ASCs will refer to the  heterogeneous population of pluripotent 
stem cells within the adipose tissue that adhere and survive multiple expansions in vitro 
following isolation from the whole tissue (15). 
  
Variations in cell composition contribute to tissue microenvironments 
Differences in the number or activation state of cell populations likely contribute 
to alterations in the inflammatory and secretory profile of a given depot (16, 17) 
Adipocyte hypertrophy is associated with the accumulation of macrophages within 
adipose tissue, in the form of crown-like-structures, in both mice and humans, and higher 
expression of TNFα (18). Studies of obese mice suggest that epididymal depots, which 
are similar to visceral depots in human (19), contain more crown-like-structures 
compared to subcutaneous (20, 21). Visceral depots also contain more endothelial cells 
compared to Abdsc, and endothelial cells isolated from VAT secrete more total protein, 
though the profiles from each depot are very similar (16). As mentioned previously VAT 
  
4 
is more inflamed and produces more inflammatory cytokines (interleukin-6 (IL-6), 
interleukin-8 (IL-8), macrophage chemoattractant protein-1, etc.) compared to Absdc 
(22). Characterizing depot differences in cell populations and the contribution of each is 
essential to understanding the deleterious effects VAT expansion. 
 
DEPOT DIFFERENCES IN CELLULARITY IMPACTS ADIPOSE TISSUE 
FUNCTION  
The size of adipocytes within a depot strongly influence both adipocyte function 
and association with metabolic disease (2). Generally, adipocyte size increases with BMI 
regardless of sex or anatomical location, and reach a plateau in massively obese 
individuals (2). However, both size and number of adipocytes are heavily influenced by 
anatomical site and sex. Subcutaneous and Om cells from men tend to be similar in size 
across all BMIs, whereas subcutaneous cells in pre-menopausal women tend to be larger 
than those from the omental depot, even at very high BMIs. However, as women reach 
menopause, this depot-difference in adipocyte size is attenuated (2). To link cell size to 
the ability of adipose tissue to generate new adipocytes, studies based on the 
incorporation of 14C into DNA due to increased nuclear bomb tests between 1955 and 
1963 were performed. These studies indicate that lower rates of new adipocyte generation 
increase the prevalence of hypertrophic growth (23).  
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DEPOT-DEPENDENT DIFFERENCES IN METABOLISM CONTRIBUTE TO 
DEPOT SIZE AND SYSTEMIC EFFECTS 
Lipid accumulation with a depot is dependent upon the balance of TAG synthesis 
and breakdown. TAG accumulation is largely determined by the action of Lipoprotein 
lipase (LPL), the enzyme responsible for the hydrolysis of TAG-rich lipoproteins that 
deliver FA to target tissues (24). The activity of LPL in adipose tissue is strongly 
dependent on adipocyte size, and depot differences in LPL activity reflect this association 
(25). In women, where subcutaneous adipocytes are significantly larger, LPL activity is 
higher in Sc compared to visceral. In men, where visceral and Sc adipocyte size are 
comparable, LPL activity is similar (25). However, males have higher rates of fatty acid 
uptake in visceral when normalized to depot weight, however total fatty acid uptake is 
higher in the subcutaneous depot (26). 
Like LPL activity, rates of lipolysis are strongly influenced by adipocyte size, and 
depot-differences in lipolytic rates reflect this dependency. As a result, most studies show 
higher basal lipolysis in subcutaneous depots (2). Upon stimulation by β-adrenergic 
agonists, lipolytic rates are similar between visceral and Sc adipocytes, making the fold 
change greater for visceral (27). Insulin suppresses lipolysis in adipocytes, and 
adipocytes from Om are resistant to this anti-lipolytic action both in isolated adipocytes 
and in-vivo. Higher doses of insulin almost completely inhibits glycerol release from Sc, 
while lipolysis in Om is inhibited by ~50% (14, 28). It is important to note, that the large 
majority (~85%) of circulating free fatty acids (FFAs) are derived from subcutaneous 
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depots. However, with increasing VAT mass, this depot can contribute as much as 50% 
of FFAs in portal circulation (7).  
 
WHAT FACTORS REGULATE VISCERAL ADIPOSITY? 
Sex differences: Sex is a major determinant of adipose tissue distribution. Men 
tend to accumulate adipose tissue in the upper body (abdomen/trunk), whereas women 
accumulate adipose tissue in the lower body (hips/thighs) (29). Additionally, men have 
greater total amounts of VAT compared to premenopausal women, and this difference is 
maintained when controlling for total body fat mass, BMI, and Abdsc fat mass (30). 
Visceral adipose mass generally increases with age, but this increase is accelerated in 
postmenopausal women (31), suggesting sex hormones play a significant role in these 
differences in depot distribution. In males, low circulating testosterone is associated with 
increased visceral adiposity, as are high concentrations of sex-hormone binding globulin, 
which reduces testosterone’s biological activity (32). Males with low-circulating 
testosterone receiving exogenous testosterone to achieve normal physiological 
concentrations reduces visceral adiposity (33). Conversely, supraphysiological 
testosterone treatment of female-to-male transsexuals results in an increase in VAT (34). 
Hormone replacement therapy in postmenopausal women decreases the normally 
observed increase in visceral adiposity, indicative of an important role of estrogens in 
body fat distribution (35).  
Growth hormone: Numerous studies have shown associations between growth 
hormone (GH) secretion and visceral adiposity, however the causal relationship remains 
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poorly understood due to interactions with sex hormones and age (2). Notably, GH 
treatment decreases visceral adiposity in men and women (36, 37) 
Glucocorticoids: Glucocorticoids are stress hormones synthesized and released by 
the adrenal cortex both in a circadian fashion and in response to stressful situations. GC 
regulate a variety of biological functions including metabolism, cell fate determination, 
endocrine function, and inflammation, in nearly every cell in the body (38). GCs are 
powerful regulators of adipose tissue distribution, and cause preferential expansion of 
central adipose depots. This is clearly demonstrated in patients with Cushing’s disease, 
who have chronic, high circulating cortisol. As measured by magnetic resonance 
imaging, both total mass of VAT and proportion of VAT compared to total adipose tissue 
are higher in patients with Cushing’s (39). Additionally, measures of VAT mass are 
higher in individuals who have high circulating cortisol levels along with perceived stress 
(40, 41). Additionally, overexpression of 11β-hydroxysteroid dehydrogenase-1 
(11βHSD), an enzyme that locally activates and thereby increases intracellular 
concentrations of the active form of corticosterone, specifically in adipocytes, increased 
the size of visceral but not other depots (42). Furthermore, mice that overexpress 
corticotrophin-releasing hormone, which promotes higher circulating corticosterone, have 
greater epididymal and mesenteric fat depot weights (43). Local activation of cortisol in 
adipose tissue is increased in obesity, although depot differences in cortisol activation is 
controversial (44). In human adipose tissue incubated in vitro, GCs increase the 
expression and activity of 11βHSD in omental adipose tissue, but not Abdsc, providing a 
feed-forward loop by which GCs could preferentially increase VAT (45). 
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GLUCOCORTICOIDS ARE POWERFUL REGULATORS OF ADIPOSE TISSUE 
FUNCTION, GROWTH, AND CELLULARITY 
Glucocorticoids exert their effects through alterations in transcription 
GCs exert their effects through interaction with the GC receptor (GR), which 
upon binding ligand, translocates to the nucleus where it associates with specific GR 
response elements in the promoter of specific genes to directly alter their transcription. 
GCs work in concert with a number of co-activators and co-repressors increase or 
decrease transcription of specific genes. The binding of GCs to specific gene elements are 
cell type and context dependent (46), which may underlie the differences in GC action in 
different cell types. Additionally, high concentrations of cortisol can activate a second 
nuclear receptor, the mineralocorticoid receptor (MR) that has distinct effects on 
adipocyte biology from the GR (47). 
Translational isoforms of GR as well as posttranslational modifications can also 
influence their activity (38). The predominant active variant of the GR is GRα, which is 
capable of associating with GC response elements and recruiting transcriptional 
machinery when bound to its ligand. Conversely, GRβ is an isoform that resides in the 
nucleus, but is incapable of binding ligand and is inactive on GC responsive genes (48). 
GRβ can act in a dominant negative fashion to inhibit GRα activity (38). Additionally, 
the activity of GRα is highly dependent on phosphorylation at multiple sites directed by 
many kinases from varied signaling pathways, including Mitogen Activated Protein 
Kinases (MAPKs) and Cyclin Dependent Kinases (CDKs). Specifically, phosphorylation 
at Ser-211 is associated with increased transcriptional activity while phosphorylation at 
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Ser-226 reduces activity (49). Phosphorylation alters other aspects of GR function, as 
mutants with very few phosphorylation sites are more stable (50) and phosphorylation at 
specific sites alter the cellular compartmentalization of GRα (51). This “GR code” 
remains poorly understood, and differences in translational isoform abundance, 
phosphorylation status or chromatin structure could contribute to differences in GC 
action between adipose depots.  
 
The metabolic actions of glucocorticoids are complex 
GCs strongly influence the metabolic actions of adipose tissue and depend on the 
nutritional and hormonal state of the tissue. In absence of insulin, GCs decrease free fatty 
acid (FFA) uptake by adipocytes, whereas in the presence of insulin, GCs act 
synergistically to promote lipogenesis (52, 53). This upregulation of FA synthesis is 
driven by upregulation of key enzymes acetyl-CoA carboxylase, fatty acid synthase (54, 
55). Additionally, GCs potentiate action of insulin to promote fat storage via LPL (56) or 
esterification.  
Reports on the in vitro effects of GCs on lipolysis are conflicting. Long-term (48 
hr) treatment with GCs stimulate lipolysis in 3T3-L1 adipocytes and isolated rat 
adipocytes (57). Interestingly, GCs exhibit little effect on lipolytic rates in primary 
cultures of newly differentiated human adipocytes, adipogenic precursors isolated from 
human adipose tissue following a 14 day adipogenic protocol (58).  
In vivo, the effects of GCs on lipolysis differ depending on duration of GC 
exposure, concentration, model, and hormonal/nutritional state (59). In a small clinical 
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study, infusion of high concentrations of GC for 11 hours in fasted lean males increased 
circulating FFA and glycerol. However, this increase in plasma FFA was not due to 
increased release by the Abdsc depot, as cortisol decreased lipolysis in this depot as 
measured by arterio-venous difference (60). Though other depots were not examined, 
peripheral adipose depots likely contributed to the increased plasma FFA and glycerol. 
GCs are characterized as causing whole body insulin resistance, however, in adipose 
tissue, GCs actually potentiate the effects of insulin to promote fat storage and increase 
glucose uptake (61, 62).  
 
Glucocorticoids have strong anti-inflammatory effects 
GCs have well-established anti-inflammatory actions, decreasing expression of 
IL-6, IL-8, and TNFα in adipose tissue (22, 63). Accordingly, inflammatory/immune 
pathways are the most highly suppressed in cultures of human adipose tissue explants 
treated with GCs (54, 64). Excess inflammation within adipose tissue can drive adipocyte 
insulin resistance and increase release of FFA (65, 66). In vivo GCs have been shown to 
reduce adipose tissue macrophage recruitment via suppression of genes involved in 
macrophage chemotaxis (67). Additionally, blood concentrations of inflammatory 
cytokines increase with obesity, supporting the notion that inflamed adipose tissue and 
adipose derived inflammatory cytokines can negatively impact systemic insulin 
sensitivity (68), and that altered GC action could exacerbate this impact.  
 
 
  
11 
Molecular mechanisms of GC action in adipose tissue 
Microarray studies indicate that GCs affect up to 20% of adipose tissue expressed 
genes (54) and ChIP-seq analyses have identified over 8000 GR binding regions in the 
genome of 3T3-L1 adipocytes (69). Similar studies in human subcutaneous adipocytes 
isolated after organ culture identified GR binding regions largely targeted at 
inflammatory mediators (70). Few metabolic genes were identified as being regulated by 
GCs in this study, however, culture conditions did not contain insulin, which strongly 
influences the metabolic effects of GC action (59). A microarray study carried out by our 
lab sought to identify genes depot-dependently regulated by a single high dose of the GR 
agonist, Dexamethasone (Dex, 25 nM), in 7 day organ cultures of Om and Abdsc adipose 
tissue (54). However this experiment did not test potential depot-dependent differences in 
sensitivity (i.e. shift in ED50) or responsiveness (defined as the increment or fold effect), 
as is seen with LPL’s response to GCs (61), or other response curves (U and inverted-U). 
Therefore a goal of this research was to identify genes that are depot- and dose-
dependently regulated by GCs in Om and Abdsc adipose tissue.   
 
Glucocorticoids are required for adipogenesis 
GCs are required for differentiation of adipocytes and maintenance of adipocyte 
specific genes in newly-differentiated human ASCs (71). siRNA mediated knockdown of 
the GR in cultures of human ASCs prevented the proadipogenic effects of cortisol, and 
blunts GC induction of leptin and adiponectin (72). There is some disagreement in the 
relative importance of the GR and MR in the proadipogenic effects of GCs, as siRNA 
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mediated knockdown of the MR prevented adipogenesis in 3T3-L1s while knockdown of 
GR did not (73). These inconsistencies may be due to differences in model or species 
used (clonal cells vs. primary, human vs. mouse). 
 
ADIPOSE TISSUE EXPANSION  
The growth of adipose tissue occurs via two processes 1) the growth of existing 
adipocytes through TAG storage (hypertrophy) and 2) increasing the number of mature 
adipocytes within a depot hyperplasia) which requires the differentiation of adipocyte 
precursors (hyperplasia) (23). Adipocyte hypertrophy is the major mechanism by which 
adipose tissue increases in size. Significant weight gain (15-25%) of non-obese men over 
several months resulted in increases in adipocyte size, but no change in adipocyte number 
(74). Large adipocytes are more prone to cell death, and are associated with infiltration of 
macrophages into the tissue (18). Given that adipocyte number is stable in adult humans, 
even in obese individuals, there must be sufficient recruitment and differentiation of new 
adipocytes to replenish those that died (75). Danforth hypothesized that an inability to 
recruit new adipocytes could force cells to take on the nutrient burden and become 
excessively hypertrophied, driving the development of type 2 diabetes (Figure 1) (76). 
Indeed, individuals with larger adipocytes have a significantly higher risk of developing 
insulin resistance, non-alcoholic fatty liver disease and other metabolic complications 
(77). Furthermore, a recent clinical study by Tchernof in 35 women of varying BMIs, 
(20-41, 25 ± 3 kg/m2) demonstrated that poor adipogenic capacity of precursors from the 
abdominal subcutaneous (Abdsc) depot predicts large adipocyte size in both the Abdsc 
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and Om depots indicating an impaired ability to recruit new adipocytes could favor 
hypertrophic growth (78). Although Tchernof and others showed that Om preadipocytes 
have poor adipogenic capacity compared to those from Abdsc when tested in vitro (11, 
78, 79), they did not assess the relationship between Om adipogenic capacity and the 
degree of Om or Abdsc hypertrophy. Additionally, no prior reports addressed the 
correlation between the adipogenic capacity of Om and Abdsc ASCs. Subject dependent 
variation in the ability of precursors to become adipocytes could exacerbate the 
hypertrophic growth of adipocytes if both depots are unable to differentiate, or lead to 
depot-specific adipose dysfunction.  
 
ADIPOGENESIS 
Transcriptional control of adipogenesis 
The process by which adipocyte precursors differentiate into mature white 
adipocytes has been heavily studied. (Reviewed in (80, 81)). The culmination of 
numerous papers support the model of a transcriptional cascade that ultimately drives the 
expression and maintenance of adipocyte specific genes (82). The initial players in 
thistranscriptional cascade belong to the CCAAT/Enhancer Binding Protein (C/EBP) 
class of proteins, namely C/EBPα, β, and δ. Both C/EBPβ and δ rise rapidly following 
induction of adipogenesis decrease hours to 3 days after, and drive the expression of 
C/EBPα (83). C/EBPα is required for the maintenance of the master regulator of 
adipogenesis, PPARγ, which in turn maintains expression of C/EPBα in the absence of 
other C/EBPs. This positive feedback loop “locks-in” the expression of PPARγ, 
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maintaining the expression of adipocyte specific genes (82, 84, 85) PPARγ is necessary 
and sufficient to induce adipogenesis in vitro (86) Additionally, mice lacking PPARγ fail 
to develop adipose tissue, and synthetic PPARγ agonists strongly increase the 
differentiation capacity of adipose precursors (87, 88).  
 
 
Figure 1.1 Expansion of adipose tissues relies on hypertrophy and hyperplasia.  
Over nutrition causes the expansion of adipose tissue through increasing the size of 
existing adipocytes (hypertrophy) and recruiting precursors to become new adipocytes 
(hyperplasia). Recruitment of new adipocytes limits hypertrophic growth of existing 
adipocytes, and allows for healthy expansion of adipose depots. Excessive hypertrophic 
growth results in cell death, inflammation, and tissue dysfunction. Figure was adapted 
from (89). 
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Adipogenesis in vitro is driven by a standard adipogenic cocktail 
Most of these transcriptional cascades were elucidated with in vitro models of 
adipogenesis often using fibroblast-like clonal lines that require a standard adipogenic 
cocktail that includes insulin, Dex, and 3-isobutyl-1-methylxanthine (IBMX). High 
concentrations of insulin are required for activation of the IGF receptor to promote 
activation of SREBP1c and suppression of FOXO1 activity (90, 91). The effects of Dex 
to promote adipogenesis differ depending on the model used. In both human 
preadipocytes and 3T3-L1 cells, Dex increases expression of C/EBPβ, and decreases the 
expression of Pref1 and Runx2, both anti-adipogenic factors. Dex is known to sensitize 
preadipocytes to the action of insulin specifically in human cells, while in 3T3-L1s it is 
required for cell survival during clonal expansion, which does not occur in humans (92-
94). IBMX increases intracellular cyclic AMP, which in turn leads to the activation of 
CREB, and participates in the induction of C/EBPβ (95). Negative regulators of 
adipogenesis often directly, or indirectly alter the activity of these key transcription 
factors. 
 
ASC populations include cells in varying stages of commitment 
Models used for studies of adipogenesis include clonal cell lines, like the 3T3-L1, 
mass cultures of ASCs isolated from whole adipose tissue, and sorted preadipocytes (15). 
As previously mentioned, ASCs refer to the  heterogeneous population of pluripotent 
stem cells within the adipose tissue that adhere and survive multiple expansions in vitro 
following isolation from the whole tissue (15).These adherent cells are capable of 
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differentiating into adipocytes, chondrocytes, and other cell populations and maintain 
distinct surface marker profiles after multiple passages (96-98). Not all cells in these 
mass cultures have adipogenic capacity, and these fail to differentiate in vitro under 
normal adipogenic stimuli (98). The term “preadipocytes” usually refers to a population 
of fibroblast like cells that are committed to the adipocyte lineage and readily 
differentiate into adipocytes. However, there is uncertainty as to what cells within ASC 
populations are “true preadipocytes.” Several studies have identified cell populations 
using surface marker sorting that have greater adipogenic capacity in vitro compared 
other sorted populations in the whole SVF, and have the potential to generate fat pads in 
vivo when transplanted into mice (99, 100). Further complicating characterization of 
adipocyte precursors, both preadipocytes and ASCs, is the observation that adipogenic 
populations from different depots have distinct cell surface markers and developmental 
origins, indicating that different fat pads have unique populations of adipogenic 
precursors (101, 102). However, much of this work to identify preadipocytes is carried 
out in mouse models, and human preadipocytes remain poorly characterized. Variations 
in the mixed populations of ASCs and number of committed preadipocytes likely 
contributes to the variations in adipogenic capacity of a given depot or subject. 
 
Adipose tissue stem cells (ASCs) from visceral depots have poor adipogenic capacity  
Adipose stem cells isolated from different depots have varying adipogenic 
capacity, in both human and rodent models. In the mouse and rat, adipose stem cells from 
the gonadal depot have a lower adipogenic capacity than those from the inguinal or 
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perirenal depots (103-105). This is similar to what is observed in humans. Following a 
standard differentiation protocol, fewer precursor cells from the Om depot accumulate 
TAG, and the expression of FABP4 (aP2), PPARγ, and C/EBPα lower compared to 
precursors from the Abdsc depot (11). These differences in adipogenic capacity are 
maintained when colonies derived from single cells were induced to differentiate, 
indicative of a cell autonomous difference between adipogenic cells between depots (11). 
The factors that underlie this depot dependent difference in adipogenic capacity are 
poorly understood. Potential mechanisms that contribute to the low adipogenic capacity 
of Om ASCs include: lower responsiveness to PPARγ agonists in Om preadipocytes (79), 
lower abundance of specific preadipocytes subtypes (106), and higher secretion of 
inflammatory cytokines (107). Others have identified differences in secreted factors 
between gonadal and inguinal subcutaneous preadipocytes that could potentially affect 
adipogenesis in mouse (108). Additionally, well differentiating subcutaneous precursors 
grown on decellularized extracellular matrix (ECM) from Om ASCs were less capable of 
undergoing adipogenesis, implicating the ECM as a regulator of adipogenic capacity 
(109). Several studies have attempted to characterize the precursor populations using 
microarrays to determine if precursors from different depots originate from distinct 
developmental populations or have unique gene expression patterns (19, 110). These 
studies indicate differential HOX gene and other developmental gene expression profiles 
for visceral and subcutaneous preadipocytes, but do not readily identify factors driving 
differential adipogenic capacity. The mechanisms that underlie this depot difference in 
adipogenic capacity remain poorly understood.  
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Negative regulators of Adipogenesis 
 Factors that negatively influence adipogenesis often act at these key 
transcriptional control points. TNFα prevents the induction of C/EBPα and PPARγ 
through activation of β-catenin/TCF4 (111). Likewise, canonical WNT signaling is a 
potent inhibitor of adipogenesis through similar mechanisms by preventing the induction 
of C/EBPα and PPARγ (112, 113). Moreover, expression of a canonical WNT ligand, 
WNT10b, is high in undifferentiated preadipocytes, is downregulated upon stimulation 
with an adipogenic cocktail, and can inhibit adipogenesis when added to cells (112).  
It is well established that members of the TGFβ family inhibit adipogenesis. 
TGFβ itself blocks differentiation of 3T3-L1 preadipocytes (114). Macdougald 
demonstrated that PRRX1, a transcription factor involved in cell fate determination, 
exerts its antiadipogenic effects though induction of TGFβ (115). Studies by Derynck’s 
group utilizing overexpression of dominant negative constructs of SMAD2 and SMAD3 
indicated that SMAD3 was more important for mediating the anti-adipogenic effects of 
TGFβ on 3T3-L1 adipogenesis (116). Other studies show that SMAD3 deficient mice are 
protected from diet induced obesity, and that MEFs from these animals are resistant to 
the antiadipogenic effect of TGFβ (117). Furthermore, Derynck showed that activated 
SMAD3 exerted its antiadipogenic effect through binding to C/EBPβ and C/EBPδ and 
blocking their transcriptional activation of PPARγ, major positive regulators in the 
adipogenic program (118). Another member of the TGFβ family, activin A, suppresses 
adipogenesis. When added to differentiating cultures of human preadipocytes, activin A 
decreased the number of cells showing visible lipid droplets and expression of late 
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adipogenic markers (119). Importantly, activin A is produced by preadipocytes and 
decreased during differentiation, but depot differences in expression are not known. 
 
The TGFβ family has strong influences on adipocyte biology 
 The TGFβ family of signaling molecules regulates a large range of cellular 
processes including cell fate determination, fibrosis, and proliferation. The direction and 
type of regulation depends on the interplay of numerous ligands, receptors and 
intracellular signaling cascades. There are 3 members of the TGFβ “class” of ligands 
(TGFβ1, 2 and 3). TGFβ is secreted non-covalently bound to a protein called latent-
associated protein (LAP) or LAP and latent-TGFβ-binding-protein (LTBP). LTBP seems 
to play a role in directing TGFβ to the extracellular matrix (120). TGFβ cannot bind to its 
receptors in these latent forms, and must be liberated via separate TGFβ activators, 
integrins αvβ6 and αvβ8. Activated TGFβ exerts its effects on target cells via interaction 
with TGFβ Type I (TGFBRI) and Type II (TGFBRII) receptors, both of which are 
serine/threonine kinases, which subsequently activate numerous downstream targets. 
Many effects of TGFβ are mediated through phosphorylation of SMAD proteins, which 
after association with a co-SMAD, SMAD4, translocate to the nucleus and alter 
transcriptional activity of numerous target genes. Specific changes in expression depend 
on the specific phosphorylated SMAD (1/5/9, 2/3), which can be altered by specific 
receptor sets, ligand type, and relative abundance of the SMADs. Alternatively, the 
TGFBR can activate a number of other pathways including those that control actin 
dynamics (Rho kinase) or mitogen signaling (MAPK, ERK). The activins comprise a 
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second set of secreted ligands in the TGFβ family that have been heavily studied in 
pituitary gland signaling and gonad function, but have recently been shown to be 
important in adipose biology (119). Activins are homo or heterodimers of beta subunits 
(A, B, C & E), that signal through a similar set of type I and type II receptors which are 
distinct from TGFβ receptors (ALK4/7and ACVRIIA/B). Similar to TGFβ, activin A 
activates its target receptors and drives phosphorylation of SMAD2/3 to alter gene 
expression and inhibit adipogenesis (119). Conversely, activin B has been implicated in 
lipid accumulation and insulin sensitivity of adipocytes (121). In addition to differences 
in receptor driven cascades, both activin A and TGFβ signaling can be altered by 
extracellular mediators. Follistatin is a secreted protein that can inhibit the action of 
activin A and TGFβ by sequestering these ligands from their membrane bound receptors. 
Another member of this extracellular regulatory network includes the non-traditional 
TGFβ receptor, TGFBR3 (Betaglycan). The structure of TGFBR3 includes a cleavable 
extracellular domain that can act in a similar way to Follistatin, sequestering TGFβ 
ligands away from their membrane bound receptors (122). Additionally, the membrane 
bound form of TGFBR3 appears to alter signaling if TGFβ from SMAD2/3 to 
SMAD1/5/9 in lung fibroblasts (123). Lastly BMPs, predominantly signal through the 
SMAD1/5/9 system, appear to be pro-adipogenic, and possibly favor brown adipogenesis 
or commitment from mesenchymal stem cells (124, 125). The role of the TGFβ family of 
signaling molecules in depot-dependent biology has not been examined. 
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GOALS OF THE DISSERTATION 
 Expansion of VAT increases the risk of developing cardiometabolic disease, and 
GCs cause preferential expansion of VAT through poorly understood mechanisms (39, 
40, 59). Adipose tissue contains multiple cells types that can respond to GCs in distinct 
ways, altering both the sensitivity and responsiveness of the tissue (46). Om adipose 
tissue is more responsive to GCs, i.e. it exhibits a greater absolute or fold change 
compared to control conditions, and less sensitive, i.e. the dose-response curve is right 
shifted (56), so depot-dependent differences in the effects to GCs will be pronounced at 
low concentrations. We previously identified genes depot-dependently regulated by a 
single, maximally stimulating dose of Dex, but did not address lower concentrations (54). 
Thus, to better understand the depot- and dose-dependent effects GCs in human visceral 
and subcutaneous adipose tissues, we performed microarrays in paired Om and Abdsc 
adipose tissue organ cultures in the presence of a range of Dex concentrations. We sought 
identify mRNAs and pathways that were depot- and dose-dependently regulated by GCs 
that could contribute to depot-dependent adipose biology. 
 Pathway analysis identified families of secreted factors as highly depot-different 
and regulated by GCs. Those pathways enriched in Om included inflammatory pathways, 
cytokine-ECM interactions, and the TGFβ pathway; all 3 are known to negatively impact 
adipogenesis (111, 126). Adipogenesis is required for healthy adipose tissue expansion as 
it allows recruitment of new adipocytes that can store excess fat, thereby limiting 
hypertrophic growth of existing adipocytes. Hypertrophic adipocytes are strongly 
associated with inflammation and adipose tissue dysfunction (18, 127). ASCs from VAT 
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differentiate very poorly in culture, despite using a very potent adipogenic cocktail, 
including GCs which are required for differentiation of human ASCs. Therefore, the 
inability to effectively recruit new adipocytes in VAT, due in part to an anti-adipogenic 
microenvironment, likely contributes to the poor outcomes associated with VAT 
expansion. Therefore we tested the hypothesis that Om tissue and ASCs secrete more 
anti-adipogenic factors compared to Abdsc by treating well-differentiating ASCs with 
conditioned media from Om and Abdsc tissues and ASCs. Additionally, we hypothesized 
that the ability of Dex to decrease the production of these secreted factors was impaired 
in Om tissue and ASCs, contributing to the poor adipogenic capacity of Om ASCs. 
Therefore, the goals of this thesis were: 
Goal 1: Identify genes and pathways depot- and dose-dependently regulated by GCs 
in Om and Abdsc adipose tissue 
A. Identify mRNAs and pathways that are differentially sensitive or responsive to a 
range of Dex concentrations between Om and Abdsc adipose tissues using an 
organ culture model system  
B. Identify GC-regulated genes and pathways that may have unanticipated roles in 
depot-dependent adipose biology, i.e. those that are predominantly expressed in 
one depot or another and are regulated by Dex in one depot 
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Goal 2: Determine the contribution of secreted factors and resistance to GCs 
contribute to the anti-adipogenic capacity of Om ASCs 
A. Test if conditioned media from Om tissue inhibits adipogenesis more than CM 
from Abdsc 
B. Determine if ASCs contribute to the anti-adipogenic secretory profile of adipose 
tissue 
C. Determine the role of the TGFβ pathway in the poor adipogenic capacity of Om 
ASCs 
1. Measure concentrations of TGFβ and activin A in CM from Om and Abdsc 
ASCs and correlate them to differentiation capacity 
2. Determine if blocking TGFβ signaling can improve adipogenesis of Om ASCs 
D. Determine if Om ASCs are resistant to the ability of GCs to suppress TGFβ 
signaling 
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CHAPTER TWO: Depot Dependent effects of dexamethasone on gene expression in 
human omental and abdominal subcutaneous adipose tissues from obese women. 
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ABSTRACT 
Glucocorticoids promote fat accumulation in visceral compared to subcutaneous 
depots, but the molecular mechanisms involved remain poorly understood. To identify 
long-term changes in gene expression that are differentially sensitive or responsive to 
glucocorticoids in these depots, paired samples of human omental (Om) and abdominal 
subcutaneous (Abdsc) adipose tissues obtained from obese women during elective 
surgery were cultured with the glucocorticoid receptor agonist dexamethasone (Dex, 0, 1, 
10, 25 and 1000 nM) for 7 days. Dex regulated 32% of the 19,741 genes on the array, 
while 53% differed by Depot and 2.5% exhibited a Depot*Dex concentration interaction. 
Gene set enrichment analysis showed Dex regulation of the expected metabolic and 
inflammatory pathways in both depots. Cluster analysis of the 460 transcripts that 
exhibited an interaction of Depot and Dex concentration revealed sets of mRNAs for 
which the responses to Dex differed in magnitude, sensitivity or direction between the 
two depots as well as mRNAs that responded to Dex only in one depot. These transcripts 
were also clearly depot different in fresh adipose tissue and are implicated in processes 
that could affect adipose tissue distribution or functions (e.g. adipogenesis, 
triacylglycerol synthesis and storage, insulin action). Elucidation of the mechanisms 
underlying the depot differences in the effect of Dex on the expression of specific genes 
and pathways that regulate adipose function may offer novel insights into understanding 
the biology of visceral adipose tissues and their links to metabolic health. 
Key terms: glucocorticoids, gene set enrichment analysis, organ culture, fat distribution, 
visceral adipose tissue 
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INTRODUCTION 
The mass of visceral fat, defined as those depots located within the abdominal 
cavity and associated with digestive organs (i.e. omental and mesenteric), is associated 
with risk for type 2 diabetes and cardiovascular disease in both men and women (128). 
Glucocorticoids (GCs) promote the preferential accumulation of fat in visceral depots as 
clearly observed in Cushing’s syndrome (39, 129, 130). Depot differences in rates of 
triacylglycerol (TAG) turnover, inflammation and adipocyte cellularity are well 
documented in humans and mouse models (131-133), but the mechanisms that underlie 
depot-dependent variations in GC action and mechanisms that link the size of this depot 
to systemic metabolic dysfunction remain incompletely understood.  
GCs integrate a wide variety of regulatory signals that control cell proliferation, 
metabolism, and inflammation (134). The activity of the GC receptor (GR) is cell-type, 
gene and dose dependent, and regulated by multiple signals (48, 135). Adipose tissue 
includes multiple cell types, including preadipocytes, endothelial cells, immune cells and 
adipocytes, all of which are targeted by GCs (17). Thus, in addition to direct GC actions 
in each cell type, paracrine and endocrine interactions likely contribute to depot 
differences in GC actions on gene expression and thereby tissue function. Although cell 
culture models provide invaluable mechanistic information on each cell type, the cellular 
composition of different depots varies and the composition of its extracellular matrix 
(ECM) likely also contributes to the depot differences in GC actions (109). Thus, 
unraveling the molecular details of crosstalk among cell types and pathways in intact 
adipose tissue is complex. The advantage of organ culture in this context is that this 
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system provides a physiologically relevant three-dimensional context for the analysis of 
human adipose tissue hormone action and comparison of depot differences.  
To gain an integrated picture of mechanisms by which GCs modulate depot-
dependent function, we chose to use an organ culture system in which the expression of 
key adipocyte genes (e.g. ADIPOQ, LEP, GLUT4, LPL) is synergistically upregulated by 
GCs and insulin, and maintained at initial levels for at least 7 days (54, 56). Our previous 
studies addressed global effects of GCs on the adipose transcriptome in organ cultures of 
the two major central adipose depots in humans, visceral (omental, Om) and abdominal 
subcutaneous (Abdsc), using a 12K microarray (54). These studies tested only one 
concentration of the type II GR agonist Dex (25 nM), added in the presence of 7 nM 
insulin (54). Dex regulated ~20 % of the adipose expressed genes and many genes and 
pathways, such as those that promote TAG synthesis and mediate insulin action, were 
affected similarly in both Om and Abdsc, but the magnitude of the effects was often 
depot-dependent (54). A limitation of this prior study was that Dex effects are highly 
concentration-dependent (135), and we have previously documented lower sensitivity to 
submaximally-stimulating concentrations of Dex on LPL and leptin gene expression (56, 
136).  
GR interacts with co-activators or co-repressors to exert complex effects on 
transcriptional networks. Mechanisms by which GR interacts directly with their binding 
sites that selectively enhance/repress the transcription of clusters of genes are rapidly 
emerging from studies of cell culture models (135, 137, 138). Toward the long-term goal 
of understanding mechanisms by which GCs differentially modulate gene expression in 
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the complex microenvironments of human visceral and subcutaneous adipose tissues, the 
two main goals of the current study were: 1) to identify transcripts that are differentially 
sensitive to a range of Dex concentrations (0, 1, 10, 25, 1000 nM) in Om and Abdsc, and 
2) to identify GC-regulated mRNAs that may play unanticipated roles in depot-dependent 
adipose biology, i.e. they were mainly expressed only in one depot and were responsive 
to Dex in that depot. We used Dex for the current mechanistic study because it is a 
specific GR agonist, and unlike cortisol, it cannot be inactivated or interact with the 
mineralocorticoid receptor (MR). To this end, we used Affymetrix Human Gene 1.0 ST 
microarrays that represent nearly all ~20,000 human genes and a more physiologically 
relevant concentration of insulin (0.7 nM) compared to our prior study (54).  
 
MATERIALS AND METHODS 
Sample collection   
Adipose tissue was sampled from elective surgeries on volunteers free of diabetes, 
cancer and inflammatory diseases by medical record, and not taking any medications that 
could affect metabolism, as previously described (136). Table 2.1 shows the 
characteristics of subjects whose tissue was used for microarray and follow-up studies. 
All studies were conducted under Institutional Review Board approved protocols at the 
Boston Medical Center. All subjects signed informed consent.  
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 Table 2.1. Characteristics of subjects used in microarray and subsequent studies.  
Age, 
yr 
Sex Surgery Chol TAG 
HbA1c 
(%) 
Race 
BMI, 
kg/m2 
Subjects used for microarray 
48 F TAH abdominal N/A N/A 5.2 AA 54 
54 F gastric bypass 151 80 N/A AA 41 
28 F gastric bypass 196 146 5.9 H 42.5 
34 F gastric bypass 136 79 5.5 H 54 
30 F gastric bypass 177 37 5.5 H 36 
Additional Subjects used for qPCR 
36 M gastric bypass 226 210 5.3 H 39 
23 F gastric bypass 171 80 4.5 H 39 
 AA-African American, H-Hispanic; Chol-Serum Cholesterol (mg/dl), serum TAG 
(mg/dl), HbA1c (Hemoglobin A1c) 
 
Tissue processing 
Immediately after excision, a small aliquot of tissue (~200 mg) was quick frozen 
in liquid nitrogen. The rest was carried to the laboratory in room temperature Medium 
199, minced into 5-10 mg fragments, quickly rinsed in 0.9% saline, and ~300-400 mg 
were placed in organ culture in 15 ml of Medium 199 supplemented with 0.7 nM insulin 
plus 0, 1, 10, 25 or 1000 nM Dex for 7d. Cultures were re-fed every other day and the 
day prior to harvest on d7 (139).    
 
Gene expression 
Total RNA was isolated with Trizol reagent (Life Technologies, Carlsbad, CA), 
cleaned with RNeasy MiniElute Cleanup Kit (Qiagen, Germantown, MD) and used for 
microarrays and quantitative PCR (qPCR). Depot differences in mRNA levels in quick 
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frozen tissue were verified by qPCR. Total RNA was reverse transcribed using 
Transcriptor First-Strand cDNA synthesis kit (Roche, Indianapolis, IN) and qPCR was 
performed on a LightCycler 480 II (Roche) with commercially available TaqMan probes 
(Life Technologies). Cyclophilin A (PPIA) was used as a reference gene, and relative 
expression levels were calculated.  
 
Microarrays 
Human Gene 1.0 ST arrays were used to profile gene expression in 3 independent 
paired samples of Om and Abdsc, after culture with Dex 0, 1, 10, and 1000 nM. Two 
samples were pooled from two different donors with similar characteristics and the 
magnitude of the Dex effect to increase GILZ and decrease IL-6 expression (by qPCR), 
and one sample represented a single donor (Table 2.1). Array results (log2-transformed) 
were normalized together using the Robust Multiarray Average algorithm and a Chip 
Definition File that maps the probes on the array to unique Entrez Gene identifiers. 
 
Gene set enrichment analysis (GSEA) 
To determine biological pathways regulated by each concentration of Dex in each 
depot, we calculated the fold change for the normalized values of gene expression in Om 
and Abdsc depot at each Dex concentration as compared to the control (0 Dex). The 
average fold change for each depot and Dex concentration was calculated and used for 
GSEA Preranked analysis (Ver. 2.1.0, Broad Institute (140, 141)). KEGG, Reactome, 
Biocarta and PID databases were queried. Because there was substantial overlap for 
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significantly enriched pathways and gene lists, only KEGG results are presented. 
Analyses based on data ranked by the T-value for the paired T-test yielded similar results 
(not shown). Significantly up and down regulated KEGG pathways (FDRq values < 0.05) 
are listed in Table 2.4A-C 
 
Statistical analyses 
A linear mixed-effects (LME) model was used. Depot (Om vs. Abdsc) and 
concentration of Dex were treated as "fixed" independent variables and donor as a 
"random" independent variable. The interaction of Depot and Dex concentration ([Dex]) 
was included in the model. [Dex] was modeled as a categorical, unordered variable so as 
not to exclude genes with a nonlinear dose response. The interaction effect measures 
whether dose effect on the expression of a given gene differs between the depots. For 
example, the concentration of Dex that consistently affects a given gene or the magnitude 
of the effect is dependent on depot. After calculation of p values for each term for each 
gene, the Benjamini-Hochberg False Discovery Rate (FDR) correction was used to obtain 
FDR-corrected p values (a.k.a. FDRq values). 
A cluster analysis was conducted on a subset of 460 genes with a FDRq less than 
0.05 for the interaction of Depot and [Dex] that also showed an effect size over 1.2 fold 
up or down in at least one concentration of Dex in one depot, and expression values 
greater than a cutoff of 20 (out of a maximum ~6000) arbitrary units. The mean values 
for expression of these at each Dex concentration were scaled across both depots (
𝑋−𝐴𝑣𝑔
𝑆𝐷
). 
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Cluster analysis was performed with JMP 10 software (using settings of complete, 1 or 2 
way cluster, scaled).  
Expression levels of selected genes of interest were verified by qPCR using 7 
paired Om and Abdsc samples. Data are normalized by PPIA gene expression (2-ΔCT) and 
presented as the mean and SEM of relative abundance. All values were log-transformed 
prior to statistical analysis. The effect of Dex within a depot was tested with a one way 
repeated measures ANOVA (on dose), with post-hoc paired t-tests as indicated, within 
each depot. Paired t-tests were used to compare values in Abdsc and Om depots within 
subjects.  
 
RESULTS 
Using a linear mixed modeling approach and conservative cutoff of FDRq < 0.05, 
6,344 out of 19,741 transcripts on the array (32%) were significantly regulated by Dex, as 
indicated by a significant main effect. 10,424 transcripts (53%) showed a Depot effect 
and 513 (2.5%) showed a Depot*[Dex] interaction. Gene lists, average expression values 
and FDRq values for the LME analysis are provided in Table 2.3. To identify transcripts 
that are depot-independently regulated by Dex, expression levels at each Dex 
concentration in each depot were pre-ranked by fold-change for statistical analysis. If the 
FDRq for the Dex and Depot effect in the LME was significant (FDRq <0.05), and there 
was no Depot*[Dex] interaction, they were considered depot independently regulated by 
Dex. A significant Depot*[Dex] interaction indicates that the Dex effect varied by Depot. 
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Similar results were obtained when genes were ranked by T-values for the Dex effect 
compared to baseline (not shown).  
  
Pathways that were regulated by Dex in a depot independent manner  
Dex upregulated pathways: Table 2.4A lists the KEGG pathways identified by 
GSEA as upregulated in both depots (FDRq < 0.05 in both) at each concentration of Dex. 
As expected from our previous work (54), insulin signaling as well as metabolic 
pathways involved in fatty acid (FA), amino acid, and carbohydrate 
degradation/oxidation through pyruvate and the Krebs cycle (glycolysis, pyruvate 
metabolism pathway) were upregulated by Dex in both depots. Also, as expected, lipid 
metabolism-related and signaling pathways that were upregulated by Dex similarly in 
both depots included FA metabolism, peroxisome, biosynthesis of unsaturated FAs, 
glycerophospholipid metabolism and glycerolipid metabolism. The gluconeogenesis 
pathway was also upregulated; this list included PCK1 which is of importance in 
adipocytes because it functions as a glyceroneogenic enzyme that regulates esterification 
of FA (142).  
A key mediator of changes in metabolic gene expression, the PPAR signaling 
pathway was significantly enriched by exposure to Dex in both Om and Abdsc. The fold 
changes in these genes tended to be higher in Om, but the Depot*[Dex] interaction term 
was not significant. Expression levels at all concentrations of Dex were higher in Abdsc; 
PCK1, LPL, ACADL, PLIN1, ME1, NR1H3 (also known as LXRA) and ACSL1 
contributed most highly to the enrichment of this pathway. Of interest for its known role 
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in adipocyte function (143), the KEGG retinol pathway was also upregulated by Dex in 
both depots. ADH1B, ADH1A, and ALDH1A1 were at the leading edge of this list in both 
depots; DGAT1, a key gene in the regulation of TAG synthesis, also contributed to the 
enrichment score for this pathway.  
Dex downregulated pathways: The most downregulated KEGG pathways 
common to Om and Abdsc depots were inflammatory and immune pathways; cytokine-
cytokine receptor interaction, chemokine signaling, intestinal immune network for IgA 
production, leukocyte transendothelial migration, antigen processing and presentation and 
Toll-like receptor signaling. Dex also downregulated TGFβ as well as JAK-STAT 
signaling pathways in both depots. Pathways related to ECM including ECM receptor 
interaction, cell adhesion molecules, focal adhesion, and axon guidance were also 
downregulated by Dex. A number of transcripts on these lists with the highest negative 
enrichments have been implicated in adipose tissue inflammation and ECM remodeling, 
for example, Dex markedly downregulated TNC (144), which topped the ECM receptor 
interaction list in both depots (normalized enrichment score (NES) -5.0 in Abdsc and -5.7 
in Om at 10 nM Dex, both p<0.0001). Table 2.4B lists the KEGG pathways identified as 
significantly downregulated in both depots at each concentration of Dex (FDRq for main 
effect of Dex < 0.05). 
 
Depot-dependent effects of Dex in Om or Abdsc   
Two pathways were clearly upregulated by Dex only in Om but not Abdsc, 
steroid biosynthesis, which is of interest from the point of view of cholesterol and cortisol 
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synthesis within adipose tissue, and the pentose phosphate pathway (Table 2.4C). The 
latter is important in generating reducing equivalents for de novo FA synthesis and 
steroid synthesis (e.g. H6PDH).  
Several downregulated pathways were clearly affected in Abdsc but not Om, 
depending on Dex concentration (Table 2.4C). Transcripts involved in ubiquitin-
mediated proteolysis, pyrimidine metabolism, homologous recombination and purine 
metabolism pathways were clearly downregulated by as little as 1 nM in Abdsc, but even 
higher concentrations of Dex had no effect in Om. The cell cycle pathway was also 
highly downregulated in Abdsc by as little as 1 nM Dex, and Om responded only to 1000 
nM Dex. Together these data suggest that culture with even very low concentrations of 
Dex decreases cellular stress in Abdsc, but much higher concentrations are required in 
Om.  
qPCR verification of depot-dependent responses to Dex: Results for PCK1 and 
LPL, two key enzymes that regulate TAG storage in adipocytes, were verified by qPCR 
(using non-pooled samples from 5-7 subjects, Figure 2.1). Similar to the microarray 
results, baseline levels of PCK1 and LPL mRNA were higher in Abdsc. In addition, the 
sensitivity to 1 nM Dex and the magnitude of the response was higher in Abdsc for 
PCK1, but similar in the two depots for LPL. These results suggest that Dex, when added 
together with a relatively low concentration of insulin, leads to the upregulation of 
PPARγ signaling and therefore to a coordinated increase in the expression of key genes 
that regulate de novo lipogenesis and FA activation. The differential sensitivity of PCK1 
in Om vs. Abdsc contrasted with the similar dose-dependent increase in GILZ mRNA, a 
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known direct target of GCs via GR. Also shown in Figure 2.1, as expected (54, 145), 
there was higher expression of IL-6 in Om at baseline. Despite a larger absolute decrease 
in its expression in Om (145), sensitivity to submaximal Dex, as a % of the maximal 
response at each concentration, was not significantly different between the two depots 
(not shown), reinforcing the concept of pathway dependent differences in sensitivity and 
responsiveness to Dex of both metabolic and inflammatory signaling.   
 
Figure 2.1. qPCR verification of concentration- and depot-dependent effects of 
glucocorticoids on selected, known glucocorticoid target genes. (A) PCK1, (B) LPL, 
(C) GILZ, and (D) IL-6. Data are mean ± SEM, n=5-7 independent subjects. The X-axis 
is a log scale. Significant depot differences at each [Dex] are indicated by an asterisk (*, 
p < 0.05, paired t-test of log transformed values). Repeated measures ANOVA verified a 
significant Dex effect in both depots for each gene (Dex effect, p ≤ 0.002). All doses in 
both Om and Abdsc were significantly different from 0 nM Dex (p ≤ 0.05, Dunnett’s 
test). 
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Cluster analysis revealed interactions of Depot and Dex concentration on adipose 
tissue gene expression.  
One-way clustering: To identify patterns of depot-dependent Dex effects among those 
transcripts that exhibited a Depot*[Dex] interaction (FDRq < 0.05) in the LME, we 
performed cluster analysis. Depot differences in the direction, sensitivity and magnitude 
of response within each cluster has the potential to suggest gene networks that are 
regulated in a coordinated fashion and co-factors that target them. This unbiased analysis 
also has the potential to identify previously unrecognized roles for GC-regulated 
pathways that may influence GC-mediated depot-differences in adipose tissue function.  
Using one-way clustering of expression values scaled across both depots, ten 
clusters were identified; each was characterized by combinations of depot differences in 
baseline values and/or the magnitude and direction of concentration dependence of the 
Dex effect. Figure 2.2 shows a parallel plot that illustrates these patterns. Complete gene 
lists for the cluster analysis are given in Table 2.5. Table 2.2 highlights depot differences 
in Dex effects for selected genes of interest from the viewpoint of adipose tissue 
metabolism, remodeling, inflammation and adipogenesis. These were selected based on 
1) at least a ~2-fold response in one depot with a clearly lower in magnitude, non-
existent, or opposite to the direction of the response in the other depot, or 2) depot 
differences in sensitivity to a submaximal concentration of Dex (1 nM) in one depot but 
not the other. In addition, this analysis highlighted transcripts that were regulated by Dex, 
but have not previously studied in the context of this tissue.  
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Figure 2.2. Parallel plot illustrating the cluster analysis of genes that exhibited a 
Depot*[Dex] interaction. 460 genes that showed a significant interaction of Depot and 
[Dex], and expression values above a threshold of 20 for at least one Dex concentration 
in one depot were included in an unsupervised hierarchical cluster analysis (JMP 10 
software), as described in Methods. The analysis with 10 clusters is shown.  
 
 
 
Table 2.2 Transcripts of interest from the cluster analysis of significant Depot*[Dex] 
interactions  
CLUSTER PATTERN 
GENES OF 
INTEREST 
B IOLOGICAL PROCESS 
IMPLICATED 
1 Similar baseline; Dex 
upregulated, greater 
sensitivity and response in 
Abdsc 
CYP4B1, 
CYP4F22, 
CYP4X1, 
CYP4Z1 
FA, steroid, lipid, 
xenobiotic metabolism 
(146) 
2 Lower baseline in Om; Dex 
upregulated, lower sensitivity 
and greater response in Om 
CD10 (MME) Adipose stem cell marker 
(147) 
ENPP2 
(autotaxin) 
Anti-adipogenic (148) 
  
39 
3 Similar baseline; Dex 
upregulated, greater 
sensitivity in Abdsc 
LEP Adipokine 
4 Similar baseline; Dex 
upregulated in Om, no 
response in Abdsc 
MUC16 ECM, PM (149) 
MMRN1  PM adhesion/ coagulation 
(150) 
ITLN1 Inflammation/adipokine 
(151) 
ACSM3, 
AGPAT9 
TAG synthesis (152)  
5 Similar or higher baseline in 
Abdsc; Dex upregulated in 
Om, downregulated in Abdsc 
FADS1 Delta 5 fatty acid 
desaturation 
GPC4 
 
Proadipogenic; insulin 
signaling; ECM, PM (153) 
6 Higher baseline in Om; Dex 
downregulated in Om, no 
effects in Abdsc 
PI15 ECM, peptidase inhibitor 
TNFRSF21, 
LEPR 
ECM, cytokine-related 
DDIT4 Inhibits TORC1 signaling 
(154) 
THBS2 ECM-receptor interaction, 
focal adhesion; potential 
role in adipogenesis (155) 
7 Similar baseline; Dex 
downregulated, greater 
sensitivity and response in 
Abdsc 
LTBP1 ECM, inhibits TGFβ 
signaling  
BGN  in obesity (BGN), 
adipose inflammation (156) 
THBS1 Regulates adipose 
expansion (157) 
8 Higher baseline in Om; Dex 
downregulated in Om, lower 
or little response in Absc 
WNT4 
 FLT1     
Pro-adipogenic (158) 
PM, pro-angiogenic; 
improved insulin action 
(159) 
GPR116 Cell adhesion, promotes 
insulin sensitivity (160) 
INHBB Decrease lipolysis (161) 
LOXL2 Fibrosis (162) 
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9 Similar baseline; 1 nM Dex 
slightly downregulated in Om, 
upregulated in Abdsc 
NRN1 Expressed in human  
adipose progenitors (147) 
HOXC8, 
HOXC9 
 
Developmental/higher in 
Abdsc (fresh tissue) (163) 
DKK2 Inhibits WNT signaling 
(proadipogenic) 
 
10 
Higher baseline in Abdsc; 
Dex downregulated in Abdsc, 
lower response in Om 
GREM2 Stimulates Wnt signaling 
(anti-adipogenic) (164) 
CCL13 Inflammation/increased in 
obesity (165) 
DDIT1L Inhibits cell growth, TOR 
signaling pathway (166) 
 
Transcripts were selected for inclusion in this Table if they exhibited a consistent ~2-fold 
change in one depot and the literature suggests that they may play a role in mediating 
depot differences in fat accumulation or depot-dependent function. Potential biological 
pathways/processes that may be modulated by each gene product were based on our 
review of the literature (Pubmed searches on the gene name and the search terms 
“adipose OR adipocyte”) and/or information in www.genecards.org. The complete lists 
of genes are in Table 2.5. Plasma membrane (PM) or ECM localization of gene products 
is noted. 
 
Two-way clustering: Two-way clustering (Depot and [Dex]) indicated that overall, 
values for both Om control and Om Dex 1 nM clustered with Abdsc control (0 Dex). This 
finding indicates that Om 1 nM values were more similar to Om control (0 Dex), but that 
Abdsc cultured with 1 nM Dex was different from Abdsc control and clustered with 
Abdsc 10 and 1000 nM and is consistent with the conclusion that overall Om is less 
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sensitive to a low concentration of Dex. The two-way clustered dendrogram is shown in 
Figure 2.S1. 
 
qPCR verification of transcripts showing depot-dependent responses to Dex in 
organ culture.  
Using individual samples from 5-7 subjects, we verified (with qPCR) depot 
differences in the Dex regulation of two genes that were much more highly expressed at 
baseline in Om and remained higher despite suppression by Dex (INHBA and GREM1, 
Fig 2.3A and B), and two genes that were expressed at very low levels in Abdsc and 
increased by Dex only in Om (PKHD1L1 and ITLN1, Fig 2.3C and D). Additionally, we 
confirmed the clear interaction of Depot*[Dex] for ITGB8 (Fig 2.3E). This gene was 
suppressed by Dex only in Abdsc, while it tended to increase in response to increasing 
Dex in Om, creating a depot difference at the higher Dex concentrations. We also verified 
that NRN1 mRNA levels were very low in Om and increased by Dex only in Abdsc (Fig 
2.3F).  
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Figure 2.3. qPCR verification of selected depot-dependent Dex effects. Transcripts for 
verification were selected for biological interest, large depot differences in the baseline 
values and/or the magnitude of the Dex effects: (A) INHBA, (B) GREM1, (C) PKHD1L1, 
(D) ITLN1, (E) ITGB8 and (F) NRN1. Depot differences are indicated by asterisks (*p < 
0.05, paired t-test at each Dex concentration). Within depot, Dex effects were tested by 
repeated measures ANOVA on log-transformed data (p values indicated in the box on 
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each graph). Post-hoc comparisons of values at each Dex concentration compared to 
baseline (0 Dex) were carried out by Dunnett’s tests. Within Abdsc, Dex effects were 
significant for INHBA at Dex concentrations of 10 nM or higher, ITGB8 at 25 and 1000 
nM and NRN1 at 1, 10 and 25 nM. Within Om, Dex effects were significant for 
PKHD1L1 at Dex concentrations of 10 nM and higher and ITLN1 at 25 and 1000 nM. 
Because of missing values for Om for INHBA, only paired t-tests were used to test the 
effect of each Dex concentration vs. baseline [p=0.051 at 1 nM (n=6), p<0.01 at 10 nM 
(n=5), 25 and 1000 nM (n=6)].  
 
Transcripts that showed depot-differences in response to Dex also exhibit depot-
differences in fresh adipose tissue.   
To determine if our results in tissues cultured with Dex for 7 days ex vivo were 
relevant to the in vivo, we examined expression levels in tissues that were snap frozen 
immediately after excision. We reasoned that genes that were more highly expressed in 
one depot at baseline (INHBA, GREM1, and NRN1), and those for which a clear depot-
difference was induced by culture with Dex (ITLN1, PKHD1L1, ITGB8, and NRN1) 
would also exhibit depot-difference in fresh adipose tissues. Fig 2.4 shows that genes that 
showed large differences after 7d of culture with Dex, INHBA, GREM1, PKHDL1, 
ITLN1, and ITGB8, were also higher in snap frozen Om, while NRN1, which was 
increased by Dex only in Abdsc, was substantially higher in fresh Abdsc tissue.  
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Figure 2.4. Depot differences in flash frozen samples of Om and Abdsc reflect 
patterns observed in tissues cultured with Dex. (A) INHBA, (B) GREM1, (C) 
PKHD1L1, (D) ITLN1, (E) ITGB8, and (F) NRN1. *p < 0.05, depot difference (paired t-
tests of log transformed values, n=6). Data presented as mean ± SEM.  
 
DISCUSSION 
Although there are some developmental similarities between rodent and human 
visceral depots, there are also notable differences (167). Thus, studies of mechanisms that 
lead to depot differences in human adipose tissue biology are especially important. The 
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analyses presented here clearly demonstrate the depot-dependence of GC action on gene 
expression in human visceral (Om) compared to Abdsc adipose tissues. Using organ 
culture as a model system to define the long-term effects of Dex on the transcriptome of 
human Om and Abdsc adipose tissue, these analyses suggest potential novel molecular 
mechanisms underlying a broad range of well-established differences between the two 
depots and point to their differential regulation by GCs. These depot differences include 
the higher inflammatory profile in Om adipose tissue, the lower adipogenic potential of 
Om preadipocytes, and the preferential accumulation of visceral fat with 
hypercortisolemia in vivo.  
The current dataset and pathway (GSEA) analyses confirm and expand our prior 
observations that many metabolic (e.g. amino acid catabolism, tricarboxylic acid cycle, 
lipogenesis) and immune-related pathways are regulated similarly by Dex in both depots. 
More importantly, with the mixed model statistical approach and cluster analysis of dose-
dependent changes in the adipose tissue transcriptome, we were able to identify depot-
dependent differences in genes and pathways that vary in sensitivity to low Dex 
concentrations and others that exhibit depot differences in the magnitude or direction of 
the Dex effects. We verified with qPCR that selected transcripts showing depot-
dependent responses to Dex in vitro (INHBA, GREM1, ITGB8, ITLN1, PKHD1L1, 
NRN1) also showed substantial depot differences in fresh tissues, supporting the 
physiological relevance of the organ culture approach and the important roles of GCs in 
driving depot differences in adipose tissue function. These results were easily detected 
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with a small sample size of almost exclusively female obese subjects, indicating the 
differences are robust and consistent.  
Dex promotion of transcripts which may modulate adipogenesis and expansion 
capacity in Om vs. Abdsc: Excess GCs lead to the expansion of central, especially 
visceral adipose tissues, but the mechanisms remain poorly understood. Available data 
indicate that increases in both adipocyte number and size contribute to this adipose 
expansion (78, 168), and that a limitation on hyperplastic expansion is associated with 
excess hypertrophy, which in turn is associated with adipose tissue inflammation as well 
as adipocyte and systemic metabolic dysfunction. Our data suggest that multiple 
pathways that regulate adipogenesis and fat accumulation, including insulin signaling and 
TAG synthesis, are depot-dependently regulated by Dex in a coordinated fashion to favor 
the hypertrophic expansion of Om.   
Adipogenesis: Transcript levels of autotaxin/ENPP2 mRNA (cluster 2), which 
inhibits adipogenesis via increased production of lysophosphatidic acid (148), was 
increased by Dex in Om but unaffected in Abdsc. Additionally, the DKK2 transcripts 
(cluster 9), a factor which inhibits canonical anti-adipogenic WNT signaling, were 
expressed at very low levels in Om and were unaffected by Dex, while Dex increased 
DKK2 expression in Abdsc, potentially promoting hyperplasia in this depot. Although 
Dex downregulated the mRNA expression of key ligands that activate TGFβ receptor 
signaling (INHBA and TGFβ) and thereby inhibit adipogenesis (119, 169), they remained 
higher in Om compared to Abdsc adipose tissue cultured with Dex, especially at 
submaximal concentrations. Thus, if translated into a functional effects, these Dex-
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induced alterations in gene expression may mediate depot-dependent changes in 
hyperplastic expansion.  
Additional secreted factors that may regulate TGFβ signaling and enhance 
adipogenesis include, ITGB8 (170), LTBP1 (171) and BGN (172, 173) (Cluster 7). BGN 
also regulates WNT signaling (174) and adiponectin production (175). Dex decreased 
LTBP1 and BGN levels in Abdsc, so that after Dex treatment, their levels were over 2-
fold lower than in Om. However, TGFβ expression is higher in Om, so its free 
concentration may still be higher in this depot. The importance of Dex in the modulation 
of TGFβ activity in adipose tissues by these abundant ECM proteoglycans merits further 
study.     
Dex promotion of omental fat accumulation: Our results highlight several pathways 
by which Dex could promote the preferential fat storage in visceral depots. Dex enhanced 
the expression of multiple transcripts that may promote TAG synthesis in both depots. 
Dex increased the expression of GPC4 mRNA, which encodes a secreted factor 
(adipokine), only in Om (cluster 5). Based on studies in mouse adipocytes, GPC4 is 
thought to promote insulin sensitivity, and clinical studies suggest that higher expression 
of GPC4 is associated with higher waist-to-hip ratio and visceral to Abdsc fat ratio in 
men (153). INHBB (cluster 8), which is increased by adipocyte differentiation and 
expressed by mature adipocytes and decreases lipolysis (161), was decreased by Dex 
only in Om, resulting in higher levels in Abdsc than Om (confirmed with qPCR, data not 
shown). INHBB expression was also higher in fresh Abdsc than Om adipose tissue (2.7 ± 
0.9 vs. 1.3 ± 0.6, relative expression by qPCR, p<0.05, n=6). At the same time, transcript 
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levels of genes likely involved in FA activation (ACSM3) and esterification (AGPAT9) 
(152) were increased by Dex only in Om (Cluster 4), which could balance the higher 
lipolysis. These changes are consistent with findings in mice which document that GCs 
promote high TAG turnover (69), and intriguingly suggest a viscerally specific effect that 
merits further investigation as a mechanism to link hypercortisolemia to visceral fat 
accumulation and metabolic dysregulation. Finally, in Abdsc compared to Om, Dex 
treatment led to a larger fold increase (1.6 fold in Om vs. 3.4 fold in Abdsc, p<0.05) of 
PPARGC1A, a transcriptional co-activator that plays a major role in increasing genes that 
regulate oxidative metabolism and thereby the metabolic health of adipocytes.  
Response to stress/mTOR signaling: Genes induced by cellular stress such as 
DDIT4L (REDD2), which inhibits mTORC1 (166), was more highly expressed at 
baseline in Abdsc and decreased by Dex in both depots. In addition, DDIT4 (REDD1) 
inhibits mTORC1 and is a negative regulator of insulin signaling (154), so its decrease by 
Dex in only Om is consistent with an enhancement of insulin action and lipogenesis in 
adipocytes. Overall these results suggest that Dex restrains the cellular stress in adipose 
tissue and thereby improves insulin action.  
Additional transcripts that encode factors that modulate lipid metabolism especially 
in Abdsc: A number of transcripts that regulate lipid metabolism were more potently 
induced by Dex in Abdsc. Three members of the Cytochrome P450, Family 4 (CYP4B1, 
CYP4F22 and CYP4X1) clustered together (Cluster 1). For example, CYP4B1 was 
expressed at a very low level under baseline conditions in Om and increased by Dex by 
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8-fold compared to 40-fold in Abdsc. These CYP4 genes have ill-defined roles in FA, 
steroid, lipid and xenobiotic metabolism (146).  
In addition to the similar Dex stimulation of genes encoding transcripts involved in 
the synthesis of very long chain fatty acids and delta 9 desaturation in Om and Abdsc, 
Dex differentially regulated FADS1 (delta 5 desaturase), which was increased by 50% in 
Om but decreased by 10% in Abdsc, and FADS2 (delta 6 desaturase), which did not 
change in Om and was decreased by Dex (30%) in Abdsc. Depot differences in the effect 
of Dex on these genes of FA metabolism have potential for regulating tissue FA 
composition, biophysical properties of membranes, and production of functionally 
important lipid mediators. 
Inflammation and immunity: Culture with Dex led to a more robust increase in 
Abdsc than Om of CD300LG which is implicated in T-cell recruitment (176) and 
P2RY14/GPR105 (Cluster 1) which modulates macrophage recruitment in diet-induced 
obesity (176-178). Cytokine-related genes (TNFRSF21, IL1RAP, TSLP, and LEPR) also 
followed this pattern, which is somewhat surprising given reports of higher inflammation 
in Om and Abdsc. STEAP4/STAMP2 mRNA, which decreases adipose inflammation and 
enhances adipocyte insulin sensitivity (179, 180), and is also important for promoting fat 
accumulation, was more responsive to Dex stimulation in Abdsc than Om (Cluster 1). 
The chemokine CCL13 (MCP-4) was more highly expressed in Abdsc at baseline and 
suppressed by Dex only in that depot (181). Taken together, there data suggest the depot 
differences in mechanisms by which GCs regulate inflammatory pathways and immune 
cell recruitment.    
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Dex induced a cluster of genes only in Om: Of the 20 genes in Cluster 4, 7 had 
similar levels of baseline expression and showed a clear dose-dependent increase in 
response to increasing concentrations of Dex in Om, but no response to Dex in Abdsc 
(MUC16, ART4, MMRN1, and MUM1L1). ITLN1 (omentin), a gene which is documented 
to be specific for visceral adipose tissue (151), also displayed this pattern (confirmed by 
qPCR, Figs 2.3 and 2.4). Genes that were much more highly expressed in Om included 
mesothelin, a marker of mesothelial cells, as previously observed by others (182). 
MUC16, MMRN1, ITLN1, and IL-18 were also upregulated by Dex in Om and are known 
to be more abundantly expressed in fresh-frozen Om than Abdsc samples ((151, 183) and 
our unpublished data). Mucin 16 is a cell surface receptor involved in cell adhesion 
whose extracellular domain is secreted and is known to bind to mesothelin, a cell surface 
protein on mesothelial cells (149). Further studies of the importance of mesothelial cells 
in the biology of human visceral adipose tissue are warranted, especially in view of a 
recent lineage tracing study which indicates that adipocytes in visceral depots derive from 
a mesothelial lineage in mice (184).  
Cell adhesion and/or migration: A number of genes in Cluster 6 were higher at 
baseline and decreased by Dex in Om, but were affected little by Dex in Abdsc. 11 genes 
in this list were functionally classified as being involved in cell adhesion and/or 
migration (DAVID analysis) (185, 186) including GPR56, AMIGO2, CDH2, CLSTN1, 
and THBS2. In addition, GPR116, which suppresses cell migration was higher in Om at 
baseline and yet more robustly downregulated by low Dex concentrations. Overall, these 
data indicate that Dex has depot-dependent effects on cell adhesion and migration 
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pathways and thus potentially on immune function and other processes that affect 
inflammation and remodeling.  
Additional transcripts regulated in a Depot-specific and Dex-dependent manner: 
PI15 (peptidase inhibitor 15, also known as protease inhibitor 15 and CRISP8) is a 
trypsin inhibitor that was expressed at fairly high levels and dose-dependently and 
markedly decreased by Dex (by ~10-fold) in Om, while it was very low at baseline and 
decreased only ~2-fold in Abdsc. Little is known about this gene, and nothing about its 
function in adipose tissue, but it was identified as a gene with a glucocorticoid binding 
region by ChIP-seq in 3T3-L1 adipocytes (69). Cluster 9 included 50 genes that were 
higher in Abdsc than Om at baseline. Especially dramatic was NRN1 (Neuritin 1). Its 
expression was ~6-7 fold lower and unchanged by Dex in Om, while in Abdsc it was 
dose-dependently increased (2-fold), resulting in a ~12 fold depot difference at maximal 
Dex (as verified by qPCR, Fig 2.3F). Very little is known about this gene other than it is 
likely GPI-anchored to the plasma membrane and expressed in the central nervous system 
where it promotes neurite outgrowth (187) and is induced by hypoxia in tumors (188). 
PKHD1L1 was increased by Dex only in Om to fairly high levels (Fig 2.3), but little is 
known of its function in any context.  
A limitation of this study is that the number of subjects studied in the initial 
microarray was small (n=3 representing a total of 5 subjects), all were severely obese, 
and 6/7 were women. However, results were robust and key findings were easily 
confirmed with n=5-7 by qPCR. These studies were not powered to detect differences in 
sensitivity or responsiveness to Dex effects between lean vs. obese or female vs. males. 
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Further studies are needed to verify additional genes of interest and assess how depot-
dependent Dex action varies as a function of level of adiposity, age, sex, fat distribution 
and metabolic status. An additional limitation of our studies was that we only tested Dex, 
and not cortisol, the physiological ligand, which acts on both MR and GR. We chose 
Dex, a specific type II GR agonist, to avoid potential confounds of depot differences in 
cortisone/cortisol activation and inactivation (72). In one of the subjects, we performed 
microarray study comparing the effects of cortisol (200 nM) and Dex in both Om and 
Abdsc, found that that effects are similar and in fact the correlation of the microarray data 
for cortisol (200 nM) and Dex (10 nM) was over r=0.95. 
It is important to note that our organ culture system includes insulin (0.7 nM), and 
we and others find the combination of insulin and Dex best promotes the expression of 
genes that regulate fat metabolism and adipokines (54, 56). A recent ChIP study in 
human adipose tissue cultured with Dex but without insulin reported similar results with 
regard to inflammation pathways, but did not observe changes in de novo lipogenic and 
TAG synthesis pathways (70). 
In summary, this study reinforces our knowledge of the pleiotropic effects of GCs 
on transcripts expressed in two major human adipose tissues, and points to the need for 
understanding gene- and cell-dependent variations in sensitivity to GC action. The 
mechanistic basis for the differential sensitivity and responsiveness to GCs in each cell 
type is likely to occur via differences in the level of transcriptional co-activators and co-
repressors, as well as changes in GR phosphorylation that may depend on the level of 
inflammation (48, 189). Our group has found that phosphorylation of GR at serine 226 is 
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higher in Om vs. Abdsc adipose tissue (Lee MJ and Fried SK, unpublished observation) 
which may contribute to the lower sensitivity to GCs in the former. Additionally, because 
adipose tissue includes multiple cell types, it is tempting to speculate that cell-specific 
actions of GCs via GR contribute to depot differences in their function. These hypothesis-
generating analyses emphasize the need to determine the cell types that express the 
secreted factors, establish which effects are cell autonomous, define the Dex-regulated 
components of the ECM that contribute to the microenvironment within specific visceral 
and sc depots, and determine their functional roles as well as which transcripts are direct 
vs. secondary targets of GCs/GR (109). Future studies of the importance of GCs in 
modulating the pathways predicted to contribute to each depot’s unique functions and 
expansion capacity have clear potential for understanding of human fat distribution and 
its impact on metabolic health.    
 
Supporting Information 
Table 2.3. Expression values for all transcripts in the microarray. Averages of 
expression values (linear scale) at each Dex concentration are given (average values of 
n=3 subjects). FDRq for LME parameters (Depot, [Dex], and Depot*[Dex] interaction) 
are given for each gene. Can be downloaded using this link: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179014/bin/pone.0167337.s002.xlsx 
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Table 2.4A: Pathways upregulated by Dex in both depots 
 
 
 
NAME SIZE NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 42 4.2 0.000 5.0 0.000 4.8 0.000 3.3 0.000 4.2 0.000 4.0 0.000
KEGG_PROPANOATE_METABOLISM 29 4.0 0.000 4.5 0.000 4.4 0.000 3.4 0.000 3.8 0.000 3.7 0.000
KEGG_OXIDATIVE_PHOSPHORYLATION 106 3.1 0.000 4.4 0.000 3.7 0.000 2.6 0.001 3.0 0.000 2.6 0.031
KEGG_FATTY_ACID_METABOLISM 35 3.7 0.000 4.4 0.000 4.1 0.000 3.3 0.000 3.3 0.000 3.2 0.001
KEGG_CITRATE_CYCLE_TCA_CYCLE 29 4.3 0.000 4.3 0.000 4.3 0.000 3.1 0.000 3.8 0.000 3.4 0.001
KEGG_BUTANOATE_METABOLISM 26 3.7 0.000 4.3 0.000 4.2 0.000 3.2 0.000 3.5 0.000 3.3 0.001
KEGG_RIBOSOME** 74 4.1 0.000 3.9 0.000 3.1 0.000 -2.0 0.018 -2.1 0.010 -2.1 0.013
KEGG_PYRUVATE_METABOLISM 35 3.4 0.000 3.9 0.000 4.1 0.000 3.2 0.000 3.5 0.000 3.2 0.001
KEGG_PEROXISOME 69 2.8 0.000 3.9 0.000 3.7 0.000 2.6 0.001 3.1 0.000 3.1 0.004
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 49 2.8 0.000 3.7 0.000 3.7 0.000 2.4 0.002 2.8 0.001 2.6 0.032
KEGG_BETA_ALANINE_METABOLISM 19 2.9 0.000 3.5 0.000 3.4 0.000 2.6 0.001 2.7 0.002 2.6 0.031
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 45 3.5 0.000 3.5 0.000 2.9 0.001 2.7 0.000 2.8 0.000 2.6 0.032
KEGG_TYROSINE_METABOLISM 34 2.7 0.000 3.3 0.000 3.3 0.000 2.5 0.001 2.6 0.003 2.6 0.032
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 40 2.6 0.000 3.3 0.000 2.9 0.001 2.9 0.000 3.4 0.000 3.0 0.007
KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS 21 3.0 0.000 3.3 0.000 3.2 0.000 2.0 0.020 2.7 0.002 2.4 0.039
KEGG_RETINOL_METABOLISM 30 2.8 0.000 3.2 0.000 3.3 0.000 2.9 0.000 3.2 0.000 3.2 0.001
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME _P450 37 2.1 0.013 2.9 0.000 2.8 0.002 2.4 0.002 2.9 0.000 2.6 0.031
KEGG_PPAR_SIGNALING_PATHWAY 54 2.6 0.001 2.8 0.001 2.8 0.002 2.8 0.000 2.8 0.001 2.2 0.055
KEGG_ARGININE_AND_PROLINE_METABOLISM 47 1.9 0.039 2.7 0.001 2.3 0.018 1.6 0.128 1.8 0.093 1.7 0.144
KEGG_TRYPTOPHAN_METABOLISM 35 2.8 0.000 2.5 0.003 2.1 0.033 2.4 0.003 2.4 0.008 2.4 0.039
KEGG_INSULIN_SIGNALING_PATHWAY 129 1.8 0.057 2.5 0.004 2.9 0.001 2.5 0.001 3.4 0.000 3.3 0.001
KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM 23 1.9 0.041 2.5 0.004 2.1 0.033 1.8 0.043 2.0 0.050 1.5 0.210
KEGG_GLYCEROLIPID_METABOLISM 40 2.0 0.030 2.5 0.005 2.4 0.013 2.0 0.026 1.9 0.067 1.8 0.108
KEGG_STARCH_AND_SUCROSE_METABOLISM 26 2.1 0.012 2.4 0.007 2.6 0.004 2.3 0.005 3.3 0.000 3.4 0.001
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 28 2.4 0.002 2.4 0.007 2.3 0.020 2.3 0.004 2.3 0.013 2.6 0.032
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM 28 2.3 0.005 2.4 0.009 2.2 0.025 1.9 0.036 1.6 0.145 1.9 0.096
KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY 61 1.6 0.150 2.3 0.010 2.4 0.011 2.2 0.007 2.8 0.000 2.7 0.033
KEGG_PHENYLALANINE_METABOLISM 16 1.7 0.076 2.2 0.024 2.2 0.024 1.9 0.033 2.2 0.027 2.2 0.052
KEGG_GLYCEROPHOSPHOLIPID_METABOLISM 70 1.8 0.051 2.1 0.029 2.1 0.033 1.8 0.047 1.7 0.134 1.7 0.145
KEGG_CARDIAC_MUSCLE_CONTRACTION 54 1.7 0.079 2.1 0.029 2.0 0.044 2.3 0.006 1.8 0.106 1.6 0.173
KEGG_LYSINE_DEGRADATION 43 1.5 0.166 2.1 0.031 2.0 0.043 1.3 0.317 2.0 0.056 1.5 0.219
KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION 21 1.3 0.281 1.8 0.080 2.1 0.035 2.6 0.001 2.3 0.011 2.3 0.043
KEGG_ABC_TRANSPORTERS 35 1.4 0.211 1.8 0.089 2.2 0.022 1.8 0.049 2.3 0.011 2.3 0.043
AbdscID1000OMID1 OMID10 OMID1000 AbdscID1 AbdscID10
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Table 2.4B: Pathways downregulated by Dex in both depots 
 
 
 
 
 
NAME SIZE NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 183 -4.3 0.000 -5.2 0.000 -4.9 0.000 -2.9 0.000 -3.6 0.000 -4.0 0.000
KEGG_ECM_RECEPTOR_INTERACTION 76 -2.6 0.004 -3.7 0.000 -3.3 0.000 -1.8 0.036 -3.0 0.000 -3.0 0.000
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA _PRODUCTION 37 -2.5 0.005 -3.6 0.000 -3.2 0.000 -1.8 0.041 -3.0 0.000 -3.0 0.000
KEGG_GRAFT_VERSUS_HOST_DISEASE 26 -3.3 0.000 -3.6 0.000 -3.4 0.000 -2.7 0.000 -3.3 0.000 -3.4 0.000
KEGG_CELL_ADHESION_MOLECULES_CAMSKEGG_CELL_ADHESION_MOLECULES_CAMS 106 -2.7 0.001 -3.5 0.000 -3.0 0.000 -2.0 0.012 -3.1 0.000 -3.1 0.000
KEGG_FOCAL_ADHESION 185 -2.4 0.007 -3.4 0.000 -2.9 0.001 -2.3 0.003 -2.5 0.001 -2.6 0.002
KEGG_ALLOGRAFT_REJECTION 26 -3.0 0.001 -3.3 0.000 -3.1 0.000 -2.4 0.002 -2.9 0.000 -3.0 0.000
KEGG_HEMATOPOIETIC_CELL_LINEAGE 60 -2.6 0.004 -3.1 0.000 -3.3 0.000 -2.6 0.000 -2.7 0.000 -3.0 0.000
KEGG_AXON_GUIDANCE 117 -2.8 0.001 -3.1 0.000 -2.9 0.001 -2.1 0.006 -2.6 0.000 -2.5 0.002
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 93 -1.9 0.066 -2.9 0.000 -3.2 0.000 -2.0 0.011 -2.7 0.000 -2.9 0.000
KEGG_OLFACTORY_TRANSDUCTION** 81 -1.0 0.579 -2.9 0.000 -1.2 0.335 2.3 0.005 1.6 0.149 1.7 0.141
KEGG_TGF_BETA_SIGNALING_PATHWAY 80 -1.9 0.053 -2.7 0.001 -2.6 0.006 -2.4 0.002 -2.6 0.000 -2.5 0.002
KEGG_JAK_STAT_SIGNALING_PATHWAY 110 -2.5 0.006 -2.6 0.001 -2.8 0.002 -1.8 0.040 -1.7 0.050 -1.9 0.027
KEGG_CHEMOKINE_SIGNALING_PATHWAY 158 -1.7 0.115 -2.5 0.002 -2.6 0.004 -1.6 0.083 -2.1 0.007 -2.6 0.001
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 55 -2.2 0.021 -2.5 0.002 -2.8 0.002 -2.6 0.000 -2.8 0.000 -2.8 0.000
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 193 -2.2 0.017 -2.4 0.004 -2.5 0.009 -2.3 0.002 -2.5 0.001 -2.7 0.000
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 59 -1.6 0.129 -2.3 0.005 -3.0 0.000 -2.5 0.000 -2.7 0.000 -3.1 0.000
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 84 -1.6 0.125 -2.3 0.006 -2.7 0.003 -2.2 0.004 -2.7 0.000 -2.6 0.001
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 95 -1.5 0.157 -2.3 0.008 -2.5 0.008 -1.3 0.200 -1.4 0.206 -2.1 0.017
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE 22 -2.1 0.024 -2.2 0.009 -1.7 0.086 -1.4 0.151 -1.8 0.035 -1.7 0.060
KEGG_ADHERENS_JUNCTION 70 -1.7 0.107 -2.1 0.015 -2.3 0.016 -2.1 0.007 -1.6 0.072 -1.8 0.037
KEGG_DORSO_VENTRAL_AXIS_FORMATIONKEGG_DORSO_VENTRAL_AXIS_FORMATION 21 -1.6 0.136 -2.1 0.018 -1.8 0.061 -1.9 0.026 -1.6 0.083 -1.8 0.042
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN _SULFATE 22 -1.8 0.074 -2.1 0.019 -1.6 0.118 -1.1 0.361 -1.8 0.038 -1.7 0.061
KEGG_SPLICEOSOME * 120 -2.3 0.010 2.0 0.037 -2.0 0.033 -5.1 0.000 -3.3 0.000 -3.1 0.000
KEGG_DILATED_CARDIOMYOPATHY 75 -1.4 0.217 -1.9 0.042 -1.8 0.070 1.4 0.219 -1.7 0.053 -1.7 0.054
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 38 -1.1 0.496 -1.8 0.061 -2.3 0.015 -1.7 0.047 -2.0 0.015 -2.2 0.008
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 178 2.7 0.000 -1.8 0.083 -1.6 0.124 4.5 0.000 2.1 0.041 2.1 0.069
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 91 -1.1 0.495 -1.4 0.228 -1.9 0.048 -1.6 0.079 -1.0 0.502 -1.6 0.088
KEGG_DNA_REPLICATION 35 -1.0 0.521 1.5 0.249 -2.0 0.034 -4.0 0.000 -3.4 0.000 -3.3 0.000
KEGG_CALCIUM_SIGNALING_PATHWAY 144 2.1 0.016 1.0 0.635 1.0 0.532 1.9 0.028 1.4 0.324 1.4 0.296
KEGG_CELL_CYCLE 115 0.9 0.727 -0.7 0.924 -2.6 0.004 -4.2 0.000 -4.1 0.000 -3.9 0.000
AbdscID1000OMID1 OMID10 OMID1000 AbdscID1 AbdscID10
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Table 2.4C: Pathways regulated by Dex only in 1 depot 
 
Table 2.4. Lists of pathways identified by GSEA as up- or down-regulated by each concentration of Dex in both depots 
(Tables 2.4A & 2.4B, respectively, sorted by NES in OMID10), or only in 1 depot by Dex (Table 2.4C, sorted by NES in 
AbdscID1). Gene lists for each depots were preranked by fold change vs. 0 nM Dex and analyzed by GSEA, as described in 
Methods. FDRq values < 0.05 were considered statistically significant. Light blue highlights FDRq values < 0.1 in Om, dark 
blue highlights FDRq values <0.05, light pink highlights FDRq values <0.1 in Abdsc, dark pink highlights FDRq values <0.05 
in Abdsc.
DOWNREGULATION
NAME SIZE NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val
KEGG_RNA_DEGRADATION 56 -1.7 0.112 1.4 0.316 -1.6 0.131 -3.0 0.000 -2.2 0.005 -2.2 0.012
KEGG_PROTEASOME 40 -1.7 0.093 1.1 0.488 -1.7 0.091 -3.3 0.000 -2.7 0.000 -2.8 0.000
KEGG_MISMATCH_REPAIR 22 -1.5 0.192 1.1 0.530 -1.5 0.171 -2.7 0.000 -2.6 0.000 -2.4 0.005
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 131 -1.3 0.285 1.1 0.547 -1.0 0.542 -2.7 0.000 -1.4 0.182 -1.1 0.370
KEGG_PYRIMIDINE_METABOLISM 93 -0.9 0.649 1.3 0.336 -0.7 0.844 -2.4 0.001 -2.4 0.002 -2.0 0.017
KEGG_HOMOLOGOUS_RECOMBINATION 25 0.6 0.950 1.0 0.619 -1.3 0.274 -2.4 0.002 -2.0 0.014 -2.1 0.016
KEGG_PROTEIN_EXPORT 21 -1.6 0.133 -1.1 0.534 -1.5 0.181 -2.2 0.003 -1.8 0.035 -1.7 0.063
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 53 -1.0 0.564 -1.1 0.455 -1.6 0.132 -2.0 0.013 -1.7 0.057 -1.8 0.042
KEGG_OOCYTE_MEIOSIS 101 1.0 0.618 0.8 0.824 -1.1 0.404 -1.9 0.023 -1.7 0.064 -1.8 0.038
KEGG_P53_SIGNALING_PATHWAY 65 0.8 0.769 -1.0 0.643 -1.8 0.066 -1.8 0.030 -2.5 0.001 -2.7 0.001
KEGG_BASAL_TRANSCRIPTION_FACTORS 32 -1.6 0.135 1.4 0.320 -0.8 0.716 -1.8 0.041 -1.2 0.330 -1.4 0.183
KEGG_GAP_JUNCTION 78 -0.7 0.838 -1.2 0.372 -1.4 0.192 -1.7 0.046 -2.1 0.011 -2.2 0.011
KEGG_VEGF_SIGNALING_PATHWAY 70 -1.3 0.313 -1.9 0.051 -1.6 0.121 -1.0 0.534 -1.2 0.287 -1.3 0.245
KEGG_NOTCH_SIGNALING_PATHWAY 46 -1.3 0.309 -2.0 0.035 -1.8 0.058 -0.9 0.626 -1.2 0.303 -1.2 0.294
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND _NEOLACTO_SERIES 19 -1.6 0.128 -2.1 0.018 -1.5 0.174 0.8 0.783 -1.2 0.317 -0.8 0.703
UPREGULATION
KEGG_LINOLEIC_ACID_METABOLISM 16 1.2 0.401 1.2 0.467 1.4 0.281 2.1 0.014 1.0 0.645 1.1 0.476
KEGG_HISTIDINE_METABOLISM 25 1.4 0.260 2.0 0.051 2.0 0.041 1.5 0.163 1.7 0.142 1.7 0.123
KEGG_ONE_CARBON_POOL_BY_FOLATE 16 2.2 0.008 2.2 0.016 2.3 0.019 1.3 0.271 1.7 0.124 1.7 0.121
KEGG_GLUTATHIONE_METABOLISM 42 2.0 0.031 2.2 0.021 1.5 0.180 1.3 0.306 1.3 0.343 1.0 0.573
KEGG_STEROID_BIOSYNTHESIS 16 1.7 0.087 2.0 0.043 1.5 0.199 1.2 0.383 0.9 0.761 1.0 0.635
KEGG_PENTOSE_PHOSPHATE_PATHWAY 23 2.1 0.016 2.2 0.019 1.7 0.125 0.5 0.979 1.2 0.490 0.8 0.765
OMID1 OMID10 OMID1000 AbdscID1 AbdscID10 AbdscID1000
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SHC3 SHC (Src homology 2 domain containing) transforming protein 30.000 0.017 0.000 1 1 67 66 62 67 86 91 163 193
ISM1 isthmin 1 homolog (zebrafish) 0.000 0.150 0.002 1 1 28 26 26 25 38 36 57 60
DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila)0.000 0.002 0.002 1 1 183 172 179 206 196 225 296 302
CLEC3B C-type lectin domain family 3, member B 0.000 0.039 0.002 1 1 55 55 52 57 54 72 86 90
PKD1L2 polycystic kidney disease 1-like 2 0.000 0.000 0.002 1 1 26 28 28 34 30 42 56 71
RANBP3L RAN binding protein 3-like 0.000 0.001 0.010 1 1 11 12 13 15 13 15 32 43
CYP4Z1 cytochrome P450, family 4, subfamily Z, polypeptide 10.00 0.003 0.010 1 1 13 14 15 18 14 18 45 80
GIPR gastric inhibitory polypeptide receptor 0.002 0.081 0.012 1 1 73 74 68 74 68 86 92 101
CD300LG CD300 molecule-like family member g 0.000 0.010 0.014 1 1 48 53 48 57 52 71 100 120
P2RY14 purinergic receptor P2Y, G-protein coupled, 14 0.000 0.001 0.017 1 1 25 24 30 40 31 25 79 98
ANO3 anoctamin 3 0.000 0.005 0.018 1 1 19 19 19 24 29 31 72 106
C1QTNF7 C1q and tumor necrosis factor related protein 7 0.007 0.010 0.018 1 1 13 12 13 14 12 12 22 23
P2RY13 purinergic receptor P2Y, G-protein coupled, 13 0.000 0.000 0.022 1 1 12 16 17 18 20 23 51 39
HERC2 hect domain and RLD 2 0.001 0.032 0.029 1 1 100 99 97 104 100 104 119 121
AK5 adenylate kinase 5 0.001 0.314 0.030 1 1 18 18 18 15 23 19 37 51
CA4 carbonic anhydrase IV 0.002 0.018 0.030 1 1 39 38 35 42 37 45 59 90
VIPR1 vasoactive intestinal peptide receptor 1 0.000 0.000 0.043 1 1 37 45 44 60 46 59 96 115
FGFBP2 fibroblast growth factor binding protein 2 0.001 0.025 0.044 1 1 12 12 13 14 12 17 38 35
KLRG1 killer cell lectin-like receptor subfamily G, member 10.000 0.000 0.045 1 1 22 26 29 32 30 33 55 66
RGL3 ral guanine nucleotide dissociation stimulator-like 30.066 0.056 0.046 1 1 36 35 36 35 33 36 39 47
RAI2 retinoic acid induced 2 0.001 0.000 0.000 1 2 120 125 145 165 112 137 199 218
CYP4X1 cytochrome P450, family 4, subfamily X, polypeptide 10.002 0.000 0.000 1 2 39 46 51 66 40 47 122 188
TAF8 TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa0.000 0.000 0.000 1 2 230 225 254 249 224 257 303 329
OSR2 odd-skipped related 2 (Drosophila) 0.000 0.000 0.000 1 2 70 78 101 112 91 148 270 298
CLSTN2 calsyntenin 2 0.001 0.000 0.001 1 2 77 76 104 112 65 114 178 185
UBL4B ubiquitin-like 4B 0.000 0.000 0.001 1 2 15 17 18 22 17 23 37 38
KIAA0040 KIAA0040 0.000 0.000 0.001 1 2 108 131 165 220 129 276 597 764
TENC1 tensin like C1 domain containing phosphatase (tensin 2)0.000 0.000 0.001 1 2 249 296 356 402 234 356 486 536
WASF3 WAS protein family, member 3 0.000 0.000 0.002 1 2 328 336 409 444 352 498 669 711
RP1 retinitis pigmentosa 1 (autosomal dominant) 0.000 0.000 0.002 1 2 9 9 12 14 9 13 27 31
TUBA8 tubulin, alpha 8 0.000 0.001 0.002 1 2 75 69 78 89 74 102 140 144
MFGE8 milk fat globule-EGF factor 8 protein 0.000 0.000 0.002 1 2 587 658 924 1105 583 965 1442 1715
SMOC1 SPARC related modular calcium binding 1 0.000 0.000 0.002 1 2 38 45 47 57 41 80 120 114
KIAA0427 KIAA0427 0.000 0.000 0.004 1 2 125 130 149 174 130 179 240 264
SLC29A2 solute carrier family 29 (nucleoside transporters), member 20.000 0.000 0.004 1 2 53 59 60 79 51 75 101 108
PKP2 plakophilin 2 0.006 0.001 0.005 1 2 70 75 91 97 50 118 206 219
CLEC16A C-type lectin domain family 16, member A 0.014 0.003 0.006 1 2 231 223 231 242 217 232 272 296
TET1 tet oncogene 1 0.000 0.000 0.006 1 2 30 34 39 41 35 41 63 62
MBNL3 muscleblind-like 3 (Drosophila) 0.000 0.000 0.009 1 2 149 150 178 189 157 197 284 300
CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 10.000 0.000 0.009 1 2 25 25 61 203 24 51 431 983
LOC100190938hypothetical LOC100190938 0.011 0.001 0.009 1 2 79 78 95 116 67 83 231 303
CILP cartilage intermediate layer protein, nucleotide pyrophosphohydrolase0.044 0.002 0.010 1 2 90 90 118 165 50 95 337 459
CYP4F22 cytochrome P450, family 4, subfamily F, polypeptide 220.001 0.000 0.010 1 2 15 16 24 46 16 22 110 176
ACSS1 acyl-CoA synthetase short-chain family member 10.000 0.000 0.011 1 2 55 50 62 67 56 71 85 88
KCNA2 potassium voltage-gated channel, shaker-related subfamily, member 20.000 0.000 0.012 1 2 20 19 23 26 21 28 36 44
FITM2 fat storage-inducing transmembrane protein 2 0.000 0.000 0.016 1 2 401 388 564 601 471 688 900 893
TACC1 transforming, acidic coiled-coil containing protein 10.000 0.000 0.018 1 2 606 642 730 756 652 647 842 923
PLEKHA7 pleckstrin homology domain containing, family A member 70.099 0.000 0.020 1 2 44 44 50 54 39 47 68 63
TMEM120B transmembrane protein 120B 0.000 0.002 0.023 1 2 96 94 102 107 96 118 131 142
CLCN4 chloride channel 4 0.000 0.000 0.023 1 2 23 25 29 31 23 32 45 52
TOB2 transducer of ERBB2, 2 0.000 0.000 0.023 1 2 278 288 302 334 273 318 381 412
VIT vitrin 0.000 0.000 0.029 1 2 31 41 81 105 66 141 346 392
PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent)0.000 0.000 0.033 1 2 51 55 60 72 62 84 127 134
LOC55908 hepatocellular carcinoma-associated gene TD26 0.000 0.000 0.035 1 2 65 103 189 223 86 232 507 506
HEXDC hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing0.000 0.000 0.035 1 2 68 71 75 82 70 82 100 99
58 
 
 
 
Symbol Description D
e
p
o
t 
FD
R
 q
[D
e
x]
  F
D
R
 q
 
D
e
p
o
t 
* 
[D
e
x]
 F
D
R
 q
 
C
lu
st
e
r
su
b
cl
u
st
e
r
 O
m
  I
D
0
 O
m
 ID
1
 O
m
 ID
1
0
 O
m
 ID
1
0
0
0
 S
c 
ID
0
 S
c 
ID
1
 S
c 
ID
1
0
 S
c 
ID
1
0
0
0
BTNL9 butyrophilin-like 9 0.000 0.000 0.035 1 2 60 87 104 146 85 150 256 316
GSN gelsolin 0.000 0.000 0.035 1 2 491 600 757 931 606 895 1522 1809
INTS3 integrator complex subunit 3 0.000 0.000 0.037 1 2 290 312 319 353 300 339 412 402
TSKU tsukushi small leucine rich proteoglycan homolog (Xenopus laevis)0.000 0.000 0.040 1 2 357 411 651 812 397 827 1224 1307
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 10.000 0.000 0.041 1 2 363 364 462 493 392 474 709 716
USP18 ubiquitin specific peptidase 18 0.000 0.000 0.043 1 2 68 67 107 127 73 112 213 237
ZNF385B zinc finger protein 385B 0.000 0.000 0.044 1 2 22 22 30 29 24 31 47 55
CALCOCO2 calcium binding and coiled-coil domain 2 0.000 0.000 0.045 1 2 304 343 426 472 325 374 510 579
NECAB1 N-terminal EF-hand calcium binding protein 1 0.000 0.000 0.046 1 2 15 17 21 28 20 42 81 91
PPTC7 PTC7 protein phosphatase homolog (S. cerevisiae)0.000 0.000 0.049 1 2 405 409 481 514 455 529 661 705
AKAP12 A kinase (PRKA) anchor protein 12 0.170 0.000 0.002 1 3 252 320 607 878 159 385 1060 1257
BMP6 bone morphogenetic protein 6 0.373 0.097 0.002 1 3 78 53 56 62 33 41 69 88
STK35 serine/threonine kinase 35 0.944 0.412 0.003 1 3 167 151 138 146 136 139 150 172
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha0.451 0.000 0.003 1 3 94 101 127 148 50 91 158 172
SLC22A3 solute carrier family 22 (extraneuronal monoamine transporter), member 30.151 0.577 0.008 1 3 241 103 120 146 118 174 244 255
LHX6 LIM homeobox 6 0.199 0.001 0.010 1 3 70 73 72 80 66 66 86 101
PICK1 protein interacting with PRKCA 1 0.709 0.000 0.011 1 3 86 87 103 114 75 90 118 116
ETNK2 ethanolamine kinase 2 0.261 0.000 0.013 1 3 119 125 168 199 92 114 246 298
ST6GALNAC3ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 30.681 0.001 0.015 1 3 87 88 102 111 61 60 136 151
APBB2 amyloid beta (A4) precursor protein-binding, family B, member 20.433 0.476 0.017 1 3 694 647 612 641 575 625 744 783
NOSTRIN nitric oxide synthase trafficker 0.066 0.023 0.019 1 3 16 13 14 15 14 12 20 31
STK24 serine/threonine kinase 24 0.149 0.052 0.020 1 3 337 328 337 331 320 315 367 400
PKP4 plakophilin 4 0.244 0.005 0.022 1 3 121 127 131 127 114 117 145 156
CYP2R1 cytochrome P450, family 2, subfamily R, polypeptide 10.450 0.578 0.025 1 3 170 163 156 157 148 162 188 169
INTS1 integrator complex subunit 1 0.129 0.306 0.027 1 3 134 132 129 134 125 139 146 140
SERINC3 serine incorporator 3 0.269 0.069 0.029 1 3 2253 2181 2209 2210 2163 2153 2340 2347
GATA2 GATA binding protein 2 0.058 0.009 0.030 1 3 66 63 66 72 47 54 70 74
SP2 Sp2 transcription factor 0.695 0.480 0.032 1 3 92 84 85 90 82 88 94 92
C17orf91 chromosome 17 open reading frame 91 0.211 0.495 0.034 1 3 198 186 180 185 185 182 215 200
TXNIP thioredoxin interacting protein 0.263 0.000 0.035 1 3 1746 2009 2743 3213 1324 1771 2927 3575
FAM117B family with sequence similarity 117, member B 0.655 0.009 0.035 1 3 171 167 172 177 150 160 188 183
MPDZ multiple PDZ domain protein 0.308 0.013 0.035 1 3 282 273 284 300 259 248 344 359
MARCH6 membrane-associated ring finger (C3HC4) 6 0.192 0.075 0.035 1 3 716 714 687 735 687 711 754 766
GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 20.034 0.074 0.035 1 3 25 26 25 26 22 30 34 35
TRAPPC10 trafficking protein particle complex 10 0.085 0.070 0.040 1 3 423 416 407 438 405 423 464 458
RHOU ras homolog gene family, member U 0.273 0.009 0.042 1 3 446 458 486 498 296 410 545 550
TAL1 T-cell acute lymphocytic leukemia 1 0.334 0.465 0.045 1 3 34 31 32 30 26 28 32 36
SQRDL sulfide quinone reductase-like (yeast) 0.138 0.050 0.001 2 1 384 436 533 496 490 486 491 465
SPRYD4 SPRY domain containing 4 0.309 0.121 0.019 2 1 146 138 163 161 134 158 154 140
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 20.160 0.000 0.020 2 1 42 54 82 100 62 75 79 82
PNPO pyridoxamine 5'-phosphate oxidase 0.235 0.012 0.022 2 1 344 328 388 369 328 353 350 360
GABPB2 GA binding protein transcription factor, beta subunit 20.004 0.001 0.033 2 1 93 102 126 118 118 113 129 120
STEAP4 STEAP family member 4 0.141 0.005 0.036 2 1 114 447 773 743 453 653 666 622
TXNRD2 thioredoxin reductase 2 0.161 0.000 0.038 2 1 186 188 227 215 170 205 217 195
DLAT dihydrolipoamide S-acetyltransferase 0.004 0.000 0.039 2 1 426 598 877 850 664 946 946 807
F13A1 coagulation factor XIII, A1 polypeptide 0.000 0.000 0.043 2 1 196 736 1748 1690 1014 1747 2395 2117
SRPX sushi-repeat-containing protein, X-linked 0.789 0.001 0.046 2 1 1405 1898 2780 2971 1971 2115 2379 2422
MME membrane metallo-endopeptidase 0.000 0.001 0.001 2 2 938 1536 2073 2207 2782 3022 3170 3153
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 20.000 0.035 0.045 2 2 379 543 761 866 1196 1120 1275 1249
SCFD2 sec1 family domain containing 2 0.007 0.536 0.012 2 3 244 253 288 284 324 294 302 273
SLAMF6 SLAM family member 6 0.026 0.361 0.023 2 3 15 18 21 23 23 23 21 21
GALT galactose-1-phosphate uridylyltransferase 0.000 0.041 0.028 2 3 87 91 101 108 111 128 125 116
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 0.000 0.000 0.038 2 3 387 438 537 559 508 635 632 598
PACRG PARK2 co-regulated 0.001 0.109 0.038 2 3 24 23 30 25 27 36 30 29
HSD17B7P2hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 20.092 0.799 0.045 2 3 76 82 97 99 102 120 93 88
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C3orf47 chromosome 3 open reading frame 47 0.166 0.549 0.002 3 1 26 26 25 34 26 37 36 26
POMZP3 POM121 and ZP3 fusion 0.016 0.174 0.011 3 1 23 28 26 37 31 51 37 29
CDAN1 congenital dyserythropoietic anemia, type I 0.003 0.473 0.013 3 1 63 60 59 66 63 68 67 65
C21orf30 chromosome 21 open reading frame 30 0.022 0.325 0.019 3 1 25 25 23 27 24 30 29 27
OR2F1 olfactory receptor, family 2, subfamily F, member 10.060 0.623 0.031 3 1 18 16 17 18 17 21 18 19
TBC1D24 TBC1 domain family, member 24 0.052 0.165 0.036 3 1 83 80 84 91 83 105 86 94
GRM2 glutamate receptor, metabotropic 2 0.824 0.475 0.038 3 1 22 20 20 22 20 23 21 21
ANKRD53 ankyrin repeat domain 53 0.714 0.420 0.004 3 2 63 52 57 60 45 66 68 61
ISCA1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae)0.949 0.348 0.008 3 2 183 164 188 184 162 196 188 174
SELP selectin P (granule membrane protein 140kDa, antigen CD62)0.000 0.001 0.009 3 2 14 13 16 18 14 24 23 28
GHDC GH3 domain containing 0.016 0.084 0.010 3 2 62 59 60 65 61 63 68 65
ABCD1 ATP-binding cassette, sub-family D (ALD), member 10.000 0.000 0.016 3 2 107 100 129 155 120 149 188 192
RAB4B RAB4B, member RAS oncogene family 0.263 0.859 0.022 3 2 193 175 181 184 173 202 195 191
MLX MAX-like protein X 0.000 0.000 0.025 3 2 466 456 548 563 503 553 601 600
PGPEP1 pyroglutamyl-peptidase I 0.000 0.068 0.028 3 2 98 92 96 106 98 113 118 114
IKZF4 IKAROS family zinc finger 4 (Eos) 0.010 0.536 0.030 3 2 75 66 66 79 69 91 96 85
ATG4D ATG4 autophagy related 4 homolog D (S. cerevisiae)0.460 0.090 0.033 3 2 179 167 177 187 145 181 182 184
ACR acrosin 0.040 0.115 0.035 3 2 30 26 31 34 26 39 36 38
SIRPB2 signal-regulatory protein beta 2 0.000 0.002 0.036 3 2 23 22 27 28 25 36 41 36
BLCAP bladder cancer associated protein 0.517 0.008 0.045 3 2 554 569 576 583 493 609 611 626
LEP leptin 0.002 0.007 0.046 3 2 365 290 445 502 309 764 1070 1139
VIPR2 vasoactive intestinal peptide receptor 2 0.000 0.046 0.009 3 3 23 25 38 43 16 19 17 17
TUBB6 tubulin, beta 6 0.134 0.164 0.030 3 3 720 746 816 834 790 850 841 766
SLC25A22 solute carrier family 25 (mitochondrial carrier: glutamate), member 220.982 0.174 0.030 3 3 101 92 106 124 97 112 107 105
POLG polymerase (DNA directed), gamma 0.021 0.007 0.033 3 3 84 89 94 105 92 101 106 98
PLCXD3 phosphatidylinositol-specific phospholipase C, X domain containing 30.000 0.000 0.034 3 3 12 24 66 60 12 16 30 26
FSTL3 follistatin-like 3 (secreted glycoprotein) 0.618 0.017 0.035 3 3 379 396 467 481 384 494 445 433
MUC16 mucin 16, cell surface associated 0.000 0.007 0.000 4 1 30 48 119 147 21 26 22 25
PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme0.000 0.068 0.001 4 1 896 893 930 968 864 787 796 815
ART4 ADP-ribosyltransferase 4 (Dombrock blood group)0.000 0.001 0.001 4 1 14 17 36 48 14 14 17 17
CTSC cathepsin C 0.000 0.547 0.003 4 1 1319 1456 1628 1472 1344 1204 1136 1049
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 0.000 0.072 0.004 4 1 77 82 119 141 73 64 70 66
ACSM3 acyl-CoA synthetase medium-chain family member 30.000 0.007 0.006 4 1 18 33 62 71 15 17 17 17
MUM1L1 melanoma associated antigen (mutated) 1-like 1 0.000 0.001 0.013 4 1 46 50 80 151 18 19 22 24
MMRN1 multimerin 1 0.000 0.000 0.022 4 1 51 104 247 224 13 14 21 23
MAP3K5 mitogen-activated protein kinase kinase kinase 5 0.000 0.425 0.023 4 1 142 168 198 208 122 122 114 110
MCAT malonyl CoA:ACP acyltransferase (mitochondrial)0.000 0.081 0.030 4 1 173 182 221 213 160 170 168 154
CCND3 cyclin D3 0.002 0.335 0.035 4 1 570 622 718 678 578 585 565 524
TRIAP1 TP53 regulated inhibitor of apoptosis 1 0.000 0.075 0.038 4 1 178 169 210 200 151 167 161 160
TFB1M transcription factor B1, mitochondrial 0.000 0.623 0.046 4 1 70 76 88 86 68 63 55 66
TRMT5 TRM5 tRNA methyltransferase 5 homolog (S. cerevisiae)0.000 0.685 0.004 4 2 200 204 233 220 195 189 181 182
ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide0.000 0.480 0.009 4 2 47 134 177 129 61 62 32 30
VPS35 vacuolar protein sorting 35 homolog (S. cerevisiae)0.003 0.680 0.028 4 2 764 823 869 814 793 739 748 745
RPSA ribosomal protein SA 0.000 0.925 0.035 4 2 18 21 31 24 16 16 10 10
NIF3L1 NIF3 NGG1 interacting factor 3-like 1 (S. pombe) 0.000 0.451 0.035 4 2 258 255 301 270 248 240 232 231
FAM65B family with sequence similarity 65, member B 0.126 0.267 0.023 4 3 25 29 36 52 34 28 26 27
NUP188 nucleoporin 188kDa 0.183 0.077 0.046 4 3 298 290 308 334 310 291 297 298
KRTAP5-7 keratin associated protein 5-7 0.387 0.031 0.002 5 1 359 348 289 355 393 378 348 290
MIIP migration and invasion inhibitory protein 0.618 0.115 0.019 5 1 120 113 114 114 112 130 107 105
ANXA2 annexin A2 0.854 0.368 0.030 5 1 2267 2174 2234 2396 2350 2403 2111 2174
ROBO3 roundabout, axon guidance receptor, homolog 3 (Drosophila)0.294 0.713 0.040 5 1 26 23 24 26 23 28 23 22
FADS2 fatty acid desaturase 2 0.979 0.043 0.013 5 2 1722 1750 1801 1694 2085 1953 1641 1410
FADS1 fatty acid desaturase 1 0.191 0.357 0.014 5 2 2146 2702 3259 3237 2719 2717 2568 2307
STEAP3 STEAP family member 3 0.730 0.477 0.018 5 2 186 229 247 239 234 245 206 194
B9D1 B9 protein domain 1 0.234 0.427 0.020 5 2 87 81 90 87 88 90 80 74
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PLA2G5 phospholipase A2, group V 0.977 0.934 0.023 5 2 63 79 91 86 100 81 70 62
GPC4 glypican 4 0.339 0.145 0.034 5 2 222 265 279 246 317 297 200 140
FAM136A family with sequence similarity 136, member A 0.504 0.735 0.040 5 2 191 196 199 206 211 194 191 182
G6PD glucose-6-phosphate dehydrogenase 0.191 0.225 0.046 5 2 779 842 989 964 851 856 858 771
KIAA1143 KIAA1143 0.894 0.884 0.050 5 2 22 23 32 27 31 29 23 23
EMP1 epithelial membrane protein 1 0.297 0.823 0.050 5 2 1775 1945 2276 2159 2262 1807 1832 1806
TNFRSF21 tumor necrosis factor receptor superfamily, member 210.000 0.011 0.001 6 1 712 539 451 438 377 397 368 366
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 0.000 0.012 0.001 6 1 279 154 85 70 37 36 33 36
IL1RAP interleukin 1 receptor accessory protein 0.000 0.000 0.002 6 1 121 86 59 54 71 52 54 47
LTBP3 latent transforming growth factor beta binding protein 30.000 0.024 0.002 6 1 264 228 194 190 168 170 166 168
DSC2 desmocollin 2 0.000 0.706 0.002 6 1 158 145 131 120 90 79 99 107
USP54 ubiquitin specific peptidase 54 0.000 0.656 0.002 6 1 74 66 57 60 49 47 54 54
LOC100133106VCEW9374 0.000 0.014 0.003 6 1 60 42 27 24 23 22 21 22
DDIT4 DNA-damage-inducible transcript 4 0.001 0.315 0.003 6 1 598 465 360 342 302 278 310 369
PI15 peptidase inhibitor 15 0.000 0.000 0.004 6 1 752 823 223 78 39 36 20 17
GPR56 G protein-coupled receptor 56 0.001 0.789 0.004 6 1 181 160 139 126 84 80 118 134
THBS2 thrombospondin 2 0.000 0.025 0.006 6 1 1549 1272 958 839 894 757 871 811
PLCG1 phospholipase C, gamma 1 0.000 0.080 0.006 6 1 253 243 214 213 208 194 209 203
TMEM88 transmembrane protein 88 0.000 0.005 0.009 6 1 136 140 76 67 64 62 54 61
RAB27B RAB27B, member RAS oncogene family 0.000 0.000 0.009 6 1 162 74 41 28 25 19 18 16
F2RL1 coagulation factor II (thrombin) receptor-like 1 0.000 0.000 0.009 6 1 134 100 73 59 47 45 36 40
MYL12A myosin, light chain 12A, regulatory, non-sarcomeric0.016 0.047 0.009 6 1 105 108 104 100 105 96 103 98
DCBLD1 discoidin, CUB and LCCL domain containing 1 0.000 0.000 0.010 6 1 329 264 193 166 147 122 112 107
HOXA2 homeobox A2 0.000 0.460 0.011 6 1 120 94 80 79 39 40 49 42
TSLP thymic stromal lymphopoietin 0.000 0.055 0.017 6 1 63 39 40 37 31 29 31 32
CSGALNACT1chondroitin sulfate N-acetylgalactosaminyltransferase 10.000 0.000 0.019 6 1 129 114 83 76 89 53 59 60
CNOT8 CCR4-NOT transcription complex, subunit 8 0.011 0.053 0.019 6 1 478 415 395 376 393 352 376 398
PCGF2 polycomb group ring finger 2 0.000 0.000 0.022 6 1 291 263 231 222 232 203 200 203
LRRC70 leucine rich repeat containing 70 0.072 0.068 0.025 6 1 23 20 18 17 19 15 18 19
KLHL4 kelch-like 4 (Drosophila) 0.000 0.449 0.026 6 1 34 31 24 25 11 9 12 12
MAP3K11 mitogen-activated protein kinase kinase kinase 110.000 0.000 0.027 6 1 185 161 141 135 150 133 139 129
FURIN furin (paired basic amino acid cleaving enzyme) 0.000 0.001 0.027 6 1 222 195 189 198 188 172 183 182
LEPR leptin receptor 0.000 0.113 0.027 6 1 118 69 68 64 38 29 41 49
BCL9 B-cell CLL/lymphoma 9 0.000 0.072 0.028 6 1 170 156 157 141 126 125 141 128
TPM1 tropomyosin 1 (alpha) 0.000 0.004 0.035 6 1 669 498 399 383 308 238 255 278
PTPRK protein tyrosine phosphatase, receptor type, K 0.002 0.000 0.039 6 1 229 172 138 136 165 124 133 135
ENC1 ectodermal-neural cortex 1 (with BTB-like domain)0.000 0.106 0.039 6 1 147 149 117 103 84 92 96 86
GPR63 G protein-coupled receptor 63 0.000 0.470 0.041 6 1 39 42 31 34 22 19 23 20
SULT1C4 sulfotransferase family, cytosolic, 1C, member 4 0.000 0.003 0.041 6 1 33 28 17 16 17 14 13 14
EDEM1 ER degradation enhancer, mannosidase alpha-like 10.000 0.004 0.047 6 1 266 261 230 220 248 180 195 190
CLSTN1 calsyntenin 1 0.000 0.000 0.049 6 1 200 182 161 164 171 146 153 153
PKNOX2 PBX/knotted 1 homeobox 2 0.000 0.010 0.049 6 1 60 48 41 39 38 40 38 34
AMIGO2 adhesion molecule with Ig-like domain 2 0.109 0.224 0.001 6 2 60 34 33 32 30 28 37 38
ITPKB inositol 1,4,5-trisphosphate 3-kinase B 0.414 0.162 0.006 6 2 69 63 54 59 64 52 65 81
ANXA3 annexin A3 0.000 0.020 0.006 6 2 115 90 99 102 19 24 60 87
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DSG2 desmoglein 2 0.000 0.265 0.009 6 2 152 126 111 112 30 29 66 86
HOXA3 homeobox A3 0.002 0.859 0.013 6 2 64 53 46 48 37 43 44 46
FNBP1L formin binding protein 1-like 0.018 0.280 0.018 6 2 209 217 200 198 148 156 193 221
RAMP2 receptor (G protein-coupled) activity modifying protein 20.697 0.379 0.019 6 2 186 127 105 116 114 94 178 233
POLR2A polymerase (RNA) II (DNA directed) polypeptide A, 220kDa0.00 0.564 0.022 6 2 327 322 291 324 249 279 289 282
SLC38A3 solute carrier family 38, member 3 0.005 0.474 0.023 6 2 24 22 20 23 17 22 19 19
SLC9A3R2 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 20.366 0.896 0.036 6 2 243 222 192 194 187 186 213 221
GOLGA8B golgin A8 family, member B 0.001 0.352 0.038 6 2 134 132 125 121 74 76 110 112
CFDP1 craniofacial development protein 1 0.000 0.054 0.039 6 2 109 106 108 104 95 85 100 101
MBD1 methyl-CpG binding domain protein 1 0.025 0.275 0.042 6 2 177 162 163 158 156 156 150 165
TMEM45A transmembrane protein 45A 0.000 0.100 0.043 6 2 277 254 260 249 147 139 204 225
ZNF850 zinc finger protein 850 0.000 0.071 0.044 6 2 66 61 56 55 54 42 51 51
CLINT1 clathrin interactor 1 0.134 0.035 0.044 6 2 1044 998 1003 1005 994 930 1003 1037
ASB3 ankyrin repeat and SOCS box-containing 3 0.413 0.439 0.049 6 2 46 43 42 36 37 33 45 44
CTSL1 cathepsin L1 0.015 0.000 0.002 7 1 1439 1416 1188 934 1765 1141 815 700
MYO1B myosin IB 0.001 0.000 0.002 7 1 935 869 596 519 1066 636 407 341
CCDC102B coiled-coil domain containing 102B 0.000 0.000 0.008 7 1 280 268 129 88 180 72 32 30
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 0.185 0.001 0.009 7 1 369 391 340 309 476 335 284 251
JAM3 junctional adhesion molecule 3 0.012 0.000 0.013 7 1 307 291 265 229 322 237 235 221
SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 70.020 0.000 0.024 7 1 294 263 194 163 348 214 153 131
ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0.167 0.000 0.027 7 1 1662 1647 1564 1415 1828 1522 1340 1375
UGCG UDP-glucose ceramide glucosyltransferase 0.031 0.000 0.046 7 1 266 251 233 196 289 216 192 183
PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1)0.000 0.000 0.009 7 2 397 360 277 240 287 181 133 131
STK17A serine/threonine kinase 17a 0.000 0.000 0.013 7 2 475 407 361 295 450 280 212 199
GUCY1B3 guanylate cyclase 1, soluble, beta 3 0.000 0.000 0.013 7 2 251 224 140 101 217 118 64 54
HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)0.000 0.000 0.014 7 2 2613 2667 2181 1788 2207 1650 1230 1169
C6orf150 chromosome 6 open reading frame 150 0.002 0.000 0.017 7 2 53 53 50 41 60 41 39 31
PDIA3P protein disulfide isomerase family A, member 3 pseudogene0.000 0.000 0.019 7 2 1739 1566 1510 1299 1481 1237 1085 1181
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog0.000 0.000 0.020 7 2 1329 1245 1175 1080 1274 1089 961 880
NIPA2 non imprinted in Prader-Willi/Angelman syndrome 20.000 0.003 0.020 7 2 430 426 423 397 426 368 346 351
POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit)0.016 0.029 0.027 7 2 73 79 86 62 107 56 50 42
PCSK1 proprotein convertase subtilisin/kexin type 1 0.000 0.000 0.028 7 2 93 63 48 36 95 39 24 20
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 10.002 0.027 0.035 7 2 555 600 539 515 664 410 351 346
IL13RA2 interleukin 13 receptor, alpha 2 0.018 0.004 0.043 7 2 504 442 428 322 711 299 189 200
HIST2H2BA histone cluster 2, H2ba 0.001 0.048 0.045 7 2 1172 1316 1297 1011 1331 922 750 742
IFI16 interferon, gamma-inducible protein 16 0.000 0.000 0.047 7 2 1984 2001 1876 1579 1950 1537 1290 1193
PPM1G protein phosphatase, Mg2+/Mn2+ dependent, 1G0.012 0.199 0.010 7 3 302 317 316 314 325 286 284 258
LOC147804 tropomyosin 3 pseudogene 0.008 0.189 0.010 7 3 243 267 270 225 268 205 197 208
RAG1AP1 recombination activating gene 1 activating protein 10.008 0.093 0.012 7 3 741 734 799 740 774 706 678 617
ERLIN1 ER lipid raft associated 1 0.479 0.743 0.024 7 3 603 646 686 635 714 609 579 593
ANXA2P1 annexin A2 pseudogene 1 0.784 0.957 0.028 7 3 156 183 202 180 201 166 159 183
AKAP11 A kinase (PRKA) anchor protein 11 0.525 0.332 0.029 7 3 352 368 365 369 400 330 343 356
USP1 ubiquitin specific peptidase 1 0.002 0.202 0.029 7 3 145 161 160 145 163 122 123 113
APITD1 apoptosis-inducing, TAF9-like domain 1 0.094 0.145 0.033 7 3 68 64 72 64 72 64 58 58
LTBP1 latent transforming growth factor beta binding protein 10.000 0.000 0.035 7 3 232 223 161 139 266 93 64 61
BMPR1B bone morphogenetic protein receptor, type IB 0.045 0.193 0.035 7 3 39 43 49 41 50 38 32 27
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor)0.370 0.232 0.036 7 3 2085 2164 2209 2116 2450 2094 1875 1909
SCML2 sex comb on midleg-like 2 (Drosophila) 0.113 0.752 0.047 7 3 32 37 39 38 39 32 33 29
CSE1L CSE1 chromosome segregation 1-like (yeast) 0.001 0.300 0.049 7 3 742 780 782 750 775 647 633 635
PSIP1 PC4 and SFRS1 interacting protein 1 0.011 0.535 0.050 7 3 130 155 150 135 156 103 103 108
TIMP1 TIMP metallopeptidase inhibitor 1 0.000 0.002 0.002 7 4 6299 5975 5979 5704 5585 4449 3561 3439
LXN latexin 0.000 0.000 0.003 7 4 343 338 273 216 169 100 69 58
RBMS1 RNA binding motif, single stranded interacting protein 10.000 0.005 0.005 7 4 1170 1234 1139 1108 1183 966 805 771
PAPPA pregnancy-associated plasma protein A, pappalysin 10.000 0.000 0.006 7 4 352 360 267 207 124 72 37 36
IFITM1 interferon induced transmembrane protein 1 (9-27)0.000 0.001 0.008 7 4 2560 2587 2607 2182 2061 1630 1370 1253
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ARSJ arylsulfatase family, member J 0.000 0.005 0.009 7 4 54 60 57 48 46 35 28 24
LY6E lymphocyte antigen 6 complex, locus E 0.000 0.002 0.010 7 4 651 657 631 591 573 550 409 346
FLJ36031 hypothetical protein FLJ36031 0.006 0.005 0.013 7 4 126 118 120 118 129 117 100 93
TSHZ2 teashirt zinc finger homeobox 2 0.000 0.000 0.017 7 4 498 414 401 400 410 333 271 240
PTPLAD1 protein tyrosine phosphatase-like A domain containing 10.000 0.000 0.019 7 4 657 626 606 595 624 520 475 467
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 0.000 0.000 0.020 7 4 5307 5087 4148 3500 3803 2989 1908 1507
ITGB8 integrin, beta 8 0.000 0.250 0.020 7 4 144 178 197 186 153 96 56 38
HMGN1 high-mobility group nucleosome binding domain 10.000 0.036 0.023 7 4 114 131 111 111 114 82 71 66
BGN biglycan 0.000 0.000 0.024 7 4 2718 2397 1643 1262 2117 1482 677 477
TXLNA taxilin alpha 0.001 0.001 0.030 7 4 299 299 293 282 302 281 257 245
MYL12B myosin, light chain 12B, regulatory 0.000 0.033 0.031 7 4 1823 1697 1803 1692 1651 1611 1438 1465
DCTD dCMP deaminase 0.000 0.019 0.033 7 4 953 956 972 928 946 875 827 773
IFITM3 interferon induced transmembrane protein 3 (1-8U)0.000 0.011 0.035 7 4 4948 5016 5066 4547 4103 3487 3042 2875
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A0.000 0.000 0.035 7 4 1237 956 848 800 828 599 419 379
THBS1 thrombospondin 1 0.000 0.000 0.036 7 4 2415 1787 1712 1687 1781 895 728 765
QSER1 glutamine and serine rich 1 0.000 0.002 0.038 7 4 437 423 417 397 422 338 312 315
UBE2L6 ubiquitin-conjugating enzyme E2L 6 0.001 0.163 0.038 7 4 412 432 432 437 387 417 346 297
TMEM123 transmembrane protein 123 0.000 0.000 0.040 7 4 1140 1136 1085 1035 1031 895 819 807
KRTAP19-5 keratin associated protein 19-5 0.091 0.219 0.043 7 4 86 102 98 98 98 96 71 88
FKBP11 FK506 binding protein 11, 19 kDa 0.000 0.000 0.046 7 4 287 277 252 210 221 167 128 115
DIRAS3 DIRAS family, GTP-binding RAS-like 3 0.002 0.759 0.050 7 4 22 23 25 22 22 20 17 19
CHIC2 cysteine-rich hydrophobic domain 2 0.000 0.004 0.003 7 5 561 555 548 517 527 387 366 365
ARHGEF25 Rho guanine nucleotide exchange factor (GEF) 250.000 0.016 0.016 7 5 145 139 131 138 94 66 77 62
SF3B3 splicing factor 3b, subunit 3, 130kDa 0.000 0.488 0.018 7 5 705 724 742 724 611 548 536 541
DPY19L3 dpy-19-like 3 (C. elegans) 0.000 0.962 0.020 7 5 183 222 228 219 156 128 133 131
TRIM2 tripartite motif-containing 2 0.000 0.828 0.023 7 5 180 190 214 211 149 125 123 121
G3BP2 GTPase activating protein (SH3 domain) binding protein 20.000 0.001 0.026 7 5 589 591 574 539 543 458 457 443
AMD1 adenosylmethionine decarboxylase 1 0.000 0.561 0.029 7 5 531 559 608 539 495 416 368 403
SLC38A2 solute carrier family 38, member 2 0.000 0.072 0.031 7 5 2206 2238 2199 2264 2119 1789 1695 1814
SEC11C SEC11 homolog C (S. cerevisiae) 0.000 0.468 0.031 7 5 89 88 98 82 73 63 66 74
KIAA1430 KIAA1430 0.000 0.967 0.034 7 5 759 834 886 804 717 635 625 680
CSNK1G3 casein kinase 1, gamma 3 0.000 0.036 0.035 7 5 196 203 191 184 192 146 139 147
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon)0.000 0.028 0.035 7 5 135 142 136 121 123 85 78 80
HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9)0.000 0.266 0.035 7 5 577 604 583 576 506 431 430 462
ZNF346 zinc finger protein 346 0.000 0.223 0.038 7 5 199 209 196 188 181 156 160 167
UIMC1 ubiquitin interaction motif containing 1 0.000 0.302 0.039 7 5 119 123 123 122 108 93 94 99
TROVE2 TROVE domain family, member 2 0.000 0.077 0.040 7 5 472 476 478 455 421 352 371 370
PTDSS1 phosphatidylserine synthase 1 0.000 0.065 0.041 7 5 810 824 840 798 752 666 656 620
ZNF876P zinc finger protein 876, pseudogene 0.001 0.358 0.043 7 5 42 40 44 33 36 30 30 35
PON3 paraoxonase 3 0.000 0.222 0.046 7 5 45 44 45 48 28 21 21 19
KHDRBS1 KH domain containing, RNA binding, signal transduction associated 10.000 0.010 0.047 7 5 731 738 734 678 684 589 566 564
HNRNPM heterogeneous nuclear ribonucleoprotein M 0.000 0.059 0.047 7 5 387 385 392 370 345 292 289 302
ZSCAN2 zinc finger and SCAN domain containing 2 0.091 0.014 0.000 8 1 43 38 34 35 39 40 40 38
COL15A1 collagen, type XV, alpha 1 0.043 0.000 0.000 8 1 575 373 154 122 574 318 213 184
NOX4 NADPH oxidase 4 0.027 0.007 0.002 8 1 74 48 29 27 68 42 51 58
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 0.001 0.048 0.002 8 1 331 306 251 246 328 318 324 330
NOTCH3 notch 3 0.002 0.000 0.002 8 1 217 177 114 111 214 182 168 172
FAM101B family with sequence similarity 101, member B 0.194 0.003 0.003 8 1 599 365 261 252 497 312 415 392
INPPL1 inositol polyphosphate phosphatase-like 1 0.149 0.142 0.003 8 1 180 173 154 161 170 172 172 175
RHOBTB1 Rho-related BTB domain containing 1 0.397 0.946 0.003 8 1 169 154 143 134 143 145 165 172
MEF2C myocyte enhancer factor 2C 0.127 0.000 0.005 8 1 723 669 477 409 709 590 599 519
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)0.001 0.000 0.006 8 1 1698 1049 204 104 1675 1139 529 263
ADA adenosine deaminase 0.015 0.324 0.008 8 1 239 233 214 183 226 231 269 246
INHBB inhibin, beta B 0.003 0.115 0.008 8 1 353 316 182 181 348 307 339 376
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme0.057 0.563 0.009 8 1 595 575 561 543 579 554 627 645
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LOXL2 lysyl oxidase-like 2 0.000 0.000 0.011 8 1 396 290 179 165 431 358 310 285
SGK223 homolog of rat pragma of Rnd2 0.009 0.000 0.012 8 1 87 65 51 53 80 71 69 68
CD82 CD82 molecule 0.895 0.000 0.024 8 1 781 448 303 267 514 429 383 341
ZNF274 zinc finger protein 274 0.246 0.801 0.024 8 1 108 101 104 96 103 103 101 114
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 90.000 0.004 0.024 8 1 513 472 335 317 613 471 500 497
RNF128 ring finger protein 128 0.903 0.072 0.033 8 1 18 14 11 12 13 15 13 14
AKAP13 A kinase (PRKA) anchor protein 13 0.073 0.023 0.033 8 1 307 273 240 241 305 254 288 288
SIPA1 signal-induced proliferation-associated 1 0.828 0.000 0.036 8 1 151 141 120 119 143 134 128 125
ARHGAP31 Rho GTPase activating protein 31 0.006 0.262 0.037 8 1 420 367 306 301 406 390 424 418
SUFU suppressor of fused homolog (Drosophila) 0.928 0.115 0.038 8 1 84 74 72 69 73 78 74 73
HSPA12B heat shock 70kD protein 12B 0.366 0.262 0.045 8 1 94 92 80 82 84 92 84 102
DAB2IP DAB2 interacting protein 0.469 0.052 0.049 8 1 95 84 78 72 80 83 77 81
RDH10 retinol dehydrogenase 10 (all-trans) 0.425 0.173 0.000 8 2 528 368 372 377 399 400 444 454
WNT4 wingless-type MMTV integration site family, member 40.005 0.081 0.001 8 2 77 45 31 33 28 33 28 33
AFAP1L1 actin filament associated protein 1-like 1 0.003 0.475 0.002 8 2 206 169 132 158 193 181 255 288
KALRN kalirin, RhoGEF kinase 0.026 0.219 0.002 8 2 63 56 47 55 58 54 66 78
CDC42 cell division cycle 42 (GTP binding protein, 25kDa)0.214 0.832 0.008 8 2 180 180 159 169 178 162 193 185
PRSS35 protease, serine, 35 0.884 0.448 0.017 8 2 26 18 15 17 17 18 20 21
CHRNB1 cholinergic receptor, nicotinic, beta 1 (muscle) 0.338 0.503 0.022 8 2 49 40 36 41 37 40 40 41
DDA1 DET1 and DDB1 associated 1 0.775 0.468 0.023 8 2 551 496 476 509 489 512 510 503
LMOD2 leiomodin 2 (cardiac) 0.071 0.932 0.035 8 2 12 12 11 12 12 12 13 12
GBA2 glucosidase, beta (bile acid) 2 0.431 0.787 0.045 8 2 184 179 155 162 172 163 182 185
LRP6 low density lipoprotein receptor-related protein 60.493 0.867 0.046 8 2 301 292 273 288 289 281 308 296
SCAMP5 secretory carrier membrane protein 5 0.010 0.006 0.002 8 3 74 63 54 51 54 55 54 52
RAB11B RAB11B, member RAS oncogene family 0.183 0.340 0.002 8 3 754 696 683 664 654 687 708 672
CYTH2 cytohesin 2 0.120 0.013 0.002 8 3 315 294 261 255 278 258 280 260
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 120.468 0.000 0.005 8 3 391 302 186 189 364 255 212 190
LOC401097 Similar to LOC166075 0.011 0.000 0.005 8 3 81 24 13 12 19 14 13 13
FLT4 fms-related tyrosine kinase 4 0.253 0.005 0.006 8 3 71 60 42 43 54 47 48 49
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 20.084 0.000 0.007 8 3 189 139 100 94 154 115 105 101
FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)0.135 0.000 0.009 8 3 210 153 57 50 148 56 56 83
WWC3 WWC family member 3 0.421 0.013 0.012 8 3 130 113 105 102 116 99 109 114
NEK7 NIMA (never in mitosis gene a)-related kinase 7 0.516 0.000 0.013 8 3 1290 888 817 739 1075 772 846 879
ELMO1 engulfment and cell motility 1 0.989 0.008 0.013 8 3 244 213 165 148 221 164 190 187
PXDN peroxidasin homolog (Drosophila) 0.994 0.003 0.015 8 3 1275 1033 786 840 1050 922 939 964
C20orf112 chromosome 20 open reading frame 112 0.000 0.000 0.017 8 3 225 167 106 93 133 92 72 68
TMC7 transmembrane channel-like 7 0.924 0.062 0.017 8 3 56 47 35 33 45 36 43 43
NCK2 NCK adaptor protein 2 0.006 0.000 0.018 8 3 634 583 515 478 549 505 498 495
PRR5L proline rich 5 like 0.000 0.000 0.020 8 3 116 75 55 46 81 56 47 46
PLEKHG1 pleckstrin homology domain containing, family G (with RhoGef domain) member 10.874 0.262 0.020 8 3 151 128 97 97 124 84 123 136
EPOR erythropoietin receptor 0.712 0.020 0.020 8 3 60 51 46 46 53 43 55 48
ELTD1 EGF, latrophilin and seven transmembrane domain containing 10.380 0.000 0.023 8 3 770 633 399 341 718 414 387 441
ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)0.113 0.000 0.023 8 3 2168 1952 1691 1630 2053 1609 1622 1775
RASIP1 Ras interacting protein 1 0.006 0.001 0.027 8 3 106 90 70 66 79 71 70 67
FMNL3 formin-like 3 0.321 0.000 0.027 8 3 268 227 148 131 248 176 152 147
PTP4A3 protein tyrosine phosphatase type IVA, member 30.000 0.000 0.028 8 3 561 438 228 203 395 229 145 147
GMFG glia maturation factor, gamma 0.188 0.000 0.028 8 3 597 499 367 319 519 397 393 339
RNF152 ring finger protein 152 0.027 0.000 0.032 8 3 98 109 72 70 99 76 73 62
GPR116 G protein-coupled receptor 116 0.405 0.005 0.032 8 3 529 410 219 212 389 228 246 307
CXorf36 chromosome X open reading frame 36 0.141 0.003 0.033 8 3 200 157 99 88 142 94 103 109
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 0.606 0.022 0.035 8 3 310 246 157 177 270 179 217 241
LBH limb bud and heart development homolog (mouse)0.181 0.000 0.037 8 3 147 81 62 58 104 62 69 65
AGRN agrin 0.000 0.000 0.038 8 3 97 73 58 62 69 66 55 48
P4HA3 prolyl 4-hydroxylase, alpha polypeptide III 0.021 0.007 0.038 8 3 154 112 81 75 90 82 86 79
TMEM26 transmembrane protein 26 0.010 0.000 0.038 8 3 30 23 18 16 21 20 17 17
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RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 0.068 0.004 0.039 8 3 101 75 56 63 72 58 64 62
IVNS1ABP influenza virus NS1A binding protein 0.854 0.008 0.040 8 3 363 291 239 239 337 225 294 283
CPSF1 cleavage and polyadenylation specific factor 1, 160kDa0.120 0.027 0.041 8 3 148 138 125 130 129 138 132 121
FLJ41309 hypothetical protein LOC645079 0.028 0.000 0.041 8 3 31 23 15 15 21 18 16 15
VLDLR very low density lipoprotein receptor 0.066 0.519 0.042 8 3 322 316 257 251 245 257 272 258
DVL3 dishevelled, dsh homolog 3 (Drosophila) 0.210 0.210 0.042 8 3 333 312 287 295 290 307 306 284
CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit0.145 0.260 0.043 8 3 27 23 21 20 20 22 21 22
LIMK2 LIM domain kinase 2 0.000 0.000 0.046 8 3 166 137 117 99 123 106 96 95
HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 0.923 0.444 0.046 8 3 41 36 30 32 34 35 39 33
ALKBH5 alkB, alkylation repair homolog 5 (E. coli) 0.273 0.000 0.047 8 3 393 315 298 291 333 310 306 302
PAG1 phosphoprotein associated with glycosphingolipid microdomains 10.576 0.046 0.047 8 3 142 115 83 83 112 82 95 104
EMCN endomucin 0.070 0.000 0.048 8 3 268 216 120 97 223 134 123 106
IQSEC2 IQ motif and Sec7 domain 2 0.001 0.406 0.000 9 4 59 49 46 53 54 62 60 61
APBB3 amyloid beta (A4) precursor protein-binding, family B, member 30.000 0.455 0.001 9 4 101 95 87 97 100 116 132 130
MAN2C1 mannosidase, alpha, class 2C, member 1 0.000 0.020 0.002 9 4 185 195 177 195 203 236 245 243
IRF4 interferon regulatory factor 4 0.000 0.196 0.003 9 4 24 24 20 24 25 30 43 39
GAB2 GRB2-associated binding protein 2 0.000 0.979 0.003 9 4 258 226 221 220 250 273 291 289
NRN1 neuritin 1 0.000 0.067 0.003 9 4 114 106 114 104 713 954 1231 1248
LOC79015 hypothetical LOC79015 0.000 0.143 0.005 9 4 18 16 17 17 19 23 27 29
SNX21 sorting nexin family member 21 0.000 0.100 0.006 9 4 101 93 100 112 123 149 158 142
SYNE1 spectrin repeat containing, nuclear envelope 1 0.000 0.185 0.007 9 4 64 58 53 57 68 64 71 79
ADPRHL1 ADP-ribosylhydrolase like 1 0.001 0.199 0.009 9 4 44 43 44 44 44 55 51 47
TSC2 tuberous sclerosis 2 0.000 0.258 0.010 9 4 235 231 218 235 244 280 299 292
LAMB2 laminin, beta 2 (laminin S) 0.000 0.763 0.011 9 4 375 347 313 313 428 440 484 455
FGFR1 fibroblast growth factor receptor 1 0.000 0.104 0.012 9 4 398 350 348 365 439 417 489 506
IDUA iduronidase, alpha-L- 0.001 0.517 0.013 9 4 138 125 123 117 129 152 145 140
PTPRM protein tyrosine phosphatase, receptor type, M 0.000 0.107 0.017 9 4 1178 1188 1102 1199 1301 1475 1648 1725
C5orf40 chromosome 5 open reading frame 40 0.029 0.992 0.018 9 4 19 17 15 18 17 19 21 19
STK32A serine/threonine kinase 32A 0.000 0.074 0.019 9 4 21 17 18 22 35 43 56 57
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 10.000 0.169 0.023 9 4 25 21 20 24 27 36 56 60
DENND2A DENN/MADD domain containing 2A 0.000 0.529 0.024 9 4 34 29 27 29 37 36 46 47
ZNF154 zinc finger protein 154 0.089 0.757 0.024 9 4 45 38 35 37 38 45 44 42
CUL9 cullin 9 0.032 0.203 0.026 9 4 72 69 63 66 67 76 70 72
CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 10.310 0.831 0.029 9 4 24 21 20 20 20 23 24 22
LGI4 leucine-rich repeat LGI family, member 4 0.000 0.332 0.029 9 4 34 32 31 34 33 44 44 43
KCNG4 potassium voltage-gated channel, subfamily G, member 40.089 0.532 0.030 9 4 26 26 21 25 23 28 29 29
HOXC8 homeobox C8 0.000 0.395 0.030 9 4 36 34 33 35 103 123 129 130
EFNB1 ephrin-B1 0.004 0.939 0.031 9 4 160 142 137 135 148 166 164 167
PACS2 phosphofurin acidic cluster sorting protein 2 0.000 0.020 0.031 9 4 91 88 90 96 99 112 124 120
TOM1L2 target of myb1-like 2 (chicken) 0.000 0.226 0.032 9 4 125 119 119 130 146 156 171 162
TAS2R14 taste receptor, type 2, member 14 0.000 0.857 0.032 9 4 55 54 46 52 61 57 67 62
PCDHGA7 protocadherin gamma subfamily A, 7 0.151 0.168 0.035 9 4 20 18 16 19 17 23 19 19
SLC7A4 solute carrier family 7 (cationic amino acid transporter, y+ system), member 40.000 0.224 0.035 9 4 33 34 29 36 37 50 48 44
CCND1 cyclin D1 0.000 0.001 0.035 9 4 531 410 368 335 1007 985 943 891
PALM2 paralemmin 2 0.000 0.117 0.035 9 4 104 81 67 73 113 97 124 102
ZDHHC18 zinc finger, DHHC-type containing 18 0.000 0.052 0.035 9 4 228 201 212 221 238 251 290 327
GDF2 growth differentiation factor 2 0.021 0.029 0.037 9 4 39 39 36 42 36 50 43 46
EIF2C1 eukaryotic translation initiation factor 2C, 1 0.015 0.970 0.037 9 4 298 288 269 291 291 302 322 307
PCLO piccolo (presynaptic cytomatrix protein) 0.000 0.148 0.038 9 4 16 16 16 16 18 19 22 24
IRX1 iroquois homeobox 1 0.000 0.535 0.039 9 4 50 47 44 48 74 95 97 94
HOXC9 homeobox C9 0.000 0.096 0.040 9 4 20 21 20 20 75 72 93 92
PDE8A phosphodiesterase 8A 0.000 0.816 0.040 9 4 357 353 310 330 394 384 417 415
ZNF358 zinc finger protein 358 0.000 0.022 0.040 9 4 259 262 263 263 299 338 357 353
DKK2 dickkopf homolog 2 (Xenopus laevis) 0.000 0.397 0.043 9 4 19 18 16 16 46 63 98 87
CCS copper chaperone for superoxide dismutase 0.092 0.732 0.045 9 4 110 102 96 102 98 117 116 106
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Table 2.5: Lists of the 460 transcripts used for cluster analysis in Fig 2.3. Genes 
exhibiting significant Depot*[Dex] interaction (p < 0.05) were used for this cluster 
analysis. Cluster and sub-cluster numbers as well as LME results and expression values 
are given for each gene [Data are the mean of the expression values (linearized scale) for 
the 3 paired samples of Om and Abdsc from the microarray analysis].  
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ECM1 extracellular matrix protein 1 0.000 0.000 0.045 9 4 251 197 183 166 398 356 355 324
CCL27 chemokine (C-C motif) ligand 27 0.042 0.144 0.045 9 4 18 18 16 19 16 21 20 21
PHF21B PHD finger protein 21B 0.055 0.109 0.046 9 4 53 54 53 52 49 59 57 61
KIAA0467 KIAA0467 0.000 0.113 0.046 9 4 89 89 84 92 92 103 109 111
C9orf96 chromosome 9 open reading frame 96 0.037 0.086 0.047 9 4 42 41 37 41 37 52 44 46
PSTPIP1 proline-serine-threonine phosphatase interacting protein 10.000 0.176 0.047 9 4 39 40 38 40 44 53 53 43
NMUR1 neuromedin U receptor 1 0.000 0.105 0.049 9 4 56 57 55 56 59 72 73 77
HTR1A 5-hydroxytryptamine (serotonin) receptor 1A 0.011 0.752 0.050 9 4 20 19 17 17 18 21 20 22
DDIT4L DNA-damage-inducible transcript 4-like 0.000 0.001 0.001 10 5 125 110 111 109 246 163 124 112
CD47 CD47 molecule 0.004 0.017 0.002 10 5 525 540 570 497 757 650 558 513
CCL13 chemokine (C-C motif) ligand 13 0.000 0.090 0.003 10 5 36 40 53 39 131 78 71 40
SEPT10 septin 10 0.230 0.108 0.005 10 5 146 148 146 139 162 148 131 162
STAT4 signal transducer and activator of transcription 4 0.014 0.141 0.006 10 5 36 36 38 39 66 49 39 37
EMP3 epithelial membrane protein 3 0.433 0.011 0.009 10 5 1095 1090 1124 1019 1275 1172 1011 998
GREM2 gremlin 2 0.001 0.002 0.010 10 5 25 21 19 20 80 33 23 22
CA12 carbonic anhydrase XII 0.626 0.000 0.010 10 5 480 515 435 380 726 554 383 287
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d20.000 0.000 0.013 10 5 15 14 10 9 53 24 16 13
CCL8 chemokine (C-C motif) ligand 8 0.087 0.000 0.018 10 5 21 25 21 12 43 29 17 13
SERTAD2 SERTA domain containing 2 0.009 0.000 0.022 10 5 177 166 159 153 239 183 164 151
ADCYAP1R1adenylate cyclase activating polypeptide 1 (pituitary) receptor type I0.259 0.000 0.023 10 5 154 131 73 69 237 163 69 56
PSME1 proteasome (prosome, macropain) activator subunit 1 (PA28 alpha)0.041 0.025 0.023 10 5 510 522 560 493 587 583 533 497
MRAP2 melanocortin 2 receptor accessory protein 2 0.071 0.039 0.035 10 5 14 14 14 14 26 16 14 13
LMNA lamin A/C 0.000 0.041 0.038 10 5 359 354 354 354 464 443 395 362
JAKMIP2 janus kinase and microtubule interacting protein 20.002 0.000 0.039 10 5 28 18 14 13 64 25 18 14
MASP1 mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)0.000 0.123 0.041 10 5 22 19 23 24 46 35 38 33
KITLG KIT ligand 0.240 0.000 0.043 10 5 78 72 61 52 131 72 53 51
LAP3 leucine aminopeptidase 3 0.166 0.167 0.043 10 5 280 315 314 303 343 346 314 277
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 0.990 0.001 0.044 10 5 68 67 61 58 87 63 59 51
SGTB small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta0.005 0.037 0.046 10 5 129 142 143 121 213 160 154 129
OSBPL8 oxysterol binding protein-like 8 0.103 0.006 0.050 10 5 519 514 498 464 701 526 478 475
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Fig 2.S1. Dendrogram of 2 way cluster analysis of transcripts exhibiting a 
Depot*[Dex] interaction. The intensity of the red or blue color in each row represents 
expression values, high or low respectively, which were scaled across both depots, and 
each column represents the culture condition (culture with 0, 1, 10, or 1000 nM Dex is 
designated Om0, Om1, Om10, Om1000, Abdsc0, Abdsc1, Abdsc10, Abdsc1000) as 
described in Methods. 
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ABSTRACT 
The size of visceral adipose tissues (VAT) is associated with risk for 
cardiovascular disease and type 2 diabetes. Glucocorticoids (GCs) cause preferential 
expansion of VAT. GCs are required for adipogenesis, the process by which adipose 
precursors differentiate into mature adipocytes. As compared to abdominal subcutaneous 
(Abdsc), ASCs isolated from VATs have a limited capacity to undergo adipogenesis. 
Impaired adipogenic capacity forces excessive growth of existing adipocytes, and this 
hypertrophic growth increases risk for cell death, inflammation, and adipose tissue 
dysfunction, as observed in omental (Om) VAT. Our published microarray study of 
cultured adipose tissue demonstrated that the anti-adipogenic TGFβ family of secreted 
factors is highly enriched in VAT. Further, the GC suppression of the TGFβ pathway was 
greater in Abdsc than Om. Thus, we hypothesized that Om tissue and ASCs secrete 
factors that inhibit adipogenesis in an autocrine/paracrine manner, that Om is resistant to 
the action of glucocorticoids to suppress these factors. .  
Conditioned media (CM) from Om adipose tissue suppressed adipogenesis more 
potently than CM from Abdsc (46 ± 10 vs. 21 ± 5 p<0.05, % suppression) and CM from 
Om ASCs suppressed differentiation more than CM from Abdsc (70 ± 10 vs. 35 ± 19, % 
suppression, p<0.05). In addition, the magnitude of the anti-adipogenic effect of CM 
correlated with the capacity of donors adipose stem cells to differentiate (R2=0.4, p<0.01, 
n=17). Addition of the glucocorticoid receptor agonist, Dexamethasone (Dex) during 
generation of CM reduced this anti-adipogenic effect and Om was less responsive to 
suppression by Dex. Protein levels of activin A (Western blot) and TGFβ (Bioassay), 
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known inhibitors of adipogenesis, were higher in Om ASC CM (activin A; 74 ± 16 AU in 
Om vs. 9 ± 4 AU in Abdsc, n=14, p<0.05 and TGFβ; 30 ± 4 vs. 10 ± 1 pM, n=14, 
p<0.05). Both factors signal via cell membrane associated receptors that lead to 
phosphorylation of SMAD2 and 3 and basal SMAD2 phosphorylation levels were higher 
in Om compared to Abdsc ASCs. Blocking TGFβ signaling using the TGFβ receptor 
kinase inhibitor, SB431542 or siRNA mediated knockdown of SMAD2/3 proteins 
markedly improved differentiation of Om ASCs. In Abdsc ASCs, Dex dose dependently 
decreased SMAD2 phosphorylation and increased the protein expression of the TGFβ co-
receptor, TGFBR3, by 5-fold, which may decrease TGFβ signaling. In contrast, Dex did 
not suppress SMAD2 phosphorylation and had only weak effects to increase TGFBR3 in 
Om ASCs. Taken together these data suggest that resistance to GC downregulation of 
TGFβ signaling contributes to the poor adipogenic capacity of Om ASCs via autocrine or 
paracrine mechanisms, possibly restraining healthy expansion of VAT. 
 
INTRODUCTION 
The size of visceral adipose depots increases risk of cardiovascular disease and 
type 2 diabetes (2). In order to store excess nutrients, adipose depots can expand via two 
processes: 1) growth of existing adipocytes, hypertrophy and 2) Increasing the number of 
mature adipocytes through recruitment and differentiation of precursors, hyperplasia. 
Adipose tissues with large, hypertrophic adipocytes exhibit higher rates of cell death, 
increased inflammation and increase risk of cardiometabolic disease (190-192). Tchernof 
showed that in 35 women of varying BMIs (20-41, 25 ± 3 kg/m2) poor adipogenic 
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capacity of adipose precursors from the abdominal subcutaneous (Abdsc) depot predicts 
large adipocyte size in both the Abdsc and visceral (Omental, Om) depots, and is 
associated with increased risk of systemic insulin resistance (78). However, the 
association of omental adipogenic rates and visceral fat cell size was not assessed. The 
poor adipogenic capacity of Om ASCs likely contributes to adipocyte hypertrophy and 
the deleterious effects of lipid spillover from Abdsc, and may be as important in the 
metabolic consequences.   
Adipose stem cells (ASCs) isolated from human visceral adipose tissue have 
lower adipogenic capacity compared to ASCs from subcutaneous depots (11, 106). The 
mechanisms that govern this difference are incompletely understood. Prevailing 
hypotheses point to distinct developmental origins of visceral and Abdsc adipocytes as 
well as differences in distinct preadipocyte populations that have variable adipogenic 
capacities (106, 110, 184). Additionally, numerous studies have identified factors that 
both negatively and positively impact adipogenesis, including secreted proteins (TNFα, 
TGFβ, WNTs, BMPs, etc.) and extracellular matrix components (108, 109). Depot 
differences in these factors could underlie the observed differences in adipogenic 
capacity. Our microarray data from Chapter 2 (64) indicated that GCs may regulate many 
of these factors in the context of whole adipose tissue. While most prior studies focused 
on the role of macrophage derived factors as effectors of adipogenic capacity, we also 
considered regulation at the level of the ASC (60, 193, 194). 
 GCs are required for the differentiation of human preadipocytes. GCs increase 
adipocyte differentiation through multiple mechanisms by both increasing the expression 
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of key adipogenic transcription factors C/EBPδ and C/EBPβ (59) and suppressing anti-
adipogenic factors (195) . However, few studies have examined the depot-dependent 
effects of GCs on adipogenesis (196). Resistance to the pro-adipogenic effects of GCs 
may contribute to the poor adipogenic capacity of visceral ASCs. Our tissue microarray 
data (64) suggested that GC may modulate many factors in the TGFβ pathway depot-
dependently, suggesting that depot differences in GC action on this pathway may be 
important for depot differences in adipogenic capacity. Understanding the mechanisms 
that underlie this depot-dependent difference in adipogenic capacity may provide 
molecular targets that could promote healthy expansion of adipose depots, limiting the 
deleterious effects of central obesity. 
The TGFβ pathway includes many secreted factors that influence adipogenesis, 
including TGFβ, activin A, and BMPs. Both TGFβ and activin A are produced by 
adipocyte precursors and inhibit adipogenesis in both 3T3-L1 and human multipotent 
adipose derived stem cells via phosphorylation of SMAD2/3 which interfere with C/EBP 
transcriptional activity (116, 118, 119). Dani’s group showed that activin A mRNA was 
expressed in Abdsc, Om and mesenteric ASCs and downregulated during differentiation 
by GCs (119). Depot differences in ASC expression of activin A mRNA are not 
addressed as data were presented only as a percent of day 0 expression within depot, 
preventing comparison of the absolute values of its expression among Om, Abdsc, and 
mesenteric ASCs. In addition, depot differences in TGFβ secretion and/or TGFβ 
signaling in ASCs were not known. Depot differences in the production of these factors 
from adipose tissue or ASCs could strongly impact the adipogenic capacity of visceral 
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and Abdsc depots and the ability of either depot to expand via hyperplasia under the 
stress of overnutrition.  
The overall objectives of these investigations were 1) To examine the contribution 
of secreted factors in the poor adipogenic capacity of Om ASCs, we assessed the effects 
of conditioned media (CM) collected from paired human Om and Abdsc ASCs and 
tissues on adipocyte differentiation, 2) To determine the contribution of the TGFβ family 
of secreted factors in the poor adipogenesis of Om ASCs, we measured the content of 
these factors in CM and whether blockade of TGFβ signaling affected adipogenesis, and 
3) To determine the role resistance to GCs plays in the poor adipogenic capacity of Om 
ASCs, we examined how GCs alter TGFβ signaling in Om and Abdsc ASCs. 
 
MATERIALS AND METHODS 
Isolation of Adipose Stem Cells 
Paired Om and Abdsc ASCs were isolated as previously described (197). Briefly, adipose 
tissue was collected from patients undergoing elective surgeries, minced and placed in 
collagenase (Type I, Worthington, Lakewood, NJ). Digested tissue was filtered through 
250 µm mesh and rinsed with PBS. Collected cells were centrifuged, allowing separation 
of the adipocyte and stromal vascular fractions (SVF). After removing the adipocyte 
fraction and supernatant, the SVF was suspended in RBC lysis buffer briefly and 
centrifuged again. The resulting pellet was suspended in growth media (α-MEM, 10% 
FBS) and cells were subcultured for up to 5 passages. All experiments were carried out in 
cells that are not pooled passaged 4 or 5 times. 
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Cell Culture 
Confluent pairs of human Om and Abdsc ASCs (4 Male, 19 Female; BMI 25-60, 44 ±2 
kg/m2; Age 20-52, 39 ± 2) were grown and induced to differentiate as described 
previously (197). Confluent ASCs were treated for 7 days using a differentiation cocktail 
of 100 nM insulin, 100 nM dexamethasone, 1 µM rosiglitazone, 2 nM T3, 10 µg/mL 
transferrin, 0.5 mM IBMX, 33 µM d-biotin and 17 µM pantothenate in DMEM/F12. 
Following induction, cells were switched to maintenance media containing 10 nM 
insulin, 10 nM Dex, 33 µM d-biotin, and 17 µM pantothenate in DMEM/F12 for an 
additional 7 days.  
 
Generation of ASC conditioned media (CM) 
Fourteen pairs of Om and Abdsc ASCs from individual subjects (4 Male, 10 Female, 
BMI 23-63, 41 ± 3 kg/m2; Age 31-58, 42 ± 1) were grown to confluence in 12 well plates 
in α-MEM + 10% FBS. Cells were switched to DMEM/F12 + 1% FBS for collection of 
CM (1 mL/well). Control media was also obtained by incubating the media without 
ASCs. After 16 hours, media from each subject was collected and divided into 500 µL 
aliquots, and stored at -80°C. For Dex modified CM, ASCs were incubated for 16 hours 
in DMEM/F12 + 1% FBS with or without 10 nM Dex. Heat inactivated CM was 
generated by incubating samples at 95°C for 15 minutes.  
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Generation of adipose tissue CM 
Paired samples of Om and Abdsc adipose tissue from 8 subjects (7F, 1M; age 34 ± 4 yr; 
BMI 41 ± 1) were taken during elective gastric bypass surgeries in obese patients free of 
diabetes, inflammatory diseases or drugs that could affect metabolism, as previously 
described (136). All subjects provided informed consent. Tissue was processed for organ 
culture as described (198, 199). Briefly, excised tissue was carried to the laboratory in 
room temperature Medium 199, minced into 5-10 mg fragments, quickly rinsed in 0.9% 
saline, and ~100-400 mg were placed in organ culture at a ratio of 15-20 mg tissue to 1 
mL of Medium 199 supplemented with 0.7 nM insulin ± 10 nM Dex. After 4 hours media 
was collected and replaced. After another 24 hours, media was collected, divided into 1 
mL aliquots and stored at -80°C. 
 
Culture with CM 
Abdsc ASCs from a single, well differentiating donor were grown to confluence. Cells 
were then differentiated in the presence of CM. For ASC CM, 375 µL 1.5x CDM and 125 
µL conditioned media collected previously, resulting in a 25% conditioned media mix. 
For tissue conditioned media, a mix of 250 µL 2X CDM and 250 µL CM was used, 
resulting in 50% CM. Cells were refed on day 3, and switched to 375 µL 1.5X 
Maintenance media + 125 µL CM on day 7 and refed on day 10 and day 13. Abdsc ASCs 
were differentiated in the presence of 5µM SB431542 (SB) ± CM from poorly 
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differentiating Om ASCs for 14 days of differentiation. Cell lysates were collected on day 
14 of differentiation.  
 
SMAD signaling in ASCs 
Confluent Abdsc and Om ASCs were fed with 1% FBS in DMEM/F12 for 16 hours. 
Basal SMAD phosphorylation was assessed in untreated cells. ASCs were incubated ± 5 
µM SB431542 (SB, Sigma-Aldrich, St. Louis, MO) for 15 minutes, followed by a 30 
minute incubation with conditioned media (25%), recombinant human TGFβ1 
(Peprotech, Rocky Hill, NJ), or control.  
 
Treatment of ASCs with TGFβ, IL-6, and SB during differentiation  
Confluent Abdsc ASCs were differentiated in the presence of TGFβ (0-400 pM), IL-6 (0-
100 ng/mL), or varying concentrations of SB (0-5 µM) during 14 days of differentiation.  
 
Measurement of activin A and IL-6 in CM 
Cellular and secreted activin A were determined by immunoblot. Secreted IL-6 content in 
CM was measured using commercial ELISA kits, following the manufacturer’s protocol 
(R&D Systems, Minneapolis, MN). Fluorescence was compared to a standard curve to 
determine final concentrations. 
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Measurement of TGFβ in CM 
Active and total TGFβ concentration in CM was determined by a PAI-1 promoter driven 
luciferase assay (200). Mink lung epithelial cells were incubated overnight with ASC CM 
(DMEM/F12 + 1%FBS) and collected in Luciferase lysis buffer (Promega, Madison, 
WI). To assess total TGFβ, CM samples were incubated at 90°C for 10 minutes, while 
active TGFβ was assessed using untreated CM. Total luciferase activity was determined 
using a BioTek Synergy HT plate reader. Luminescence values were compared to a 
standard curve generated from cells treated with control media containing recombinant 
human TGFβ. 
 
siRNA Transfection of ASCs 
siRNA transfection was carried out as described previously (201). Briefly, ASCs were 
seeded at 7,500 cells/cm2 in 12 well plates in the morning in α-MEM + 10% FBS. After 6 
hours, Hiperfect and siRNA (Applied Biosystems, Foster City, CA) were mixed in 
100uL/well serum free α-MEM and allowed to sit for 15 minutes with intermittent 
shaking. Media was replaced with 250 µL α-MEM + 5% FBS and 100 µL of the siRNA/ 
Hiperfect/ serum free α-MEM mix were slowly added to the media in the well (final 
concentration 40 nM). Cells were refed with growth media after an overnight 
transfection, grown to confluence and differentiated with standard protocol. Scrambled 
siRNA was used as a control. 
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Cell processing and Western blot analysis 
Cells were rinsed with ice cold PBS and collected in cell lysis buffer (Cell Signaling, 
Danvers, MA) supplemented with protease inhibitor cocktail (Roche). Samples were 
sonicated, centrifuged, and combined with 4X LDS loading buffer (Thermo-Fisher) and 
boiled for 5 minutes. Proteins were resolved in NuPAGE 10% Bis-Tris Midi gels 
(Thermo Fisher), transferred, blocked in 5% milk then probed for proteins of interest. 
Primary antibodies used were rabbit-anti-activin A (Abcam, Cambridge, UK), rabbit anti-
HSP90 (Santa Cruz), rabbit anti-ATGL (Generated in lab (58), 1/5000), rabbit anti-
PPARγ (Cell Signaling), rabbit anti-SMAD2/3 (Abcam), rabbit anti-Phospho-SMAD2 
(Ser465/467) (Cell Signaling), rabbit anti SMAD4 (Cell Signaling), and rabbit anti-
TGFBR3 (Cell Signaling). All primary antibodies were used at a dilution of 1/1000, 
unless otherwise noted. After incubating with HRP-linked secondary antibodies, 
chemiluminescence images were captured and band intensities were quantified using 
Multi Gauge software (Fuji Film, Japan). 
 
Gene Expression 
Total RNA was isolated using Trizol (Life technologies, Carlsbad, CA), and used for 
quantitative PCR (qPCR). Total RNA was reverse transcribed using Transcriptor First-
Strand cDNA synthesis kit (Roche, Indianapolis, IN) and qPCR was performed on a 
LightCycler 480 II (Roche) with commercially available TaqMan probes (Life 
Technologies). Cyclophilin A (PPIA) was used as a reference gene, and relative 
expression levels were calculated (ΔCT).  
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Measurement of triacylglycerol (TAG) content 
TAG was assessed from cell lysates at day 14 of differentiation using a modified 
commercial protocol. Briefly, a fraction of cell lysates were incubated at 37°C for 90 
minutes with Triacylglycerol Reagent (Sigma). Following this incubation, free glycerol 
was determined using a fluorometric assay.  
 
Measurement of DNA content 
DNA content was assessed using a QuantiT™ Picogreen® dsDNA kit (Thermo-Fisher). 
Cell lysates were diluted 1:50 in Tris-EDTA with 1/200 Picogreen® dye and mixed for 5 
minutes. Fluorescence was determined on a TECAN Infinite® M1000 microplate reader. 
Sample fluorescence was compared to a standard curve to determine DNA content. 
TAG/DNA was calculated. 
 
Statistics 
Data are presented as mean ± SEM and analyzed using Graphpad Prism. 2-Way ANOVA 
was used to assess the interaction of depot, differentiation degree, and Dex treatment. 
When the main effect was significant, Student’s T tests were used to compare groups. 
Comparisons between groups within differentiation category (Good Om vs. Poor Om) 
utilized unpaired T tests and comparisons between depots were paired T tests. 
Differences between means were considered significant when p<0.05.  
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RESULTS 
The TGFβ pathway is enriched in Om adipose tissue and highly regulated by GCs 
We previously performed microarray analysis on adipose tissue from Abdsc and 
Om depots in the presence of various doses of the glucocortiocoid recptor agonist 
Dexamethasone (Dex, 0, 1, 10, 1000 nM) (Chapter 2, (64)). Gene set enrichement 
analysis (GSEA) identified the TGFβ signaling pathway as being highly downregulated 
by Dex in both depots (Figure 3.1). A separate GSEA analysis confirmed that basal 
enrichment is higher in Om compared to Abdsc. Om tissue showed higher basal 
expression of TGFβ family members (INHBA, TGFβ1/2/3, THBS1/2) and remained at 
higher expression leves after culture with Dex compared to Abdsc. Inhibin Beta A 
(INHBA) has 4 fold greater expression compared to Abdsc at 0 nM Dex, and remains 
more than 2 fold greater expression at higher doses of Dex; this expression pattern was 
confirmed by qPCR (64). TGFβ 1, 2 and 3 were expressed between 1.5 and 2 fold greater 
at baseline (d7 culture with insulin alone in Omental tissue (as assessed by microarray) 
and remain higher than Abdsc after culture with all doses of Dex. This differential 
enrichment of TGFβ signaling molecules prompted us to investigate the role of activin A 
and TGFβ in determining the adipogenic capacity of Om and Abdsc ASCs.  
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Figure 3.1. Heat map of Dex suppressed secreted factors in the TGFβ pathway. Gene 
set enrichment analysis identified the TGFβ signaling pathway as highly downregulated 
by Dex in Om and Abdsc adipose organ cultures as determined by fold change compared 
to 0 nM. Data are an average of 3 mRNA expression values from 3 independent subjects, 
red=high; blue=low. Expression data used for GSEA analysis were derived from Chapter 
2 (64).  
 
Large variability in the adipogenic capacity of Om and Abdsc ASCs in vitro 
It is well known that human and mouse ASCs from visceral depots differentiate poorly in 
vitro (11, 103, 106). We confirmed these previous findings in 23 human Om and Abdsc 
ASC pairs (19F, 4M; 9AA, 6H, 8CC; BMI 44 ± 2 kg/m2; Age 39 ± 2). Overall, the 
degree of Om and Abdsc differentiation within subject correlated well (i.e. good 
Om=very good Abdsc). Despite using a very potent adipogenic cocktail (88), most Om 
ASCs were only able to reach approximately 10% of cells showing visible lipid droplets. 
Of these 23 pairs, only 6 Om samples were able to differentiate to more than 50% of cells 
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showing visible lipid droplets. In contrast, their paired Abdsc ASCs range from 40-95% 
of cells differentiating (Figure 3.2A). This range of visible, TAG laden cells was reflected 
in the protein expression of the late adipogenic marker, PPARγ, measured on day 14 of 
differentiation, (Figure 3.2B, 0.3 ± 0.1 AU vs. 1.4 ±0.1 in Om vs. 0.8 ± 0.2 vs. 1.6 ± 0.1 
in Abdsc, p<0.05, good vs. poor differentiators). ATGL, another marker used for 
assessment of differentiation, correlated with PPARγ expression (Figure 3.2C). 
Mechanisms that underlie this lower adipogenic potential in Om vs. Abdsc ASCs and 
poor vs. better Om ASCs are unclear.  
 
Figure 3.2. Variability in the differentiation capacity of Om ASCs. The adipogenic 
capacity (as measured by PPARγ and ATGL protein at day 14 of differentiation) of Om 
ASCs is lower than that of Abdsc ASCs. (A) Representative images of 23 pairs of ASCs 
after 14 days of differentiation are shown. (B) A subset of Om ASCs differentiated 
significantly better than most as measured by PPARγ protein expression at day 14 (n=6 of 
23, p=0.001). PPARγ protein levels were measured in Om and Abdsc ASCs at day 14 of 
differentiation and were normalized to HSP90. (C) ATGL correlated well with PPARγ, 
and was used as a measure of differentiation in experiments   
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Conditioned media from adipose organ culture inhibited adipogenesis of Abdsc 
ASCs and Dex decreased the negative effect of OmCM  
 
Adipose tissue is comprised of multiple cell types that may be contributing to the 
paracrine environment of ASCs, possibly contributing to their adipogenic capacity. GCs 
are known to decrease inflammation and promote adipogenesis. To test the hypothesis 
that Om tissue secretes factors that inhibit adipogenesis, and GCs decrease the production 
of these factors, we collected CM from 8 paired Om and Abdsc tissues during 24 hr 
adipose organ cultures in serum-free media plus 0.7 nM insulin (-Dex) or 0.7 nM insulin 
+ 2.5 nM Dex (7F, 1M, 34 ± 4 yrs, BMI 41 ± 1 kg/m2). Addition of CM from both depots 
during differentiation decreased adipogenesis of Abdsc ASCs, as measured by TAG 
accumulation (mg TAG/mg DNA). CM from Om tissue reduced TAG accumulation 
significantly more than CM from Abdsc (Figure 3.3, 70% ± 4% reduction by Om-Dex vs. 
35% ± 7% reduction by Abdsc-Dex, compared to the control, Om vs. Abdsc, p<0.05, 
n=8). Addition of Dex during the organ cultures reduced the anti-adipogenic effect of Om 
tissue CM (Om-Dex; 71 ± 7 vs. Om+Dex 56 ± 17, p<0.001, n=8, % Suppression vs. 
control TAG, mg TAG/mg DNA). In contrast, Dex had no effect on the inhibitory effect 
of AbdscCM (Abdsc-Dex; 35 ± 7 vs. Abdsc+Dex; 40 ± 5, p>0.05, n=8, % Suppression vs 
Control TAG mg TAG/mg DNA). 
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Figure 3.3. CM from adipose organ culture inhibited differentiation of Abdsc ASCs. 
Media conditioned for 24h with organ cultures of paired Om and Abdsc adipose tissue 
(50%) was added to Abdsc ASCs during a maximal differentiation protocol of 14 days. 
TAG and DNA were measured (mg TAG/mg DNA) as a marker of adipogenesis and data 
are presented as mean % suppression ± SEM compared to control. CM from Om tissue 
inhibited differentiation more than CM from Abdsc (n=8, p<0.001, paired T test). 
Addition of Dex to organ cultures partially prevented the negative effect of OmCM, but 
not AbdscCM (n=8, *p<0.05 by paired T test).  
 
Conditioned media from poorly differentiating Om ASCs inhibited adipogenesis 
and Dex suppressed secretion of anti-adipogenic factors in the CM. 
To determine if ASCs contribute to an anti-adipogenic secretory profile in vitro and 
control their adipogenic potential through autocrine and paracrine actions, we collected 
CM from paired Om and Abdsc ASCs and tested their effects on differentiation. CM 
from poorly differentiating Om ASCs inhibited differentiation the most (81 ± 3 % 
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suppression), followed by their Abdsc pairs (33 ± 18% suppression). CM from well 
differentiating Om and Abdsc ASCs inhibited differentiation only by 16 ± 9 and 10 ± 
12%, respectively. These data suggest that Om ASCs with low adipogenic capacity 
secrete more anti-adipogenic factors that act in an autocrine and paracrine fashion. 
To test whether Dex suppressed the secretion of anti-adipogenic factors from 
ASCs, we obtained CM in the presence or absence of Dex (10 nM) during the overnight 
collection. 10 nM Dex alone did not affect differentiation (Control; 161 mg TAG/mg 
DNA vs. 10 nM Dex; 153mgTG/mg DNA). Addition of Dex during the collection of CM 
decreased the inhibitory effect of both Om and AbdscCM (Figure 3.4B, Om-Dex 62 ± 
11% vs. Om+Dex 33 ± 7% and Abdsc-Dex 29 ± 6% vs. Abdsc+Dex 9 ±6%, p<0.001, 
n=5).  
To confirm that the anti-adipogenic effects of CM were due to secreted protein 
factors and not smaller organic molecules or depletion of essential nutrients, we heat 
inactivated CM (90°C for 30 mins). Heat inactivation of Om ASC CM prevented its anti-
adipogenic effects (Figure 3.4C, 64 ± 16 vs. 36 ± 16%, Control vs. Heat inactivated 
%suppression, p<0.05, n=5), suggesting that the inhibitory effect is likely to be due to 
secreted proteins.  
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Figure 3.4. CM from poorly differentiating Om ASCs inhibited adipogenesis of 
Abdsc ASCs: Dex suppressed the secretion of anti-adipogenic factors in the CM. (A) 
Treating well differentiating Abdsc ASCs with CM from poorly differentiating Om ASCs 
(25%) decreased differentiation more than their Abdsc Pairs and well differentiating Om 
ASCs, n=7, p=0.003). TAG/DNA content was used as a measure of differentiation degree 
and data are presented as % suppression compared to the control media. (B) Addition of 
Dex during overnight collection prevented some of the inhibitory effect of OmCM, n=5, 
p<0.05. (C) Heat inactivation of OmCM (OmCM HI) reduced the inhibitory effect of CM 
n=5, p<0.05. 
 
 Conditioned media from poorly differentiating Om ASCs contained more IL-6, but 
IL-6 did not inhibit differentiation. 
We next investigated what factors may be contributing to the anti-adipogenic 
effect of CM. Given that Om adipose tissue is known to be more inflamed than Abdsc 
and proinflammatory cytokines are known to be antiadipogenic (21, 190), we measured if 
cultures of Om ASCs secrete more inflammatory cytokines. We used IL-6 as a measure 
of general inflammation. CM from poorly differentiating Om ASCs had significantly 
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more IL-6 than their Abdsc pairs (Figure 3.5A, Om; 2719 ± 332 pg/mL vs. Abdsc; 319 ± 
90 pg/ml, p<0.05 n=7). Additionally, CM from poor differentiating Om ASCs contained 
significantly more IL-6 than well differentiating Om (Poor; 2719 ± 332 pg/mL vs. good; 
442 ± 79 pg/mL). We next tested whether high IL-6 mediated the anti-adipogenic effects 
of CM. The addition of IL-6 (10 or 100 ng/mL) however, did not decrease differentiation, 
and at higher doses IL-6 increased differentiation by >50% at high doses (Figure 3.5B, 
p<0.05 vs. control), while TNFα inhibited. 
 
Figure 3.5. CM from poorly differentiating Om ASCs contained significantly more 
IL-6 than CM from well differentiating ASCs, but IL-6 did not inhibit 
differentiation. (A) Poorly differentiating Om ASCs secreted significantly more IL-6 
than their Abdsc pairs as measured by ELISA n=7, different letters indicate significant 
differences between groups, p<0.05, (B) Addition of IL-6 during differentiation to Abdsc 
ASCs did not decrease differentiation degree, as measured by TAG (mgTAG/mgDNA) 
accumulation, but rather increased it compared to control at higher doses. TNFα, used as 
a positive control, inhibited differentiation, *p<0.05, n=4 mean ± SEM) 
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ROLE OF TGFβ PATHWAY IN MODULATING ADIPOGENESIS 
Poorly differentiating Om ASCs secreted more activin A, knockdown modestly 
improved differentiation 
Expression of INHBA, a known anti-adipogenic factor (119) was higher in Om 
tissue (64). We tested the hypothesis that secretion of activin A is higher in CM from Om 
ASCs. CM from poorly differentiating Om ASCs had significantly more activin A than 
their Abdsc pairs (Figure 3.6A, p<0.05, n=7). In addition, poorly differentiating Om 
ASCs secrete significantly more activin A than well-differentiating Om ASCs (p<0.05, 
n=7). To test the hypothesis that high activin A contributes to the poor differentiation of 
Om ASCs, we performed siRNA mediated knockdown of the activin A gene, INHBA 
(201). siRNA mediated knockdown (KD) resulted in >90% reduction in cellular and 
secreted activin A protein (Figure 3.6B). INHBA knockdown increased adipogenesis of 
Om ASCs as demonstrated by in an 11 fold in increase in LPL mRNA (Figure 3.6C, 
p<0.05, n=3), and only a 2 fold increase in LPL mRNA in Abdsc ASCs. Although 
INHBA knockdown greatly improved differentiation of Om ASCs, they did not reach the 
same levels observed in Abdsc ASCs, indicating other secretory factors also play a role in 
the poor adipogenic capacity of Om ASCs.  
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Figure 3.6. Conditioned Media from poorly differentiating Om ASCs contained 
more activin A and knockdown of the INHBA gene improved differentiation. (A) 
Conditioned media from poorly differentiating Om ASCs (O) secreted significantly more 
activin A than their Abdsc (S) pairs. Immunoblot samples are arranged in pairs in order of 
adipogenic capacity of Om (n=14). (B) siRNA mediated knockdown of INHBA in ASCs 
decreased secreted and cellular INHBA >90% (n=3). (C) INHBA KD resulted in an 
improvement in differentiation, determined by 11 fold increase in LPL expression ( in 
Om ASCs (n=3, p<0.05, by paired T test). mRNA data are shown as delta-CP using PPIA 
as control. 
 
Active TGFβ was significantly higher in from poorly differentiating Om ASCs and 
TGFβ inhibited adipogenesis 
Given INHBA KD did not increase the differentiation of Om ASCs to the levels 
of Abdsc ASCs, we examined other factors that could contribute to the anti-adipogenic 
effect of OmCM. Like INHBA, mRNAs for all 3 isoforms of TGFβ were more highly 
expressed in Om tissue according to our microarray (Fig 3.1). Active TGFβ levels, as 
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measured by a PAI-1 promoter driven luciferase assay (200), were higher in CM from 
poor differentiating Om ASCs compared to their Abdsc pairs (Figure 3.7A, 39 ± 3 vs. 10 
± 1 pM, n=7, p<0.05). Poor differentiating Om ASCs also secreted significantly more 
active TGFβ than well differentiating Om and Abdsc ASCs (20 ± 3 and 9 ± 1 pM, n=7 
p<0.05). Additionally, poorly differentiating Om ASCs had significantly more total 
TGFβ compared to well differentiating Om. (Poor Om, 50 ± 4 pM vs. good Om 23 ± 3 
pM total TGFβ, n=7; assessed by the same method, following heat activation). A greater 
percentage of the active TGFβ was higher in CM from Om ASCs, compared to Abdsc 
(Figure 3.7C, Om 69 ± 9 vs. Abdsc 31 ± 8 % total). Treatment of well differentiating 
Abdsc ASCs with TGFβ (400 pM) decreased differentiation of Abdsc ASCs as measured 
by TAG accumulation on d14, compared to control (Figure 3.7D, 12.7 ± 1.3 vs. 3.2 ± 0.5 
mg TAG/mg DNA, p<0.05, n=4).  
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Figure 3.7. Poorly differentiating Om ASCs secreted significantly more active TGFβ 
and TGFβ suppressed differentiation of Abdsc ASCs. Levels of (A) active and (B) 
total TGFβ were assessed in CM from paired samples of Om and Abdsc ASCs using a 
bioassay. CM from poorly differentiating Om ASCs secreted significantly more active 
and total TGFβ than their Abdsc pairs (*p<0.05, n=7). Poorly differentiating Om ASCs 
had a greater proportion (C) of TGFβ in the active form. (D) Addition of TGFβ during 
differentiation suppressed adipogenesis of Abdsc ASCs (*p<0.05 compared to control by 
paired T test, n=4) 
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Basal SMAD2 phosphorylation was higher in OM ASCs. 
Both activin A and TGFβ signal through the TGFβ receptors that phosphorylate SMAD2 
and 3. Therefore we hypothesized that basal phosphorylation of SMAD2 would be higher 
in poor differentiating Om ASCs due to higher levels of these ligands in CM. Indeed, 
basal SMAD2 phosphorylation was higher in Om ASCs compared to Abdsc (Figure 
3.8A, 0.8 ± 0.2 vs. 0.3 ± 0.1, n=5, p<0.05). Additionally, SMAD2 phosphorylation levels 
in preadipocytes negatively correlated with their differentiation capacity, as measured by 
ATGL on d14 of differentiation in both depots (Figure 3.8B, Om, r=-0.9, p<0.001; Abdsc 
r=-0.6, p<0.001, n=5).  
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Figure 3.8. Smad2 Phosphorylation was higher in poorly differentiating Om ASCs 
and correlated with differentiation capacity. (A) Basal SMAD2 phosphorylation levels 
were higher in cell lysates of poorly differentiating Om ASCs compared to their Abdsc 
pairs and compared to well differentiating Om ASCS. (B) Basal SMAD2 phosphorylation 
in ASCs negatively correlated with ATGL protein at day 14 of Differentiation (Om r=-
.90, p<0.001; Abdsc r=-0.64, p<0.05 by paired or unpaired T test) 
 
OmCM increased SMAD2 phosphorylation and the TGFβ receptor kinase inhibitor 
SB431542 reduced the anti-adipogenic effect of CM  
The higher basal activity of TGFβ-Smad2/3 signaling in Om ASC cultures prompted us 
to test if OmCM can induce SMAD2 phosphorylation. Indeed, OmCM increased SMAD2 
phosphorylation and this was blocked by preincubation with the TGFBR1 kinase 
inhibitor SB431542 (SB, 5 µM) (Figure 3.9 A, n=1). We next tested if inhibition of 
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TGFβ signaling can prevent the anti-adipogenic effect of OmCM and improve the 
differentiation of Om ASCs. SB increased differentiation of Om and Abdsc ASCs, as 
measured by ATGL (Figure 3.9B & C, p<0.05, n=4). Additionally, SB blocked the anti-
adipogenic effects of OmCM (p<0.05, n=4, paired T test).  
 
Figure 3.9. OmCM increased SMAD2 phosphorylation and SB improved the 
differentiation Om and Abdsc ASCs and prevented the negative effects of OmCM. 
(A) Treatment of Abdsc ASCs with CM from Om ASCs increased SMAD2 
phosphorylation similar to 40 pM TGFβ (n=1). (B) Om ASCs treated with SB during 
differentiation had increased adipogenic capacity in a dose dependent manner, as 
measured by ATGL protein at day 14 of differentiation (n=4, p<0.05). (C) Treatment of 
Abdsc ASCs during differentiation blocked the anti-adipogenic effect of OmCM 
(*p<0.05 by paired t test, n=4).  
 
Knockdown of SMADs improved differentiation of Om and Abdsc ASCs 
To define the importance of SMADs in mediating the anti-adipogenic effect of TGFβ in 
Om and Abdsc ASCs, we performed siRNA mediated KD of SMAD2, SMAD3, and the 
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co-SMAD, SMAD4, in Om ASCs (Figure 3.10). We were able to achieve >90% 
knockdown of SMAD2, ~60% KD of SMAD3, and ~90% KD of SMAD4. KD of 
SMAD2 improved adipogenesis by 3-fold, as measured by FABP4 on day 14 (127 ± 77 
vs. 325 ± 127, p<0.05 n=5) and partially blocked the anti-adipogenic effect of TGFβ in 
newly differentiated Om ASCs (86 ± 9 vs. 36 ± 19 % Suppression, p<0.05, n=5 by paired 
ttest). SMAD3 KD did not improve differentiation of Om ASCs and did not decrease the 
anti-adipogenic effect of TGFβ. Combined KD of SMAD2/3 improved differentiation 
similarly to that of SMAD2 KD (388 ± 160 p<0.05, n=5) and completely blocked the 
anti-adipogenic effect of TGFβ (23 ± 18 % Suppression vs. no TGFβ, p<0.05 n=5). 
Additionally, knockdown of the co-SMAD, SMAD4, improved differentiation by ~2 fold 
(p<0.05, n=5), and partially blocked the negative effect of TGFβ (46 ± 12 %Suppression, 
p=0.07, n=5). Similar effects were seen with Abdsc ASCs.  
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Figure 3.10. Knockdown of SMAD2, 3 and 4 improved differentiation of Om ASCs 
and are required for the antiadipogenic effects of TGFβ. (A) Representative blots of 
SMAD 2,3, and 4 in Om ASCs following siRNA mediated knockdown. (B) Knockdown 
of SMAD2 improved differentiation in Om ASCs as measured by mRNA expression of 
the late adipogenic marker FABP4 and partially blocked the anti-adipogenic effect of 
TGFβ. Combined KD of SMAD2/3 improved differentiation and blocked the effect of 
TGFβ. Knockdown of SMAD4 also increased differentiation of Om ASCs, n=5, *p<0.05 
significantly different from control, Φp<0.05 different from -TGFβ, paired T test. 
 
Dex decreased activin A and TGFβ content in CM from Om and Abdsc ASCs 
To test if Dex can decrease the concentrations of activin A and TGFβ in conditioned 
media from ASCs, we incubated 5 pairs of Om and Abdsc ASCs in the presence or 
absence of Dex (10 nM) for 16 hours. Dex decreased activin A in both Om and Abdsc 
ASCs Om (Figure 3.11A, n=5, Om-Dex 66 ± 17 vs. Om+Dex 34 ± 13, AU p<0.05; 
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 Abdsc-Dex 6 ± 2 vs. Abdsc+Dex 3 ± 1 AU, p<0.05, paired ttest), though it remained 
higher in Om ASCs (Om+Dex 34 ± 13 vs. Abdsc+Dex 3 ± 1, p<0.05 paired ttest). TGFβ 
exhibited a similar pattern, (Figure 3.11B, n=5, Om-Dex 2797 ± 951 vs. Om+Dex 1626 ± 
396, p<0.05 paired test), but Dex did not decrease TGFβ from Abdsc ASCs. 
Figure 3.11. Dex decreased activin A and TGFβ in CM from Om ASCs. Overnight 
treatment of pairs of Om and Abdsc ASCs with Dex decreased (A) activin A and (B) 
TGFβ in CM. n=5, different letters indicate significant differences p<0.05 by paired 
ttests. 
 
Om ASCs were less sensitive to Dex-mediated suppression of SMAD2-P and 
induction of TGFBR3 
To address if Dex can directly influence expression of the TGFβ receptors and 
downstream signaling in ASCs, we treated ASCs from Om and Abdsc overnight with 
Dex ranging from 0-1000 nM. Overnight treatment of ASCs with Dex decreased SMAD2 
phosphorylation, only in Abdsc and even very high concentrations of Dex did not affect 
SMAD2 phosphorylation in Om ASCs (Figure 3.12, Abdsc 0 nM; 1.73 ± 0.51 vs. 0.25 
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nM; 0.55 ± 0.21, p<0.05, n=6). This decrease in SMAD2 phosphorylation mirrored an 
increase in the expression of TGFBR3 in both Om and Abdsc. Abdsc ASCs were much 
more sensitive and responsive to the effect of Dex to increase TGFBR3. Significant 
induction of Abdsc TGFBR3 occurred at 0.25nM Dex (Abdsc 0nm; 0.31 ± 0.16 vs. 0.25 
nM 0.77 ± 0.11, AU, p<0.05, n=6), whereas Om induction only reached significance at 
25nM Dex (Om 0 nM; 0.04 ± 0.08 vs. 25 nM; 0.30 ± 0.12, AU, p<0.05, n=6).  
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Figure 3.12: Overnight treatment with Dex decreased SMAD2 phosphorylation and 
increased TGFBR3 in Abdsc ASCs. (A) Representative blots of SMAD2 
phosphorylation, TGFBR3 and HSP90 from 6 Om and Abdsc ASCs pairs treated 
overnight with Dex. (B) Overnight treatment of ASCs with Dex decreased SMAD2 
phosphorylation in Abdsc ASCs, but not in Om ASCs (*p<0.05 compared to 0 nM Dex, 
φp<0.05 compared to Abdsc, n=6). (C) Overnight incubation with Dex increased 
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expression protein of TGFBR3 in Abdsc ASCs at low concentrations. Dex increased 
TGFBR3 protein expression only at high concentrations. HSP90 was used as a loading 
control 
 
DISCUSSION 
Our data indicate that TGFβ ligands and signaling play an important role in 
human ASC differentiation and may underlie differences in adipogenic capacity between 
subcutaneous and visceral adipose depots. CM from poorly differentiating Om ASCs 
inhibits differentiation more than CM from Abdsc, and contains more active TGFβ and 
activin A. Most likely as a consequence, Om ASCs have greater basal phosphorylation of 
SMAD2. These data combined with the proadipogenic effect of the TGFβ receptor kinase 
inhibitor, SB, strongly implicate TGFβ and activin A as autocrine/paracrine anti-
adipogenic factors in human ASC adipogenesis. We confirmed that ASCs from human 
Om compared to Abdsc adipose tissue differentiate less well and documented a subset of 
Om ASCs with higher adipogenic capacity that exhibited low activation of TGFβ 
signaling. Collectively, our data indicate that Om ASCs secrete factors that activate 
TGFβ signaling in an autocrine/paracrine fashion that inhibits adipogenesis, and may 
underlie their poor adipogenic capacity in vivo and in vitro.  
It has long been established that GCs are required for adipogenesis. Our data 
indicate that GC downregulation of activin A and TGFβ production and hence 
suppression of SMAD signaling is important for promoting adipogenesis in both Abdsc 
and Om ASCs. Additionally, our data imply that lower sensitivity and responsiveness to 
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GCs contributes to the low differentiation capacity of Om ASCs. While a low 
concentration of GC decreased SMAD2 phosphorylation in Abdsc ASCs, GCs failed to 
downregulate SMAD2 phosphorylation in Om ASCs even at very high concentrations 
despite reducing production of TGFβ and activin A by more than 50%. It is important to 
note that, despite this suppression by Dex, both TGFβ and activin A remained higher in 
CM from Om ASCs compared to Abdsc. TGFBR3, a TGFβ co-receptor known to 
modulate TGFβ driven SMAD signaling, was induced by GCs in Abdsc ASCs at low 
concentrations, but only in Om ASCs at very high concentrations of Dex. Recent data 
suggest that GC mediated induction of TGFBR3 in lung fibroblasts induces a shift from 
SMAD2/3 signaling to SMAD1/5/9, which could attenuate the anti-adipogenic effect of 
TGFβ in the context of ASCs (123). We were unable to detect PSMAD1 under basal 
conditions or after GC treatment, but we have yet to test alterations in TGFβ driven 
signaling. Taken together these data suggest that resistance to GC stimulation TGFBR3 
expression may be preventing the progression of poorly differentiating Om ASCs to the 
adipogenic program due to persistent high SMAD2/3 phosphorylation.  
 
Higher TGFβ signaling contributes to the poor adipogenic capacity of Om ASCs  
TGFβ has long been known to inhibit adipogenesis in 3T3-L1 preadipocytes (114) 
and there is a body of literature examining the molecular details behind this inhibition, 
but studies in human models are limited. Studies by Derynck’s group on 3T3-L1 
adipogenesis utilizing overexpression of dominant negative constructs of SMAD2 and 
SMAD3 indicated that SMAD3 was more important for mediating the anti-adipogenic 
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effects of TGFβ (116). MEFs from SMAD3 deficient mice are resistant to the anti-
adipogenic effect of TGFβ (117), indicating SMAD3 is important for this inhibition. 
Furthermore, Derynck showed that activated SMAD3 exerted its antiadipogenic effect 
through binding to C/EBPβ and C/EBPδ and blocking their transcriptional activation of 
PPARγ, major positive regulators in the adipogenic program (118). In contrast, when we 
utilized siRNAs targeted against SMAD2 and SMAD3, we showed that knockdown of 
SMAD2 results in a much greater improvement in adipogenesis, compared to SMAD3 in 
Om ASCs. This effect closely resembles data from Dani’s group that showed knockdown 
of SMAD2 could block the antiadipogenic effect of activin A in human multipotent 
adipose-derived stem cells (119). These data indicate that in human ASCs, SMAD2 
might be more important than SMAD3 in mediating the anti-adipogenic effect of TGFβ. 
However, these differences in effectiveness may be due to variability in the efficiency the 
siRNAs used, as knockdown efficiency was ~95% for SMAD2 and only ~70% for 
SMAD3. Further studies utilizing CRISPER/CAS9, dominant negative constructs, or 
more effective siRNAs are needed to more fully elucidate the differences between these 
SMAD isoforms.  
The production of TGFβ and activin A by cells with adipogenic capacity is 
consistent with previous publications that show both 3T3-L1 preadipocytes and sorted 
human adipose derived stem cells from lipoaspirate from Abdsc (positive for CD29, 
CD44, CD73, CD90, CD105, and CD166; negative CD14, CD31, CD45, and Lin1) are 
capable of producing TGFβ (202). Depot-dependent differences in TGFβ were not 
assessed. Dani showed that activin A is produced by human adipose derived stem cells, 
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and can inhibit adipogenesis. They also showed that activin A mRNA is expressed in 
preadipocytes from Abdsc, Om, and Mesenteric adipose depots and it decreases during 
differentiation in all 3, but only show percent changes from the undifferentiated cells, 
which does not allow direct comparisons of absolute values between depots (119). We 
clearly demonstrate that poorly differentiating human Om ASCs produce more TGFβ and 
activin A than their Abdsc pairs. Additionally, explants of Om adipose tissue secrete 
more TGFβ than their Abdsc pairs in obese individuals, and that most TGFβ was 
produced by the stromal fraction, which includes ASCs (203). While we show that ASCs 
represent a significant source of TGFβ and activin A, adipose tissue macrophages have 
been identified to be a major source of adipose derived TGFβ (204), but not activin A 
(119). While ASC cultures contain few to no macrophages, as subculturing decreases 
macrophage survival (205) and few macrophage markers are expressed in our mass 
cultures (unpublished microarray data from our lab). CM from macrophages potently 
induced the production of activin A from ASCs, indicating that the tissue 
microenvironment can alter the secretion profile of ASCs (119) and that the deleterious 
effects of macrophage CM can, in part, be mediated by the secretory response of ASCs. 
 In addition to macrophages, other cell types within the tissue or mixed ASC 
cultures may contribute to the secretory profile or adipogenic capacity of a particular 
depot. For example, visceral depots contain more endothelial cells compared to Abdsc, 
and endothelial cells isolated from VAT secrete more total protein, though the secretory 
profiles are very similar (16). Additionally, preliminary data from our lab indicate that 
cultures of Om ASCs have a much higher proportion of myofibroblast like cells as 
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demonstrated by a greater number of cells staining for SMA using immunofluorescence, 
as well as more intense staining compared to Abdsc (data not shown). A recent study that 
showed CM from macrophages found in Abdsc adipose tissue induced a more 
myofibroblast like phenotype compared to those from Om (204), which may indicate the 
tissue environment of Abdsc is more prone to developing fibrosis compared to Om. 
However our data indicate Om ASCs in culture display a more myofibroblast like 
phenotype and produce factors that maintain this phenotype (TGFβ and activin A). In 
addition to alterations in the secretory profile of ASC cultures, conversion of cells to the 
myofibroblast lineage likely prevents them from undergoing adipogenesis. Future studies 
examining the contribution of different cell types to the secretory profile of tissues and 
mixed cultures will be valuable in understanding depot dependent differences in 
adipogenesis.   
 
GCs suppress SMAD2 phosphorylation only in Abdsc, potential role for TGFBR3 
Despite the ability of GCs to decrease both TGFβ and activin A in both Om and 
Abdsc ASCs, only in Abdsc did Dex also decrease SMAD2 phophorylation. This finding 
prompted us to examine other mechanisms by which GCs could decrease TGFβ 
signaling. A recent publication showed that the induction of the accessory type III TGFβ 
receptor (TGFBR3) by glucocorticoids drove a shift in TGFβ mediated signaling from 
SMAD2/3 phosphorylation to SMAD1/5/8 in lung fibroblasts, endothelial cells, and 
smooth muscle cells (123). TGFBR3, also known as betaglycan, binds multiple members 
of the TGFβ family and its action on TGFβ signaling is both cell type and context 
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dependent (122). As TGFBR3 lacks an internal signaling domain, it traditionally has been 
characterized as a co-receptor, serving to present TGFβ to its type II receptor(206), 
though its action directing altered signaling cascades remains poorly understood. In 
addition to its membrane bound form TGFBR3 can be cleaved to a soluble form that can 
sequester ligands to generally antagonize TGFβ signaling (207, 208). Consistent with this 
role in suppressing TGFβ signaling, we observe TGFBR3 was induced by GCs only in 
Abdsc ASCs, and decreases in SMAD2 phosphorylation mirrored the induction of 
TGBR3. Only high concentrations Dex induced TGFBR3 in Om ASCs, but they did not 
decrease SMAD2 phosphorylation. These data may indicate a that the inability of Om 
ASCs to differentiate may be tied to the inability of GCs to induce TGFBR3, which then 
can decrease or alter TGFβ signaling in order to permit adipogenesis.  
Our study measured TGFβ biological activity and was capable of distinguishing 
active and total TGFβ via a PAI-1 promoter driven luciferase construct. It is important to 
distinguish active vs. total TGFβ as there are multiple regulatory proteins that modulate 
the ability of TGFβ exert its effects. These proteins can activate or sequester TGFβ, 
providing a rather complex regulatory network that may not be reflected in studies that 
utilize other methods of measuring TGFβ. One of these proteins is the soluble TGFβ 
neutralizing protein, follistatin (FST). FST inhibits TGFβ and activin A signaling by 
preventing both molecules from binding their receptors. Production of FST is higher in 
Abdsc adipose tissue compared to Om and improves adipogenesis, therefore the 
difference in TGFβ signaling could in part be due to differences in FST secretion (209). 
Specific integrins are positive regulators of TGFβ activity and are required for liberation 
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of TGFβ from its latent complex, namely αVβ8 and αVβ6 (210, 211). Differences in 
expression of these proteins could alter the overall activity of TGFβ, as seen in knockouts 
of both integrins αVβ8 and αVβ6 that phenocopy TGFβ knockout mice (170). While 
ITGB6 was not expressed in human tissue, data from our Chapter 2 indicate that 
expression of ITGB8 (a component of αVβ8) is substantially higher in tissue from the 
omental depot (64), and it is differentially regulated by Dex, increasing in Om and 
decreasing in Abdsc. We showed that a greater percentage of total TGFβ was higher in 
Om vs. Absdc ASCs, and it is possible that higher ITGB8 expression could contribute to 
this difference. Future studies are needed to examine if the differences at the tissue level 
persist into culture of ASCs and if alterations in ITGB8 expression can impact both 
activation of TGFβ and adipogenesis.  
 
Glucocorticoid resistance may prevent Om ASCs from undergoing differentiation 
The inability of GCs to increase the expression of TGFBR3 and decrease SMAD2 
phosphorylation in Om ASCs indicates that these cells may be resistant to the 
proadipogenic effects of GCs. Om tissue is resistant to the increase in LPL expression 
and activity induced by glucocorticoids compared to Abdsc. Submaximal concentrations 
of Dex (0.25 nM) in the presence of insulin are capable of increasing LPL activity in 
Abdsc tissue by >2 fold, while little effect is observed in Om. However, at higher 
concentrations (25 nM), induction of LPL activity in Om tissue is >12 fold, bringing 
activity close to that of Abdsc, though basal activity is lower in Om (56). This lower 
sensitivity and higher responsiveness of Om adipose tissue may underlie the differences 
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observed in states of high circulating glucocorticoids, in terms of adipose tissue 
redistribution. 
Mechanisms underlying GC resistance are complex and exist at multiple levels, 
including receptor translational isoforms, chromatin architecture, and post-translational 
modifications. There are 2 major translational isoforms of the GC receptor (GR): GRα 
and GRβ. GRα is capable of binding ligands and normally alters transcription of target 
genes while GRβ is incapable of binding ligands and can act in a dominant negative 
fashion to inhibit normal glucocorticoid action (38). As a result, higher expression of 
GRβ can result in GC resistance. In other models, inflammation selectively increases 
expression of GRβ (212); it is possible that the higher inflammatory state of Om ASCs 
contributes GC resistance within the depot. Differences in GR translational isoforms 
between adipose depots are not known. In addition to translational isoforms, GRα has 
multiple phosphorylation sites that alter its activity, both positively and negatively. This 
regulation is complex and involves kinases from multiple signaling cascades, including 
MAPKs, CDKs, and GSK3β. Over or under phosphorylation of these specific sites can 
alter GR signaling. Finally GR activity can be heavily influenced by chromatin 
architecture, GR binding to DNA is cell type specific, and this can be largely due to 
altered chromatin structure masking or opening specific regions of DNA (213).  
 
Summary and conclusions:  
We demonstrated that high TGFβ signaling likely contributes to the poor 
adipogenic capacity of Om ASCs, and that ASCs are a significant source of anti-
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adipogenic factors from adipose tissue. A contributing factor of this high activation of 
TGFβ signaling in poorly differentiating Om ASCs was related to the inability of GCs to 
decrease SMAD2 phosphorylation, potentially through lack of induction of TGFBR3. 
These findings support the hypothesis that visceral ASCs differentiate poorly both 
because of an anti-adipogenic microenvironment and resistance to the proadipogenic 
effects of GCs. The low adipogenic capacity of Om ASCs likely contributes to 
hypertrophic growth and impaired ability to expand in a healthy fashion, driving 
inflammation and overall tissue dysfunction.
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CHAPTER FOUR: General Discussion 
GCs promote preferential expansion of central adipose depots, and in extreme 
cases, cause wasting of peripheral adipose depots through poorly understood 
mechanisms. GCs exert these depot-dependent effects via actions at the level of the 
adipocyte and other cell types within the tissue. Utilizing an adipose organ culture 
system, we identified pathways and novel genes that are depot-dependently and dose-
dependently regulated by GCs in human Om and Abdsc adipose tissues. As expected, GC 
induced the expression of pathways that regulate FA uptake and esterification and well as 
lipolysis. In addition, GSEA showed that GC repressed expression of the TGFβ pathway. 
Many of the differentially regulated genes we identified were secreted factors that had 
established roles in regulating adipogenesis, including members of the TGFβ family of 
signaling molecules. Given these results, we examined contribution of secreted factors 
from adipose tissue and ASCs to the adipogenic capacity of adipocyte precursors from 
Om and Abdsc adipose depots. Both CM from Om tissue and ASCs suppressed 
adipogenesis of well-differentiating Abdsc ASCs, and contained more TGFβ and activin 
A compared to CM from Abdsc. Accordingly, basal pSMAD2, a readout of TGFβ 
signaling, was significantly higher in poorly differentiating Om ASCs. Phosphorylated 
SMAD2 suppresses adipogenesis through interactions with C/EBPs, disrupting the 
adipogenic program (118). Dex was able to decrease production of TGFβ and activin A, 
though Om ASCs still produced more. Low concentrations of Dex suppressed pSMAD2 
in Abdsc ASCs, while it had little effect on Om ASCs. Dex increased expression of the 
TGFβ co-receptor, TGFBR3, in Abdsc ASCs at low concentrations of Dex and only in 
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Om ASCs at high concentrations of Dex. TGFBR3 can suppress SMAD2P either by 
sequestering TGFβ away from its receptors or by interacting with other TGFβ receptors 
(122). As illustrated in Figure 4.1, in addition to the well-established anti-inflammatory 
and other proadipogenic effects of GCs, we identifed the suppression of TGFβ signaling 
as another major effect of GCs in promoting adipogenesis. Additionally, we show that 
resistance to these effects of GCs in Om ASCs may underlie their poor adipogenic 
capacity and ability to promote healthy adipose tissue expansion.  
 
 
Figure 4.1: Om adipose tissue is resistant to the proadipogenic effects of GCs, 
potentially limiting healthy adipose tissue expansion. Adipogenesis is required for 
healthy adipose tissue expansion. Glucocorticoids promote adipogenesis, partially 
through suppression of inflammation, however, adipocyte precursors from visceral depots 
(Om) differentiate poorly compared to those from Abdsc. TGFβ ligands were basally 
higher in Om ASCs, and glucocorticoids were less capable of suppressing the production 
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of these ligands. Additionally, GCs failed to increase the expression of TGFBR3 in Om 
ASCs, which can decrease TGFβ signaling. As a result, Om ASCs had high basal 
activation of TGFβ signaling, and it was less well suppressed by Glucocorticoids, 
limiting adipogenesis in these cells. Conversely, GCs suppressed the basally low levels of 
TGFβ ligands, and robustly induced TGFBR3, which resulted in strong suppression of 
TGFβ signaling. As a result, adipogenesis can continue unimpaired, and promote healthy 
adipose tissue expansion. 
 
Glucocorticoids exert depot- and dose-dependent effects on genes and pathways 
 Performing microarray analysis on organ-cultures of Om and Abdsc adipose 
tissues exposed to a dose response of the GR agonist Dexamethasone allowed us to 
identify genes and pathways regulated by GCs in a depot- and dose-dependent manner. 
We identified and confirmed the expression pattern of genes expressed and affected by 
Dex only in one depot that have unknown roles in adipose tissue biology such as 
PKHD1L1 and NRN1. Also of note was GREM1, a BMP antagonist recently identified 
as a negative regulator of adipogenesis (124), which had higher basal expression in Om 
tissue, and resistant to suppression by GCs. This resistance may contribute to the poor 
adipogenic capacity of Om ASCs by high Gremlin 1 inhibiting the proadipogenic effect 
of BMPs(125, 214, 215). Additionally, we identified a subset of mRNAs exhibited 
opposite regulation by Dex. ITGB8, an integrin that can activate TGFβ(170, 211), was 
increased by Dex in Om and decreased in Abdsc, and was significantly higher in Om in 
fresh frozen tissue. This difference in expression may drive higher activation of TGFβ in 
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Om adipose tissue, preserving an anti-dipogenic environment despite the presence of 
GCs. 
 In addition to unique expression patterns of individual genes, we sought to 
identify pathways differentially regulated by GCs between Om and Abdsc adipose tissue 
by utilizing Gene Set Enrichment Analysis. As expected GCs strongly upregulated 
pathways involved in amino acid metabolism and fatty acid metabolism, while 
downregulating pathways related to inflammation and cell-cell communication (Table 
2.4A & 2.4B). Of note, the TGFβ pathway was highly enriched in Om and, though 
suppressed by Dex, enrichment remained higher at all doses of Dex. We identified some 
pathways regulated in one depot but not another, such as steroid biosynthesis or RNA 
degradation, but changes in individual transcripts were relatively small, so we did not 
investigate further. However, future studies should examine how changes in these 
pathways may drive depot-dependent differences in the response to GCs. 
 
Secreted factors from tissue and ASCs significantly influence adipogenesis 
We clearly show that secreted factors from human Om adipose tissue more 
potently inhibits adipogenesis than Abdsc, and that ASCs are a significant contributor to 
this anti-adipogenic secretory profile. Heat inactivation of Om CM We show that Om 
ASCs secrete significantly more TGFβ and activin A than their Abdsc pairs, and that that 
TGFβ pathway impacts the adipogenic capacity of ASCs. However, we cannot rule out 
that other factors are contributing to the anti-adipogenic microenvironment of Om tissue 
and the secretory profile of Om ASCs. Given the higher inflammatory state of Om ASCs, 
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as indicated by greater IL-6 concentrations in OmCM, examination of the potential 
contribution of other inflammatory cytokines to the anti-adipogenic secretory profile of 
Om tissue and ASCs is warranted. TNFα is a well-known anti-adipogenic factor 
produced by adipose tissue, though its production by preadipocytes remains controversial 
(190, 191). The ability of TNFα to inhibit adipogenesis relies on the induction of a 
second family of developmentally important secreted factors, WNTs (190). Canonical 
WNT signaling inhibits adipogenesis, and is associated with hypertrophic growth of 
adipose tissues (216). Greater production and/or dysregulation of these anti-adipogenic 
pathways within the Om depot could also contribute to the poor adipogenic capacity of 
precursor cells. While depot differences in inflammatory cytokine production are well 
established, the differences in WNT signaling have not been examined. Experiments 
detailing β-catenin localization in Om and Abdsc ASCs as well as testing the effect of 
WNT inhibitors during adipogenesis would provide insight into the role this pathway 
plays in adipocyte differentiation.  
Many secreted factors identified interact with or are part of the extracellular 
matrix (ECM). Studies examining the role of the ECM as a regulator of adipogenesis 
have demonstrated its importance in the capacity of cells to differentiate into mature 
adipocytes. A recent publication by Wofrum’s group utilizing mouse adipocyte 
precursors showed that poorly differentiating perigonadal (a model of mouse VAT) ASCs 
grown on decellularized ECM from well differentiating inguinal ASCs (mouse 
subcutaneous AT) differentiated better than those grown on perigonadal ECM (109). 
They identify flotillin2, a protein that regulates lipid raft formations in cell membranes, 
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as a major component of this more pro-adipogenic extracellular matrix of subcutaneous 
ASCs. However, our microarray show no depot-differences in flotillin 2 expression, 
which may reflect differences between human vs. mouse. He did not examine the related 
hypothesis that the ECM of visceral ASCs is potentially anti-adipogenic. Given these 
findings in mice, conducting similar studies utilizing decellularized matrix from human 
ASCs and tissue will provide greater insight into the contribution of the ECM to an anti-
adipogenic microenvironment. Related to these findings is the observation that ASCs 
differentiated on low stiffness substrates differentiate better than those on stiff substrates 
and that stiffness alone can drive dramatically different differentiation programs (217, 
218). The question remains why the 2D culture environment is significantly worse for 
visceral ASCs compared to Abdsc. Interestingly, major pathways identified by our 
microarray as being both depot-different and depot-dependently regulated by GCs were 
ECM-receptor interactions and focal adhesions, both of which include multiple integrins, 
collagens, and adhesion molecules that could dictate responses to different substrates. It 
is possible that these systems that interact with matrix stiffness are different between Om 
and Abdsc ASCs, and that if grown on softer substrates, the differences in differentiation 
capacity would disappear.   
 
Differences in cell composition likely impact adipogenic potential 
Adipose tissue is comprised of multiple cell types that contribute to the overall 
secretory profile and microenvironment of a given depot. Therefore, depot differences in 
cell composition may underlie differences in tissue function, adipogenic capacity, or 
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response to hormones. Furthermore, mass cultures isolated from different depots used for 
our studies likely contain multiple cell types that contribute to adipogenic capacity. For 
example, Om adipose tissue contains a population of mesothelial cells not found in Abdsc 
that form a protective barrier around the tissue (219).  In addition to this physical role, the 
mesothelial layer and component cells serve an immunomodulatory role via secretion of 
IL-8 and IL-1β (219). Linage tracing using a mesothelial specific Wilm’s Tumor-1 driven 
CRE suggests a mesothelial origin for ~70% of the adipocytes in mouse visceral adipose 
tissues, and no such cells were found in subcutaneous depots, suggesting distinct 
developmental origin of each depot (220). The contribution of the mesothelial lineage to 
adipocytes in humans remains unclear. Data from our lab indicate that mesothelial cells 
may not survive normal ASC culture conditions, as expression of mesothelial cell 
specific mRNAs are nearly undetectable in cultured ASCs (unpublished observation). 
However, mesothelial signatures are detected in our organ culture samples, and are 
clearly apparent in microarrays of ‘fresh’ Om but not Abdsc adipose tissue, potentially 
contributing to the anti-adipogenic secretory profile of intact Om tissue. 
In addition to these mesothelial populations, the mass cultures we use for studies 
on adipogenesis potentially contain endothelial cells, myofibroblasts, and non-committed 
preadipocytes that could alter both the adipogenic capacity and secretion profiles from 
these cultures. Preliminary data from our lab indicate that cultures of Om ASCs have a 
much higher proportion of myofibroblast like cells, as demonstrated by a greater number 
of cells staining for SMA using immunofluorescence, as well as more intense staining 
compared to Abdsc (Pickering and Lee, unpublished observation). Interestingly, a recent 
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study (204) showed CM derived from adipose tissue macrophages from Abdsc could 
induce a myofibroblast like phenotype in Abdsc ASCs, and that blocking TGFβ and 
activin A could prevent this phenotype. The study did not compare Om and AbdscCM, 
but given our data showing higher TGFβ and activin A expression in Om tissue and 
secretion by Om ASCs, it’s possible that the tissue microenviroment promotes the 
development of myofibroblast like cells (204). These myofibroblast like cells may 
contribute to the anti-adipogenic secretory profile or represent a population of cells 
within the mixed culture that strongly resistant to our adipogenic cocktail. Recent interest 
has been given to the myofibroblast to adipocyte transition in the context of wound 
healing in mice. During this process, BMPs are required for myofibroblasts to be 
responsive to adipogenic stimuli (221). However, when we treated with Om ASCs with 
BMP2 or 4 (15 nM and 3 nM respectively), we saw very little impact on the 
differentiation capacity (not shown). This variability in response to BMPs may be due to 
level of commitment of cells or in treatment protocols, and future studies examining the 
role of BMPs in human adipogenesis are necessary to better define the impact of these 
developmentally important ligands.  
 
Is TGFBR3 required for adipogenesis? 
Our data imply a role of TGFBR3 in suppressing TGFβ signaling via SMAD2/3 
in Abdsc ASCs. However, GCs did not induce TGFBR3 in poorly differentiating Om 
ASCs, which indicates TGFBR3 may be important in the adipogenic program. Future 
studies to determine the contribution of TGFBR3 to adipogenic capacity will be 
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important. Preliminary studies in well differentiating ASCs indicate that siRNA mediated 
knockdown of TGFBR3 decreases adipogenesis, but these findings must be repeated in 
more samples to determine if it is required for this process. Examining the adipogenic 
capacity of Om ASCs following overexpression of TGBR3 would provide further 
evidence for the role this protein plays in the adipogenic program. Whether or not 
TGFBR3 simply blocks TGFβ signaling or alters it towards the SMAD1 pathway in 
adipocytes, as it does in fibroblasts, remains unclear (222), and presents another set of 
experiments that need to be performed. 
 
Associations of adipogenic capacity with physiological traits and outcomes 
While our data was able to distinguish variations in adipogenic capacity in both 
Om and Abdsc ASCs, and associate these variances with the production of anti-
adipogenic factors like TGFβ and activin A, our sample set varied substantially by race, 
age and sex. This variation in subject characteristics prevents us from making more broad 
conclusions on the impact of these traits on adipogenic capacity, or associations with a 
depot’s adipogenic capacity on adipocyte size, insulin resistance, or other metabolic 
traits. Tchernof’s group showed strong associations with the adipogenic capacity of 
Abdsc ASCs and the size of Om and Abdsc adipocytes as well as serum lipids and insulin 
resistance (78). However, they did not address how the differentiation of Om ASCs can 
affect these factors. Expanding our pool of subjects would allow us to make these 
comparisons, as well as relate adipogenic capacity of different depots to sex, age, and 
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metabolic profiles to better understand the factors that drive depot-dependent differences 
in adipogenic capacity and disease risk. 
Implications 
 The inability of adipose tissues to recruit new adipocytes from a precursor pool 
during overnutrition puts the nutrient burden on existing adipocytes, thus driving 
hypertrophic expansion. Hypertrophied adipocytes have greater rates of cell death and are 
associated with tissue dysfunction (191). If new cells cannot be recruited to replace dead 
adipocytes, existing cells are burdened with excess nutrients, continuing cycle of 
hypertrophy and cell death until storage capacity of the depot is exceeded, forcing lipids 
to be stored in tissues ill equipped to handle excess TAG (76). This ectopic lipid 
accumulation can drive the development of insulin resistance, type 2 diabetes and non-
alcoholic fatty liver disease (223). In individuals that have preferential growth of VAT 
(males, post-menopausal females, high GCs), the limited capacity of visceral ASCs likely 
contribute to the negative consequences associated with increased VAT area, due to a 
limited expansion capacity. Our results indicate that ASCs from Om adipose tissue are 
resistant to the pro-adipogenic effects of GCs, while our microarrays in Om tissue show 
GC strongly stimulate lipogenic pathways. These combined effects could promote 
excessive hypertrophy, and greater tissue dysfunction.  
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